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Abstract 
Transglutaminase-2 (TG2) is a Ca2+-dependent crosslinking enzyme involved in the post-translational 
modification of proteins via the formation of Nε(γ-glutamyl)lysine isodipeptides. TG2 is externalised 
in the extracellular matrix (ECM) through an unconventional and not fully understood pathway. Under 
normal conditions, TG2 modulates cell adhesion, proliferation and tissue repair. Under continuous cell 
insult higher expression and elevated extracellular trafficking of TG2 contribute to the pathogenesis of 
tissue scarring. TG2 is known to have affinity for heparin, and in a previous study cell-surface heparan 
sulphate (HS) has been implicated in extracellular TG2 mediated RGD-independent cell adhesion, a 
non-enzymatic process independent from the α5β1 integrin-binding to the RGD domain on FN 
(Verderio et al., 2003). Hence HS proteoglycan (HSPG) could act as cell surface co-receptor for FN-
bound TG2 or contribute to the regulation of extracellular TG2 activity in cell adhesion and tissue 
repair. 
The aims of this study were: 1) to study the role of externalised TG2 in cell adhesion in primary 
fibroblasts. 2) to investigate the role of HSPG syndecan-4 (Sdc-4), a crucial component of focal 
adhesions in TG2-mediated cell-adhesion. 3) to characterise the interaction between TG2 and HSPG, in 
particular Sdc-4, and to investigate how this interaction can influence TG2 biological functions in 
vitro. 4) to examine the role of Sdc-4 as a regulator of pro-fibrotic TG2 activity in experimental model 
of kidney fibrosis (UUO).  
The results obtained have shown that: 1) externalised TG2 plays an important role in 
mediating early events of cell adhesion in primary fibroblasts. 2) FN-bound TG2 relies on the 
presence of Sdc-4 for its role in RGD-independent cell adhesion. 3) TG2 has a high affinity 
for HS (Kd ~ 20 nM) and it is associated with Sdc-4 at the cell surface in primary fibroblasts. 
4) TG2 crosslinking activity at the cell surface relies on the presence of the HS chains of Sdc-
4 and other HS proteoglycans. HS-binding does not have a direct role in TG2 activity 
regulation, but the presence of intact Sdc-4 is essential for TG2 localisation at the cell surface. 
5) Sdc-4 is protective against the development of UUO and it regulates the release and activity 
of the pro-fibrotic factor TG2 in UUO, suggesting a possible co-operative role of TG2 and 
Sdc-4 in the development of kidney fibrosis.   
 In conclusion, HSPG, and in particular Sdc-4 emerged to have a crucial role in the cell-
surface trafficking and regulation of TG2 biological activities both in vitro and in vivo. 
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1.1 The Transglutaminase family 
The term transglutaminase (TG) was introduced in 1957 by Sarkar and colleagues  (Sarkar 
et al., 1957) to describe the transamidating activity detected in brain and liver extracts from 
guinea pig. After this first discovery, transglutaminase activity has been described in 
microrganisms (Kanaji et al., 1993), plants (Del Duca et al., 1995), invertebrates (Mehta et 
al., 1992; Singh and Mehta, 1994) and  higher animals, including fish (Oppen-Berntsen et 
al., 1990; Yasueda et al., 1994), amphibians (Zhang and Masui, 1997) and birds (Puszkin 
and Raghuraman, 1985).  
1.1.1 Post-translational modification of proteins 
The main role of transglutaminases is the post-translational modification of proteins 
(Figure  1-1), which mainly occurs through transamidation. The most studied reaction is 
protein crosslinking, consisting in the formation of a Nε(γ-glutamyl)lysine isodipeptide 
bond between a deprotonated Lys residue (donor) of one protein and a Gln residue 
(acceptor) of a second protein or of the same polypeptide chain (Lorand and Graham, 
2003). The transamidation reaction is Ca2+-dependent and it occurs in two separate steps; 
firstly the acceptor binds to the enzyme forming a γ-glutamythiolester with the Cys residue 
of the active site. The complex formed is defined as an acylenzyme intermediate; ammonia 
(NH3) is released during this process and it is immediately protonated to the NH4+ form 
under physiological conditions. In the second step the donor binds to the acylenzyme 
intermediate and attacks the γ-glutamythiolester bond, re-establishing the original form of 
the Cys in the TG active centre. The covalent isodipeptide bond formed by TG is stable 
and resistant to proteolysis, thus increasing the resistance of crosslinked proteins (and 
therefore tissues where they are localised) to chemical, enzymatic and physical degradation 
(Folk and Finlayson, 1977).  
Even though the crosslinking is considered as the main protein-modification, other TG-
catalysed reactions (Figure  1-1) have important roles in cell/tissue homeostasis. For 
example, protein esterification, catalysed by TG1 has an essential role in the final 
differentiation of keratinocytes (Nemes et al., 1999). Deamidation, which replaces a 
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Figure  1-1 Biochemical activities of transglutaminases. Image taken from Lorand and 
Graham (2003).  
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Figure  1-2 Structure of TG2. Adapted from (Griffin et al., 2002). The backbone structure 
of TG2 is represented; domains I-V are represented in magenta, orange, blue and green 
respectively. The regulatory loop between domain II and III is shown in red. Amino acids 
involved in the active site (Cys277, His335, Asp358), Ca2+-binding (Ser449, Pro446, 
Glu451, Glu452) and GTP interaction (Ser171, Lys173, Arg478, Val479, Arg580) are 
coloured in yellow, dark blue and grey, in order. 
1.1.2 Regulation of TG activity 
Tissue transglutaminase (tTG or TG2) is used as a model to study the catalytic mechanism 
of all the TG family. In this process, the Cys of the active plays a central role, forming an 
acyl-enzyme thioester intermediate with a peptide-bound Gln; this intermediate can then 
react with a nucleofile (primary amine, peptide-bound Lys or water), resulting in amine 
incorporation, protein crosslinking or deamidation (Folk and Finlayson, 1977). Even 
though there is a certain level of substrate specificity in TG2-mediated transamidation, 
many proteins can be potential targets, given their abundance of exposed Gln and Lys 
residues (Esposito and Caputo, 2005); for this reason, cofactors and spatial localisation of 
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TG2 play important roles in preventing excessive protein crosslinking and potential 
autoimmune activation following protein deamidation.        
The charge-relay catalytic triad of TG2 (Cys277, His335, Asp358) is analogous to the one 
of thiol proteinases like papain; Cys277 localisation makes it highly reactive in the 
presence of the activator Ca2+, and determines the formation of thioesters with 
peptidylglutamine partners in the protein substrate. The activity is largely decreased in the 
absence of Ca2+, when the enzyme assumes the basic latent conformation and the active 
site, located within domain 2 is “buried” by domains 3 and 4, thus preventing the contact 
with substrates. In these conditions, also, Cys277 reactivity is diminished by the formation 
of hydrogen bonds with either Cys336 or the phenolic hydroxyl group of Tyr525. The 
structure of TG2 is shown in Figure  1-2. 
The first insight into TG2 GTPase activity came from the discovery that its transamidating 
activity was inhibited by GTP in an allosteric fashion (Achyuthan and Greenberg, 1987; 
Greenberg et al., 1991). Later on, a novel G protein (Gh) isolated from rat liver plasma 
membrane came out to be TG2, thus indicating the binding/hydrolysis potential of TG2 
(Nakaoka et al., 1994). TG2 has a high affinity for GTP/GDP and can hydrolyse GTP in a 
rate comparable to small Ras-type G-proteins and α subunits of large heterotrimetric G 
proteins; the GTP/GDP-bound form does not have transamidating activity, that can 
however be restored in the presence of Ca2+ (Achyuthan and Greenberg, 1987). This 
represents an efficient mechanism of regulating the different functions of TG2 in separate 
cell compartments: in the cytosol, where the concentration of free Ca2+ is low (0.1 μM) and 
GTP is present at a concentration of 100-150 μM, TG2 is mainly in GTP/GDP-bound 
form. If cells are treated wit a calcium ionophore (i.e. calcimycin), which transport free 
calcium across membranes by diffusion, the intracellular level of Ca2+ becomes high 
enough to activate TG2 (Siefring, Jr. et al., 1978; Zhang et al., 1998). An analogous 
situation is present when the cell loses calcium homeostasis following tissue damage, 
apoptosis or necrosis (Afford and Randhawa, 2000; Nicholas et al., 2003); in this case, 
TG2-mediated crosslinking can prevent the release of intracellular proteins and the 
consequent inflammatory response (Fesus et al., 1987).  TG2 is also secreted to the cell 
surface and extracellular matrix, where the higher Ca2+-concentration (0.5-1.5 mM) 
switches the enzyme into the catalytically active form, which is responsible for protein 
crosslinking (Achyuthan and Greenberg, 1987; Lansdown, 2002).  
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1.1.3 Substrates of transglutaminases 
TG substrates have been identified in the extracellular space and in the intracellular 
compartment, and their expression is a key regulator of the specific functions of TG family 
members. Many extracellular proteins are known substrates of the cross-linking reactions, 
for example fibronectin (Barsigian et al., 1991), collagen (Kleman et al., 1995), vitronectin 
(Sane et al., 1988) and osteonectin (Prince et al., 1991); these substrates point to a role for 
TG in the stabilisatin of the extracellular matrix (Kleman et al., 1995). Several cytoskeletal 
proteins have also been characterised as TG substrates, such as actin, tubulin and 
cytokeratin (Robinson et al., 2007), thus suggesting a role for TG in the covalent 
stabilisation of the cytoskeleton in a similar way to its action in the ECM. Another class of 
TG substrates is represented by histones, which can be modified by TG2 in vitro, affecting 
chromatin condensation which occurs during apoptosis (Ballestar et al., 1996).  
The study of specific crosslinking substrates of TG activity is not easy, since the products 
of transamidation are highly cross-linked insoluble polymers with a complicated structure, 
thus difficult to analyse. Furthermore, when the products of TG activity are investigated in 
vitro, the concentration of Ca2+ used to activate the enzymes can activate a variety of other 
enzymes, including proteases (i.e. calpain), introducing another source of protein 
modification independent from TG (Velasco et al., 1990). Moreover, the state of 
phosphorylation  (Owen et al., 1988), the proteolytic cleavage or the loss of native compact 
structure of a protein can influence their transamidation (Griffin et al., 2002). Studies based 
on incorporation of labelled primary amines or Gln-rich peptides have shown that different 
TG are selective in the Gln residues used for the transamidation, even within the same 
substrate protein (Fesus et al., 1986); also, in different tissues, distinct proteins can act as 
either acyl donors or acceptors or both. A list of TG substrates is presented in Appendix 1. 
 
 
1.2 Transglutaminases in mammalian tissues 
Nine distinct genes for transglutaminases have been isolated in mammalian tissues, and 
they include factor XIII (zymogen that is activated into transglutaminase factor XIIIa), 
keratinocytes TG, ubiquitous type 2 TG, epidermal TG, prostatic TG, type 5-7 TG and the 
TG-like erythrocyte-band 4.2 (Table  1-1).  
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Protein Gene Gene locus Gene 
size (kb) 
Number 
of exons 
Amino acid 
residues 
Molecular 
weight (kDa) 
TG1 TGM1 14q11.2-13 14 15 814 90 
TG2 TGM2 20q11-12 37 13 686 78 
TG3 TGM3 20q11-12 43 13 692 77 
TG4 TGM4 3p21-p22 35 13 684 77 
TG5 TGM5 15q15.2 35 13 720 81 
TG6 TGM6 20q11 45 13 625 70 
TG7 TGM7 15q15.2 26 12 710 80 
F XIIIa F13A1 6p24-25 160 15 732 83 
Band 4.2 EPB4.2 15q15.2 20 13 690 72 
Table  1-1 Human transglutaminases: genes and proteins. Adapted from Mehta (2005).  
 
 
The mammalian TG isoforms have a high level of structural homology, belong to the 
superfamily of papain-like proteins and are codified by genes that arose from 
duplication/rearrangement of an ancestral gene. All the members of the TG family contain 
a catalytic triad of Cys-His-Asp or Cys-His-Asn, with the exception of erythrocyte band 
4.2 which presents an Ala residue instead of the Cys of the active site, resulting in a loss of 
activity (Figure  1-3).  
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Figure  1-3 Alignment of the catalytic site region of the human TG proteins. Allignment 
redrawn from Mehta (2005).  The amino acids of the core fold containing the catalytic 
cysteine residue (C) are shown in bold red text. 
 
1.2.1 Factor XIII 
Factor XIII (FXIII), or fibrin stabilising factor, is a well characterised plasma 
transglutaminase with a Mr of 83 kDa involved in blood coagulation. It circulates in the 
blood in form of a heterotetramer (A2B2) (Lorand et al., 1980) composed by two catalytic 
A subunits (XIIIa), consisting of 731 amino acids (Ichinose et al., 1986a), and two non-
catalytic B subunits (XIIIb), consisting of 641 amino acids (Ichinose et al., 1986b). 
Sequence analysis showed that the B subunit is related to the family of proteins containing 
the small consensus repeats, or Sushi domains (involved in protein–protein and protein–
ligand interactions) (Ichinose et al., 1990); B subunits are also highly sialylated, resulting 
in an elevated heterogeneity (Lorand et al., 1981). Analysis of the A subunit showed 
instead homology with Ca2+-dependent transglutaminases, with the papain-like catalytic 
domain made of Cys-His-Asp (Pedersen et al., 1994). In particular, the catalytic subunit 
presents four distinct domains: an N-terminal β-sandwich, the papain-like active site, a 
barrel 1 and a barrel 2 domain (Yee et al., 1994). FXIII is a zymogen and it is activated in 
the final stages of the coagulation process by the subsequent action of thrombin and Ca2+, 
as illustrated in Figure  1-4. In the first step, thrombin catalyses the cleavage of a 37 residue 
peptide (activation peptide) from the N-terminus of the two A subunits by hydrolysing the 
peptide bond between Arg37 and Gly38 (Schwartz et al., 1973; Takagi and Doolittle, 
1975); the cleavage of activation peptides also weakens the interactions between A and B 
 7
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Figure  1-4 Activation of Factor XIII. In the first step the zymogen FXIII is converted by 
thrombin to FXIII’ allozymogen, that does not have catalytic activity; in the second step 
the calcium-dependent dissociation of the B subunits determines the conformational 
changes necessary for the presentation of the catalytic site in the catalytic subunit.  
 
Thrombin plays a central role in the homeostatic process by synchronising the conversion 
of fibrinogen into fibrin and the activation of FXIII; moreover, fibrin itself can accelerate 
the thrombin-mediated activation of FXIII (Janus et al., 1983; Lewis et al., 1985) and 
facilitate the dissociation of the inert modified zymogen FXIII’ generating the active 
enzyme at a physiological plasma concentration of Ca2+. The dissociation step can also 
take place in the absence of Ca2+, but the presence of fibrin is essential, this is a regulatory 
mechanism that allows crosslinking activity of FXIIIa to take place only when the specific 
substrate is present (Curtis et al., 1974). 
 
 
Figure  1-5 Crosslinking reaction catalysed by factor XIIIa.  
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The crosslinking reaction catalysed by the active FXIIIa (Figure  1-5) is a transamidation 
that occurs between specific Gln and Lys residues on adjacent proteins (fibrin fibres or 
molecules incorporated in the fibrin matrix). There are two different kinds of crosslinking 
taking place: the first one determines the end-to-end linear association of fibrin units, the 
second one involves α chains of fibrin molecules located in separated filaments; together, 
the two processes contribute to the formation of strong urea-insoluble clots (Chen and 
Doolittle, 1971; McKee et al., 1970). The crosslinking action of FXIIIa has little effect on 
the morphology of the single fibrin fibres, but it changes dramatically the properties of the 
clot, providing it with stiffness that allows wound closure and with resistance against 
thrombolytic enzymes (Lorand, 2001). In particular, the resistance to thrombolytic agents 
is determined by FXIIIa-mediated covalent attachment of the α2 plasmin inhibitor present 
in plasma to the α chains of some fibrin fibres (Ichinose et al., 1983; Sakata and Aoki, 
1982). 
There are several pathological conditions related to the deficiency of FXIII, which is an 
autosomal recessive disorder often diagnosed after birth from bleeding of the umbilical 
cord (Seitz et al., 1989). Common symptoms are superficial bruises and hematomas in 
subcutaneous tissue and muscle, sometimes accompanied by bleeding, moreover, affected 
individuals can present abnormal wound healing and repetitive spontaneous miscarriage 
due to impaired haemostasis and angiogenesis; these symptoms can be reversed by FXIII 
supplementation (Muszbek et al., 2008). In 25% of the patients FXIII deficiency causes 
intracranial haemorrhage, which is the main cause of death (Ichinose, 2005). 
1.2.2 Keratinocyte TG (Type 1 or TGK) 
TG1 is expressed in the granular, suprabasal and spinous layers of the epidermis (Iizuka et 
al., 2003; Thacher and Rice, 1985), where is involved in the formation of the cornified 
envelope (CE), the outermost protective layer of the epidermis. TG1 is present as a 
zymogen of approximately 106 kDa, with a low specific activity, in differentiating 
keratinocytes. When the cells reach the final stages of the differentiation, TG1 is converted 
by proteolysis into a 10, 33 and 67 kDa complex, where the different subunits are held 
together via non-covalent binding (Kim et al., 1995). This complex is characterised by high 
transamidating activity and is responsible for the enzymatic action of TG1. Calpain 
(intracellular, Ca2+-dependent) and cathepsin D (lysosomal) are the candidate proteases 
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involved in the formation of the 10/33/67 kDa complex by cleavage of the cleavage sites 
exposed at the N-terminus of each fragment (Egberts et al., 2004; Kim and Bae, 1998). 
Even though TG3 and TG5 are involved in CE formation together with TG1, it appears 
that the different enzymes are involved in separate processes, since mice lacking TG1 have 
an aberrant CE formation that can not be compensated by TG3 or TG5 (Hitomi, 2005; 
Matsuki et al., 1998). Mutations in TG1 are also the most common cause of autosomal 
recessive congenital ichthyosis (ARCI), presenting a structurally defective or attenuated 
cornified cell envelope (Mehta, 2005). Several of these mutations have been characterised 
and mostly consist of missense or nonsense mutations leading to changes in the binding 
site for transcription factors in the promoter region (Herman et al., 2009).  
1.2.3 Epidermal TG (Type 3 or TGE) 
Type 3 transglutaminase is expressed in several tissues, but the main role is in the 
epidermis, where, together with TG1 (paragraph  1.2.2) it participates in the formation of 
the CE through the crosslinking of different components (Candi et al., 1999). The most 
abundant substrates of TG3 are loricrin, small Pro-rich proteins (SPRs) and involucrin; 
these proteins are rich in Gln and lys and their main function is the composition of the CE. 
TG3 has also a role in the hair follicle, where the crosslinking of trichohyalin and keratin 
intermediate filaments determines the morphogenesis of the hair fibre by hardening the 
inner root cover (Lee et al., 1996). Preliminary studies performed on TG3 -/- mice 
demonstrated the role of the enzyme in the ultrastructure of hair and whiskers related to 
altered crosslinking (Thiebach et al., 2007). The enzyme is expressed as a soluble pro-
enzyme of 77 kDa, which is converted by cathepsin L-mediated proteolysis into two 
globular domains that remain held together, an N-terminal of 50 kDa, bearing the active 
site, and a C-terminal of 27 kDa (Cheng et al., 2006; Kim et al., 1990). The site for 
proteolytic digestion is located in a flexible loop which connects the two domains; this 
loop is specific for transglutaminase 3 in terms of length and sequence, and the cleavage of 
analogous sites in TG2 or FXIII determines loss of activity of the enzymes (Kim et al., 
2001). There is biochemical and crystallographic evidence of TG3 active site binding to 
GTP/GDP with a structural motif conserved between TG3 and TG2; as shown for TG2, 
TG3 is also able to hydrolyse GTP (Ahvazi et al., 2004; Candi et al., 2004). 
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To date, there are not TG3 mutations linked to specific diseases, but the expression of TG3 
has been shown to be down-regulated in certain cancers such as oesophageal, head and 
neck squamous cell carcinoma and in laryngeal carcinoma (Mehta, 2005) 
1.2.4 Prostate TG (Type 4 or TGP) 
Many of the information regarding prostate transglutaminase, or TG4, came from the rat 
isoforms of the enzyme, dorsal protein 1 (DP1) (Ho et al., 1992). In rat the enzyme is 
highly expressed in the dorsal prostate, coagulatory gland and lateral type 1 prostate 
(Hayashi et al., 1991), and the expression is regulated by androgens (Ho et al., 1992). The 
main function of DP1 is considered to be the cross-linking of proteins involved in the 
formation of the copulatory plug after mating (Wilson and French, 1980).  
The human isoform of TG4 has a lower level of expression compared to DP1 and its 
function has not been fully determined yet. The enzyme may be involved in semen 
coagulation or in the process of semen transfer to the female by crosslinking seminal 
plasma components to the surface of the male gametes (Dubbink et al., 1998; Porta et al., 
1986). Interestingly, there is only one transcript produced by the gene codifying for human 
TG4, that can then mature in two splicing isoforms, one of which is  characterised by in 
frame insertions of an antisense Alu sequence of 135 bp. The Alu sequence does not 
interfere with the functionality of the enzyme, but may play a role in the localisation of the 
protein within the cell and possibly in the excretion of prostate transglutaminase 
(Makalowski et al., 1994).  
1.2.5 TG X (Type 5) 
TG5 cDNA was firstly isolated from human foreskin keratinocytes; further studies showed 
that TG5 is mainly expressed in the granular layer of the epidermis where it is involved in 
keratinocytes differentiation and, together with TG1 and TG3 it contributes to the 
formation of the CE (Candi et al., 2002). Recent studies have shown TG5 expression in 
other tissues, such as mammary and salivary glands, prostate and placenta, thus suggesting 
the involvement of the enzyme in other physiological functions (Candi et al., 2004). In an 
analogous way to TG1 and TG3, TG5 is synthesised as an 81 kDa protein that does require 
proteolytic degradation to become active (Pietroni et al., 2008).  As shown for TG2 and 
TG3, TG5 is also able to bind and hydrolyse GTP (Candi et al., 2004); GTP/GDP binding 
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is a regulator of the Ca2+-dependent crosslinking activity of the enzyme, even though the 
ability of GTP/GDP to inhibit TG5 activity is lower compared to the inhibition potential on 
TG2; TG5 also responds less to Ca2+-mediated activation compared to TG2 (Candi et al., 
2004). 
Mutations which cause loss of function of TG5 are linked to acral peeling skin syndrome, 
an autosomal recessive genodermatosis characterized by the shedding of the outer 
epidermis (Cassidy et al., 2005). 
1.2.6 TG Y (Type 6) 
TG6 is part of the TG expressed and active in the basal epidermal layers and it is the 
closest homologue of TG3 (Grenard et al., 2001); as TG3, TG6 appears to be involved in 
the formation of CE and in hair morphogenesis (Thiebach et al., 2007).   
1.2.7 TG Z (Type 7) 
TG7 is codified by a gene localised on chromosome 15 in a cluster including the gene for 
TG5 and for the erythrocyte band 4.2 and it was initially identified in human prostate 
carcinoma tissue by Greenard and colleagues (Grenard et al., 2001). Studies on the 
expression of the enzyme have shown a widespread low expression level, with peaks in the 
female reproductive system (uterus, placenta, ovaries and mammary gland), fetal tissues, 
testis and lungs (Grenard et al., 2001). No specific functions have been ascribed to TG7 so 
far, but the putative protein is known to possess transamidating activity and it contains a 
conserved Ca2+-binding site.  
1.2.8 Erythrocyte membrane protein band 4.2 
Human erythrocyte band 4.2 is a highly expressed membrane-associated protein of 77 kDa 
(Korsgren and Cohen, 1986; Korsgren and Cohen, 1988) with an essential but still not fully 
defined function in erythrocytes (Ideguchi et al., 1990; Rybicki et al., 1988). Protein band 
4.2 has high sequence homology with guinea pig liver transglutaminase and subunit A of 
factor XIII, including the region containing the active site for transamidation activity (Folk, 
1980; Lorand and Conrad, 1984). Interestingly, however, the protein does not have 
demonstrable crosslinking activity when tested in vitro (Korsgren et al., 1990), therefore its 
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role in erythrocyte functionality could be purely structural. Studies on the expression 
pattern of protein band 4.2 have revealed high expression level in bone marrow, fetal 
spleen and fetal liver, in accordance with its role in hematopietic cells; no expression was 
detected in the other tissues (Grenard et al., 2001). 
1.2.9 Tissue TG (Type 2 or TGT) 
TG2 is a widespread member of the TG family, with distinct functions in different cellular 
locations. TG2 is a peculiar member of the TG family since it can act as a GTPase 
(Nakaoka et al., 1994), protein disulfide isomerase (Hasegawa et al., 2003) and protein 
kinase (Mishra et al., 2007) together with having transamidating activity.  
1.2.9.1 Organisation and regulation of TG2 gene 
The gene for TG2 measures 32.5 kb and is located in chromosome 20 of the human 
genome (in mouse the gene is localised in chromosome 2, in a region syntenic to human 
chromosome 20) (Nanda et al., 1999). The gene contains 13 exons and 12 introns, with 
intron size ranging from 921 bp to >5kb and a total codifying region of 4 kb, of which 50% 
is constituted by exon XIII, containing the coding region of the protein C-terminus (Gentile 
et al., 1994; Lu et al., 1995). There are several responsive elements and binding sites for 
regulating factors in a functional TG2 promoter, as indicated in Figure  1-6. In particular, 
CAAT and TATA boxes, together with 4 SP sites upstream to the ATG starting codon are 
sufficient to guarantee a high constitutive transcription level (Lu et al., 1995). SP1 and SP2 
sites can be methylated, and this has an influence on the level of expression of TG2 in 
different cell types/tissues (Aeschlimann and Thomazy, 2000). Methylation has a function 
in negative regulation of TG2 expression, thus balancing the high basal level of 
transcription (Lu et al., 1995). On the other side, treatment of cell with DNA demethylating 
drug 5-azacytidine determines an increase in TG2 level (Lu and Davies, 1997).  Retinoids 
have a strong effect in promoting TG2 transcription in several cell types and they are 
considered as the most generalised inducers of TG2 expression (Aeschlimann and 
Thomazy, 2000). It has been shown that treatment of rats with retinoic acid determines an 
augmented TG2 expression and activity (Driscoll et al., 1997), whereas lack of vitamin A 
can determine a decreased level of TG2 expression in some body tissues (Aeschlimann and 
Paulsson, 1994; Verma et al., 1992). There are experimental evidence of the action of 
different retinoids in TG2 activation; the specificity of expression of these molecules and 
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Figure  1-6 Representation of TG2 core promoter and regulatory factors. Redrawn 
from (Aeschlimann and Thomazy, 2000). RAR, retinoic acid receptor; RXR, retinoid X 
receptor; cisHR, cis regulatory element for retinoid activation; RE IL6, interleukin-6 
responsive element; TRE, TGF-β response element; SP1 and SP2, SP1 and SP2 binding 
sites; NF-kB, nuclear factor kB; TNF-α, tumour necrosis factor-α; IL-6, interleukin-6; 
TGFβ1 and TGFβ2, transforming growth factor β1 and β2; BMP2 and BMP4, bone 
morphogenetic protein 2 and 4. 
 
TG2 promoter also contains a responsive element (TRE) for members of the transforming 
growth factor-β (TGF-β) family, in particular TGF-β1 and TGF-β2, which can induce or 
inhibit TG2 expression in a tissue-specific manner. In particular, there is a regulatory loop 
involving TG2 and TGF-β1, since the expression of the growth factor is positively 
regulated by TG2 (Kojima et al., 1993). TRE element also is involved in the transcriptional 
repression mediated by bone morphogenetic proteins (BMP) 2 and 4 (Ritter and Davies, 
1998). Another class of molecules involved in the regulation of TG2 expression is pro-
inflammatory cytokines, in particular interleuchin-6 (IL-6) can positively affect TG2 
transcription by binding its responsive element localised in TG2 promoter (RE IL-6) (Ikura 
et al., 1994; Lu et al., 1995). Tumour necrosis factor-α (TNF-α) also induces TG2 
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expression through its binding to nuclear factor kB (NF-kB) site on the TG2 promoter 
(Kuncio et al., 1998; Lu et al., 1995).  
 
1.2.9.2 Structure of TG2 
All the information available on TG2 structure comes from the enzyme crystallised in the 
GDP-bound form; so far the Ca2+-bound form has not been resolved so the information 
about Ca2+-binding are only derived from studies of homology with factor XIII. TG2 has 
four separate domains: an N-terminal β-sandwich, a catalytic core, and two β-barrel 
domains at the C-terminal (Noguchi et al., 2001) (Figure  1-2 and Figure  1-7). The β-
sandwich domain contains binding sites for FN and integrins, represented respectively by 
residues 2AEELVLE7 and by the 28 kDa N-terminal region of the protein (Fesus and 
Piacentini, 2002; Gaudry et al., 1999). The catalytic core contains the catalytic triad 
represented by Cys277, His335 and Asp358 together with residues involved in the 
stabilisation of the active site, in particular Trp241, essential for catalytic activity (Murthy 
et al., 2002). When the enzyme is bound to a guanine nucleotide, two loops block the 
access to the catalytic site and the Cys277 is hydrogen-bond to a Tyr residue (Liu et al., 
2002). The first β-barrel domain includes a GTP/GDP binding site that is unique for TG2 
and is codified by exon X, which presents low sequence homology with the same exon 
from other members of the TG family (Liu et al., 2002). As shown in Figure  1-7, some of 
the residues essential for GTP hydrolysis are situated in the catalytic core (Iismaa et al., 
2000). The second of the two β-barrel domains contains a binding site for phospholipase C, 
important in the function of TG2 as signal transduction factor (Hwang et al., 1995). TG2 
also presents two regions corresponding to nuclear localisation signals (NLS1 and NLS2), 
predicted by comparison with non-structural proteins of influenza virus (Peng et al., 1999). 
Two different conformations have been proposed for TG2, an open and a closed one, with 
distinct features (Begg et al., 2006; Pinkas et al., 2007); the close conformation is 
analogous to the GTP/GDP form of TG2 and it is characterised by a compact structure. 
 
Chapter 1: Introduction 
 
Figure  1-7 Structural and functional elements of human TG2. (A) Structural domains 
are shown, with first and last codifying residue. In blue the last amino acid codifying for 
each codon is shown. (B)  Functional domains are pointed by the arrows; catalytic triad is 
indicated in blue, active residues for transamidating activity in red; residues involved in 
GTP/GDP binding are shown in green, putative residues involved in Ca2+-binding in pink. 
FN, fibronectin; BH3, BH3 motif of the Bcl-2 protein family; NLS1 and 2, nuclear 
localization signals predicted on the basis of homology to the NLS of the NS1 non-
structural protein of influenza virus; PLCγ, interaction site for phospholipase Cγ  (Fesus 
and Piacentini, 2002). 
 
1.2.9.3 TG2 and cell adhesion  
The localisation of TG2 at the cell surface and in the ECM has been demonstrated in 
several cell types, such as fibroblasts, macrophages, hepatocytes and endothelial cells 
(Fesus and Piacentini, 2002; Gaudry et al., 1999; Kojima et al., 1997; Lorand and Graham, 
2003; Verderio et al., 1998). Several experimental findings suggest a role for extracellular 
TG2 in cell adhesion and migration through its interaction and enzymatic action with the 
cell surface and ECM components. Initial in vitro cell-adhesion assays showed that NIH 
3T3 fibroblasts induced to over-express TG2 are more resistant to trypsin-induced 
detachment (Gentile et al., 1992). On the other side, reduced expression of TG2 or 
inactivation of the enzyme determines a reduced level of cell adhesion and spreading 
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(Jones et al., 1997). There are some controversies regarding the mechanism correlating 
TG2 to cell adhesion, since some studies demonstrate the importance of TG2-mediated 
cross-links of ECM components (Aeschlimann and Thomazy, 2000; Jones et al., 1997) and 
some others suggest that the involvement of TG2 is independent from its transamidation 
activity (Akimov et al., 2000; Balklava et al., 2002; Takahashi et al., 2000). The latter 
studies suggest a role for TG2 as co-receptor for β1 and β3 integrins in the cell-adhesion to 
the 42 kDa gelatin-binding domain of FN (Akimov et al., 2000) or, conversely, an 
independent adhesive role for TG2 correlated to the specific binding of integrins α4β1 and 
α9β1 (Takahashi et al., 2000). More recently, a novel role for TG2 in cell adhesion, 
independent from interactions of integrins α5β1 with the Arg-Gly-Asp (RGD) domain of 
FN has been discovered (Verderio et al., 2003). In this mechanism, TG2 action is 
independent from its cross linking potential and it is related to the formation of an 
extracellular complex of TG2 and FN. This system could have a critical importance in 
situations of cell stress, when the ordinary cell-adhesion, related to the interaction of 
integrins to FN can be compromised by FN fragmentation. 
TG2 has been ascribed different roles in regulating cell-matrix interactions, based on its 
crosslinking activity or independent from the enzymatic reaction (Akimov et al., 2000; 
Balklava et al., 2002). It has been demonstrated that TG2 over-expression in fibroblasts has 
a marginal effect in enhancing cell attachment, but can significantly alter cell spreading 
modulating the interactions of the cells with the adhesion substrate (Stephens et al., 2004). 
Focal adhesions (FA) are the contact points between adhering cells and the substrate and 
they have a function in both cellular support and signal transmission between the 
cytoskeleton and the extracellular environment. FA are molecular complexes constituted 
by structural molecules (vinculin, talin, actin), transmembrane receptors, such as Sdc-4, 
and signalling molecules, in particular focal adhesion kinase (FAK). For the assembly of 
FA it is necessary for both α5β1 integrin clusters and Sdc-4 to bind the ECM component 
FN (RGD domain and heparin-binding domain) (Jeong et al., 2001). FAK is the main FA 
component involved in cell-spreading and migration and its action is mediated by the small 
GTPase RhoA, which influences actin reorganisation. Loss of FAK is correlated with 
decreased cell migration and an increased FA size (Ren et al., 2000), on the other side, 
FAK over-expression determines increased cell motility (Owen et al., 1999). The role of 
FAK in initial cell adhesion depends on its activation, which occurs by Sdc-4 mediated 
auto-phosphorylation of Tyr397 (Y397) (Wilcox-Adelman et al., 2002); this explains the 
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increased level of FAK phosphorylation at Y397 when, during initial cell adhesion events, 
Sdc-4 on the cell surface binds FN. It has been demonstrated that the role of Sdc-4 in cell 
spreading can be encompassed by stimulating directly RhoA with lysophosphatidic acid 
(LPA) (Wilcox-Adelman et al., 2002).  
1.2.9.4  TG2-related diseases 
TG2 is known to participate in the pathogenesis of several diseases, including celiac 
disease (Molberg et al., 2000), cancer (Mangala and Mehta, 2005) and neurodegenerative 
diseases (Hoffner and Djian, 2005). The role of TG2 in these diseases is mainly related to 
its enzymatic activity; therefore several inhibitors directed to the active site of TG2 are 
being studied as a therapeutic strategy to inhibit the establishment of the diseases (Huang 
et al., 2009; Siegel and Khosla, 2007). 
1.2.9.4.1 Celiac disease 
Celiac disease is a T-cell mediated disorder of the small intestine which affects 1-2 % of 
the general population and 0.5 % of European population. The disease is caused by 
prolamins, a class of proteins present in wheat, barley and rye (Sollid, 2000); these 
proteins, being rich in Pro and Glu, are resistant to natural gastric, pancreatic and intestinal 
proteases, and peptidases. Therefore the digestive process leaves small peptides (longer 
than 9 amino acids) that can penetrate in the intestinal lamina, where they cause 
inflammation and destruction of intestinal architecture by activating a T-cell mediated 
immune response (Piper et al., 2004; Shan et al., 2002; Sollid, 2000). TG2 has a double 
role in the etiology of the disease, firstly it converts Gln of prolamine peptides to Glu 
through deamidation (see Figure  1-1); this increases the affinity of the peptides for HLA-
DQ2/8 proteins, which mediate T-cell response (Quarsten et al., 1999; Xia et al., 2006). 
Secondly, TG2 is the target of an autoimmune response in celiac patients (Dieterich et al., 
1997), that produces anti TG2 antibodies which co-localise with TG2 in the small intestine 
(Korponay-Szabo et al., 2004) and in the blood (Sardy et al., 1999). Anti TG2 antibodies in 
blood are used as a diagnostic tool for celiac disease.  
1.2.9.4.2 Diabetes 
TG2 is the main member of the TG family expressed in pancreatic islets, where it 
modulates glucose-stimulated insulin secretion through its transamidating activity (Bungay 
et al., 1986).  
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Type 1 diabetes (insulin-dependent diabetes) is an autoimmune disease characterised by 
loss of insulin secretion as a consequence of pancreatic islet β-cells destruction mediated 
by T cells (Mallone and Van Endert, 2008). Experimental evidence indicated a role for the 
gut immune system in the development of type-1 diabetes, similarly to what happens in 
celiac disease, and suggested an association between the two pathologies (Maglio et al., 
2009). This idea was confirmed by the finding that anti-TG2 antibodies, characteristic of 
celiac disease, can be found in the small intestine of most type-1 diabetes patients and that 
the production of anti-TG2 antibodies appears to be gluten-sensitive (Maglio et al., 2009).  
TG2 is also involved in the pathogenesis of type-2 diabetes, characterised by high blood 
glucose level due to both insulin-deficiency and insulin-resistance. Several TG2 mutations, 
located in the area of the active site have been linked to type-2 diabetes, in accordance with 
the role of TG2 in the secretion of insulin (Porzio et al., 2007). Mutated TG2 also seems to 
interact with factors which regulate insulin-resistance, thus determining the high blood 
glucose status (Porzio et al., 2007). 
1.2.9.4.3 Neurodegenerative diseases 
Several neurodegenerative diseases are characterised by the accumulation of protein 
aggregates in the brain, resulting from TG-mediated cross-linking. TG2 expression and 
activity are upregulated in many neurodegenerative diseases, and TG2 has been shown to 
account for at least two thirds of the total transamidase activity in mouse brain, where it is 
mainly localised in neurons (Krasnikov et al., 2005). TG2 is involved in the pathogenesis 
of Huntington’s disease, an autosomal dominant disorder characterised by neuronal cell 
apoptosis leading to progressive motor dysfunction and dementia. Patients affected by 
Huntington’s disease present insoluble aggregates of the cytosolic protein huntingtin (htt) 
in the striatum and cortex, and there is a positive correlation between the amount of 
aggregates and the severity of the disease, so the aggregates have been considered the 
cause of neurotoxicity (MacDonald et al., 1993). The cause of Huntington’s disease is an 
expansion of CAG repeats (codifying for Gln) in the gene encoding htt protein; this 
modification determines the production of an htt protein with a poly-Gln N-terminus 
(MacDonald et al., 1993). Since Gln is a potential substrate of TG-mediated crosslinking, 
TG2 was initially implicated in the formation of the insoluble htt aggregates (Hoffner and 
Djian, 2005). It was demonstrated that the soluble mutant htt protein determines 
neurotoxicity, not the aggregates (Ruan and Johnson, 2007). It is still unclear whether TG2 
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plays a role in aggregate formation, since crossing R6/1 or R6/2 mice (animal model for 
Huntington’s disease) with TG2 null mice determines an increased number of protein 
aggregates compared to the controls; these mice also show an increased life span, in 
accordance with the non-neurotoxicity of htt aggregates (Mastroberardino et al., 2002). In 
vitro studies have shown that TG2-mediated crosslinks can increase the solubility of htt 
aggregates, so TG2 could have an implication in the pathogenesis of Huntington’s disease 
by promoting the neurotoxic action of soluble htt proteins (Iismaa et al., 2009; Lai et al., 
2004).  
Alzheimer’s disease (AD), the most common cause of dementia in the elderly, is a 
progressive neurodegenerative disorder characterised by the presence of extracellular 
senile plaques composed of aggregated amyloid-β protein and intracellular neurofibrillary 
tangles consisting of a highly phosphorylated form of the protein tau (Siegel and Khosla, 
2007). These proteins are good substrates of TG in vitro (Junn et al., 2003), moreover TG 
activity and TG2 expression are higher in diseased regions of PD brains compared to 
normal regions (Ruan and Johnson, 2007). Despite these observations suggesting a role for 
TG2 in the formation of protein aggregates, to date there are no demonstrations of TG2 
involvement in aggregate formation in vivo (Iismaa et al., 2009). Interestingly, a short-
splice variant of TG2, encoding for a protein lacking the GTP-binding site, has been found 
in AD cerebral cortex (Citron et al., 2002); this variant, lacking the inhibition by GTP, 
could be involved in the aggregates formation or stabilisation.  
Parkinson’s disease (PD) is the second most common neurodegenerative disease, affecting 
1% of the population over the age of 65 years. PD determines the degeneration of 
dopaminergic neurons accompanied by the formation of α-synuclein protein aggregates 
aggregates (Lewy bodies) localised in cytoplasm of affected neurons (Hoffner and Djian, 
2005). As for AD, TG2 mRNA and protein level is upregulated in PD brains compared to 
normal age-matched controls (Bailey et al., 2005). As for AD, even though α-synuclein is 
a good TG2-substrate in vitro, there is no evidence for a direct role of TG2 in the formation 
of Lewy bodies in vivo and the function of TG2 in PD is not clear (Bailey et al., 2005; 
Iismaa et al., 2009).   
1.2.9.4.4 Cancer 
There are several pieces of experimental evidence indicating TG2 involvement in the 
development of several types of cancer, in fact TG2 is upregulated in cancerous tissues 
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such as glioblastomas (Yuan et al., 2007), malignant melanomas (Fok et al., 2006) and 
pancreatic ductal adenocarcinomas (Verma et al., 2006). Moreover, there is a positive 
correlation between TG2 expresion levels and metastatic potential and chemotherapeutic 
resistance of certain cancers (Mehta et al., 2004). Different mechanisms have been 
proposed for TG2-mediated oncogenesis, firstly TG2 can activate the transcription factor 
NF-κB by crosslinking its inhibitory subunit; this promotes the expression of Bcl-xL and 
BFL1, anti-apoptotic proteins (Lee et al., 2004; Mann et al., 2006). Another mechanism 
involves TG2-mediated activation of FAK, which, in turn, activates anti-apoptotic factors 
promoting uncontrolled cell growth (Verma et al., 2006). TG2 has also been shown to have 
anti-apoptotic effect in some cell types and, on the contrary, TG2 down-regulation via 
siRNA or inhibitors makes the cells more sensitive to apoptosis (Antonyak et al., 2004). In 
certain types of cancer, however, TG2 expression is down-regulated, and it seems to act as 
tumour suppressing protein (Jones et al., 2006; Xu et al., 2006), thus the role of TG2 in 
cancer appears to be correlated to the type, stage and location of the cancer and to the 
cancer cell type. Summarising, the expresson of TG2 appears to be upregulated in primary 
tumours and during tumour progression, while the enzyme is downregulated in secondary 
metastatic tumours (in accordance with the role of TG2 in cell adhesion) and in case of 
resistance to chemotherapy (Hwang et al., 2008; Kotsakis and Griffin, 2007). It has been 
demonstrated that the interaction of externalised TG2 with the ECM is an important 
regulator of tumour growth, metastatic spread and angiogeneis, therefore, factors that 
control TG2 externalisation and localisation at the cell surface and matrix 
metalloproteases, which degrade TG2, could play a role in regulating TG2 involvement in 
cancer development.  
1.2.9.5 TG2 in wound healing and fibrosis 
Wound healing is a complex process occurring in any compartment of the body and it 
consists of three overlapping and inter-related events: inflammation, proliferation and 
remodelling (Singer and Clark, 1999).  The process sees the participation of different cell 
types, cytokines and other factors, including transglutaminases, involved in tissue repair 
and stabilisation (Griffin et al., 2002; Lorand and Graham, 2003).  
TG2 over-expression and increased transamidating activity have been monitored in wound 
healing models both in vivo (Haroon et al., 1999) and in vitro (Nicholas et al., 2003; 
Verderio et al., 2004). The role of TG2 seems to be the stabilisation of the wound area and 
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of the neo-formed tissue. When the repair process is completed, then TG2 level is reduced 
through proteolytic degradation and the enzyme is mainly present in its fragmented forms. 
The importance of TG2 in the repair process is related to the fact that the enzyme can be 
externalised, thus having access to ECM components; in fact, TG2 externalisation is 
significantly increased in situations of cell-stress and tissue damage (Haroon et al., 1999; 
Johnson et al., 1999; Li et al., 2002; Upchurch et al., 1991).  
TG2 is also involved in abnormal wound repair mechanism, characterised by an excessive 
accumulation of ECM components and leading to the development of fibrotic diseases 
(Singer and Clark, 1999). During the normal wound healing process, new ECM is 
deposited and it plays an important role in supporting cell migration in the wounded area. 
After the migration is completed, the matrix is degraded and this contributes to the wound 
closure (Verderio et al., 2004); the degradation process is regulated by metalloproteinases 
(MMPs), plasminogen activators and inhibitors of proteases. TG2, being able to crosslink 
several ECM components, is involved in ECM stabilisation and protection by the action of 
MMP (Verderio et al., 2004). Furthermore, TG2 can influence matrix deposition by 
activating fibrogenic cytokine transforming growth factor β1 (TGF β1), which controls 
proliferation and ECM synthesis of fibroblasts (Nunes et al., 1997; Verderio et al., 1999); 
in turns, TGF β1 can activate TG2 expression through the TGF-β1 responsive element on 
the TG2 promoter (Figure  1-6), thus generating a loop which determines the progression of 
the wound healing process into tissue fibrosis. TG2 has been shown to activate TGF-β1 
through two separate ways, both dependent on its transamidating activity, the first way 
involves direct activation of latent TGF-β1 in the ECM, while the second involves TG2-
mediated NF-κB activation (Telci et al., 2009). 
1.2.9.6 Cellular localisation of TG2 
TG2 is reported to be an ubiquitous enzyme, with considerable levels of the protein  
present in  the cytosol, nucleus, plasma membrane and in the extracellular matrix (Fesus 
and Piacentini, 2002).  
1.2.9.6.1 Cytosolic TG2 
In the cytosol, given the insufficient Ca2+ concentration for TG2 activation and the 
presence of inactivating levels of GTP, TG2 transamidating activity is mainly latent and 
the enzyme mostly acts as a GTPase involved in signal transduction (Monsonego et al., 
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1998). TG2 crosslinking activity seems to be activated intracellularly only during 
apoptosis, even though there is a debate on the pro- or anti-apoptotic role of TG2 
transamidating activity in cell death (Gundemir and Johnson, 2009). In fact, according to 
the cell type analysed and the agent inducing apoptosis, TG2 activity appears to have 
opposite roles in determining cell fate (Fesus and Szondy, 2005), by either protecting cells 
from apoptosis (Yamaguchi and Wang, 2006) or facilitating the cell death process 
(Tucholski and Johnson, 2002). Despite the contradictory role ascribed to crosslinking 
activity, it is known that guanine nucleotide binding of TG2 is protective against apoptosis 
(Datta et al., 2007),  even though it is not clear if this depends on the action of TG2 as a G-
protein or on the inhibition of the crosslinking activity. Another event when cytosolic TG2 
crosslinking is involved is cell differentiation; one example is chondrocyte hypertrophic 
differentiation, promoted by TG2 mediated oligomerisation of activating cytokines (Cecil 
and Terkeltaub, 2008). 
TG2 can also act as Ser/Thr kinase in apoptosis signalling upon PKA-induced 
phosphorylation (Mishra et al., 2007b). In human breast cancer TG2 kinase activity was 
reported to activate insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) thus 
determining an IGF-independent activation of signalling, leading to apoptosis (Mishra and 
Murphy, 2004).  
Another function ascribed to TG2 in the endoplasmic reticulum is the one of protein 
disulfide isomerase (PDI), involved in the regulation of protein conformation (Hasegawa et 
al., 2003); an example of this activity is the TG2-mediated conversion of 
inactive/denaturated RNaseA into the native active form. TG2 PDI function does not 
involve the active site for protein transamidation, nor does it require the presence of Ca2+, 
and is not influenced by the presence of guanine nucleotides (Hasegawa et al., 2003). 
1.2.9.6.2 Nuclear TG2 
TG2 is traslocated from the cytosol to the nucleus through a mechanism involving nuclear 
transport protein importin-α3 (Peng et al., 1999). In this cell compartment TG2 is involved 
in post-translational histone modification by crosslinking of core histone subunits; this 
modification regulates the chromatin structure, thus influencing mitosis, transcription, 
DNA replication and DNA repair (Mishra et al., 2007a; Peng et al., 1999). Recent studies 
have shown that TG2 also modifies histones through its Ser/Thr kinase activity, in 
particular in situations of cell stress and apoptosis (Mishra et al., 2007). TG2 nuclear 
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kinase activity has also an important function in the regulation of retinoblastoma protein 
(Rb) a primarily nuclear protein with a key role in the regulation of apoptosis (Mishra et 
al., 2007).  
1.2.9.6.3 Extracellular TG2 
The mechanism of TG2 externalisation at the cell surface and in the ECM is still unknown, 
since the enzyme is a leaderless protein and does not have post-translational modifications 
linked to the targeting to the endoplasmic reticulum or to the Golgi (Thomazy and Fesus, 
1989).  It has been reported that TG2 needs to have an intact active site to be externalised, 
in fact, Swiss 3T3 fibroblasts induced to over-express a mutant TG2 where Cys 277 of the 
active site was substituted by Ser, showed a significantly lower level of externalised TG2 
compared to the same cells induced to over-express normal TG2 (Balklava et al., 2002). 
Very recently, (Telci et al., 2009), using the same cell system of Swiss 3T3 fibroblasts with 
inducible TG2 expression have demonstrated that TG2 transamidating activity is not 
essential for enzyme externalisation, since the process was not affected by active site 
directed TG inhibitor R283. It is therefore possible that the presence of Cys at the active 
site is required to have a specific conformation necessary for the secretion process, 
independently from the catalytic state of the enzyme. 
Once TG2 is externalised, it is mainly associated to cell surface and ECM FN (Akimov et 
al., 2000; Verderio et al., 1998), which is stabilised by the formation of Ca2+-dependent 
cross-links (Jones et al., 1997). On the other side,  the association with FN protects TG2 
against proteolytic degradation (Belkin et al., 2001) and controls its enzymatic activity in 
order to prevent an excessive crosslinking in the Ca2+-rich extracellular environment 
(LeMosy et al., 1992). Probably, after the externalisation and association with FN, TG2 
gradually loses its activity and becomes a structural element of the ECM; this is supported 
by the finding that under physiological conditions extracellular TG2 is mostly inactive and 
only gets activated following tissue injury (Siegel et al., 2008). It has been shown that a 
matrix constituted by TG2 in complex with FN (TG2-FN matrix) can promote a novel cell 
adhesion pathway independent from the classical adhesion mediated by α5β1 integrins 
(Verderio et al., 2003). TG2-mediated RGD-independent adhesion has been shown to rely 
on the presence of cell surface heparan sulphate (HS), in fact it is inhibited by a treatment 
of the cells with heparitinase, which digests HS chains (Verderio et al., 2003); this suggests 
a possible implication of HS in the regulation of TG2 extracellular activity. 
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1.3 Glycosaminoglycans 
Glycosaminoglycans (GAG) are linear polysaccharides of high molecular weight 
consisting of repeating disaccharide units formed by an amino sugar (N-
acetylglucosamine, glucosamine with various N-substitutions, or N-acetylgalactosamine) 
and an uronic acid (glucuronic acid or iduronic acid) or galactose (Hacker et al., 2005). 
GAG chains are characterised by a high level of heterogeneicity, due to the different 
hexosamine, hexose or hexuronic acid that they contain and to the geometry of the 
glycosidic linkage between these units (α or β) (Sasisekharan and Venkataraman, 2000). 
They are the most abundant heteropolysaccharides in vertebrates, involved in the binding 
and regulation of several proteins including chemokines, growth factors, cytokines 
morphogenic enzymes and adhesion molecules (Jackson et al., 1991). GAG can be 
separated in two main groups: unsulphated proteoglycans, including hyaluronic acid (HA) 
and sulphated ones, including chondroitin sulphate (CS), dermatan sulphate (DS), keratan 
sulphate (KS), heparin and heparan sulphate (HS). CS and DS are localised in the ECM, 
while heparin/HS proteoglycans are usually associated to the cell surface. The majority of 
GAG chains in vertebrates are present in the form of proteoglycans, linked to a core 
protein. 
 
 
Figure  1-8 Structure of GAG chains. The composition and sulphation level of the main 
GAG chains, attached to a core protein is shown; the core protein is represented in dark 
blue and the Ser residues adjacent to the GAG attachment site are indicated. The 
composition of hyaluronic acid, not attached to a core protein, is also represented.  
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1.3.1  Heparan sulphate 
Heparan sulphate is a linear polysaccharide present in all animal tissues in the form of 
proteoglycan; HS chains at the cell surface are mostly attached to syndecans and glypicans 
core proteins (Bernfield et al., 1999). In contrast with other complex carbohydrates, overall 
HS structure is conserved from flies to humans. HS synthesis starts with the formation of 
the region for protein linking, followed by elongation and modification of the chain. The 
length of HS chains can vary over 10-fold with cell type and core protein, but the chain 
termination mechanisms are mostly unknown (Bernfield et al., 1999). Generally HS chains 
consist of 50-150 disaccharides and are modified by enzymatic reactions in which the 
products of one are substrates for the following one. The specific expression of modifying 
enzymes and the availability of substrates/cofactors generate a huge diversity of HS chains. 
HS chains on the same core protein from different cell types can show consistent and 
reproducible structural differences: variations in domain number, spacing or size and O-
sulfation pattern (Kato et al., 1994). In all HS chains it is possible to recognise highly 
sulphated domains (HSD), resembling heparin domains, alternated to unmodified domains 
(UMD) (Maccarana et al., 1996). HSD, often involved in HS interactions with binding 
partners, are rigid and highly anionic and can have access to basic residues on protein 
surfaces thanks to the adjacent, more flexible, UMD. HS chains are responsible for much 
of the biological activity of HS proteoglycans (HSPG); the core proteins, that dictate 
cellular location and metabolism of HS chains, have evolved to maximise the efficiency of 
HS chains in their roles (Bernfield et al., 1999; Varki et al., 2009).  
1.3.2 Heparin binding proteins 
Proteins bind HS chains via basic residues on their surfaces, mostly via distinct protein 
domains (Bernfield et al., 1999). Binding domains of recent evolution show sequence 
resemblance and are easy to identify, but domains that arose during ancient times may only 
be apparent after 3D structural analysis (Doolittle, 1995). Some HS binding proteins 
contain linear clusters of basic residues often in a distinct pattern, but most differ in their 
HS-binding sequences, indicating ancient origin (Hileman et al., 1998). 
Cell surface HS can immobilise the ligand, increase its local concentration, change its 
conformation, present it to signalling receptors or modify the molecular encounters 
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between ligands and receptors. The general effect is generally to enhance receptor 
activation at low ligand concentrations (Carey et al., 1997). 
1.4 Proteoglycans  
Proteoglycans consist of one or more GAG chains covalently bound to a core protein at 
specific sites; these chains are attached to the core protein in the Golgi, before 
proteoglycan externalisation. For most of the proteoglycans, the GAG chains represent the 
predominant part of the molecule, conferring a molecular weight that varies from 100 to 
10,000 kDa; given that, it comes natural that the GAG chains are the main determinant of 
proteoglycans chemical properties and interactions with binding partners (Gandhi and 
Mancera, 2008). These molecules are characterised by a huge structural variability that is 
due to the variety of core proteins and to their level of substitution (number, type and 
composition of GAG chains). The stoichiometry of GAG chains substitution, determining 
which GAG attachment sites are preferably used, is also involved in generating variability. 
Some proteoglycans can be “part time”, presenting or not bound GAG chains or binding 
truncated oligosaccharides. Finally, the same proteoglycans can present essential 
differences if expressed in different cell types, showing a different number, length and 
sulphation pattern of the GAG chains (Bernfield et al., 1999). It is possible to distinguish 
two main classes of proteoglycans: membrane proteoglycans (glypican and syndecans) and 
proteoglycans of the extracellular matrix (Aggrecan, Perlecan, Decorin and Biglycan), as 
illustrated in Figure  1-9 (Varki et al., 2009). The extracellular space, the ECM, consists of 
fibrous proteins (collagens and elastins), providing elasticity and tensile strength and 
adhesive glycoproteins (fibronectin, laminin and tenascin); the various proteoglycans 
interact with these components to form a hydrated gel resistant to compressive force, thus 
stabilising the ECM. In some cells, proteoglycans are stored in secretory granules, where 
they are involved in regulating the availability of positively charged components such as 
proteases and bioactive amines (Varki et al., 2009). 
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Figure  1-9 Proteoglycans classification. Image from (Varki et al., 2009). The structure of 
the main cell-surface and extracellular matrix proteoglycans is represented.  
 
 
 
Localisation GAG chain Core protein size (kDa) Principal members 
ECM HA, CS, KS 225-250 Aggrecan, versican 
Collagen-associated CS, DS, KS 40 Decorin, biglycan, 
fibromodulin 
Basement membrane HS 120 Perlecan 
Cell-surface HS, CS 33-60 Syndecans, 
glypicans 
Intracellular granules Heparin, CS 17-19 Serglycin 
Table  1-2 Classification of proteoglycans based on cellular localisatin and 
predominant GAG chain. ECM, extracellular matrix; CS, chondroitin sulfate; DS, 
dermatan sulfate; KS, keratan sulfate; HA, hyaluronic acid; HS, heparan sulfate. 
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1.4.1 Extracellular matrix proteoglycans 
Interstitial proteoglycans are only produced in vertebrates and their composition varies 
according to the tissue analised. Two main classes of molecules can be identified: small 
Leu-rich proteoglycans (SLRP) and the aggrecan family of proteoglycans. The first group, 
characterised by Leu-rich repeats flanked by Cys in the central domain, carries CS, DS or 
KS chains and it is involved in the stabilisation of collagen fibres (Varki et al., 2009). The 
second group consists of aggrecan, versican, brevican and neurocan, characterised by the 
presence of an N-terminal domain which is able to bind hyaluronan, a central domain 
binding CS chains and a C-terminal domain containing a C-type lectin domain (Roughley, 
2006). The larger part of information regarding this family is related to aggrecan, which is 
the major proteoglycan in the cartilage. Aggrecan can contain up to 100 CS or KS chains, 
reaching a molecular weight of 2500 kDa; these chains can be highly hydrated and form a 
filling gel that contributes to the physical strength of cartilaginous tissue and provides 
resistance to compressive loads (Roughley, 2006). Versican, mainly produced by cells of 
the connective tissue seems to be involved in neural crest and axonal migration. Neurocan 
and brevican are expressed in the late phases of development of the central nervous system 
and act inhibiting neurite growth.   
1.4.2 Proteoglycans of secretory granules 
The main proteoglycan contained in cytoplasmic secretory granules is serglycin, which can 
be found in endothelial, endocrine and haematopoietic cells (Kolset and Gallagher, 1990). 
Serglycin can carry a variable number of CS or, most importantly, heparin chains; notably, 
heparin is only made on serglycin contained in secretory granules of secretory tissue type 
mast cells. Given the properties of their GAG chains, serglycin-expressing cells participate 
to a wide range of biological activities, such as regulation of blood coagulation, tumour 
cell killing and bacteria defence during wound repair (Kolset et al., 2004).  
1.4.3 Basement membrane proteoglycans 
Depending on the tissue considered, four different proteoglycans can be isolated in the 
basement membrane (layer of the ECM that lies against epithelial cells): perlecan, agrin, 
collagen type XVIII and leprecan (Iozzo, 2005). The first three carry HS chains, with the 
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exception of perlecan, which can also carry CS chains in cartilage, while leprecan carries 
CS chains. Perlecan and agrin are the best characterised members of this group; the former 
is involved in embryogenesis and tissue morphogenesis, especially in cartilage, the latter 
acts in neuromuscular junctions and renal tubules, where it determines the filtrating 
properties of the glomerulus (Varki et al., 2009).  
1.4.4 Membrane-bound proteoglycans 
The two major families of membrane-bound proteoglycans consist of syndecans (Sdc) and 
glypicans (Bernfield et al., 1999). The Sdc family includes four members, as described in 
paragraph  1.4.5; all of them are characterised by a small cytoplasmic domain, a 
hydrophobic transmembrane domain and a large extracellular domain, carrying HS and, in 
smaller amount, CS chains (Kokenyesi and Bernfield, 1994). HS chains of syndecans can 
bind a large variety of extracellular molecules, concentrating them in specific areas of the 
cell surface and facilitating their binding to specific receptors (Bernfield et al., 1992). 
Given their structure, syndecans are also able to transmit signals from the extracellular 
environment to the cytosol and cytoskeleton, acting in signal transduction (Anderson, 
1998). Sdc ectodomains, carrying the GAG chains, can be shed by action of 
metalloproteases and be released in the ECM, where they can be involved in the regulation 
of important biological functions by competing with membrane-bound Sdc for the binding 
of specific ligands; the shedding process also regulates the availability of proteoglycans at 
the cell surface (Bernfield et al., 1999).  
The glypican family consists of six members, all attached to the cell surface by a C-
terminal glycosylphosphatidylinositol (GPI) anchor. The core protein of glypicans is rich 
in cysteine residues and has a globular structure substantially different from the proline-
rich linear extracellular domain of Sdc (Bernfield et al., 1999). The only GAG chains 
carried by glypicans are HS, involved in the binding of factors essential for the 
development and morphogenesis. The different way in which syndecans and glypicans are 
associated to the membrane determines a different metabolic fate for their ligands; in fact, 
ligands internalised through glypicans can be recycled together with their receptor, while 
ligands internalised with syndecans go through endocytosis and lysosomal degradation 
(Fransson et al., 1995; Rosenberg et al., 1997).  
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1.4.5 The syndecan family 
The Sdc family, representing the major group of transmembrane heparan sulphate 
proteoglycans, includes 4 distinct genes in mammals, originated from gene duplication and 
divergent evolution from a single ancestral gene; syndecan 1 and 3 (Sdc-1 and Sdc-3) and 
syndecan 2 and 4 (Sdc-2 and Sdc-4) represent subfamilies originated from the ancestral 
gene (Bernfield et al., 1992). Each gene product is a single type-1 membrane–spanning 
protein with extracellular domain of varying size containing covalently attached HS chains 
distal from plasma membrane. In vivo experiments have suggested that each Sdc is 
expressed at specific stages of the development and in specific cell types (Bernfield et al., 
1992). All of the Sdc (4 members in mammals and one in Drosophila and Caenorhabditis 
elagans) share homologous regions for GAG chain attachment and a putative protease 
cleavage site in the ectodomain proximal to the membrane (Figure  1-10). Transmembrane 
and cytoplasmic domains are highly conserved, suggesting a potential biological role for 
these domains. In fact, syndecans have important roles as cell surface receptors in cell-cell 
and cell-matrix interactions. Sdc-4 is of particular interest since it is selectively enriched 
and widespread in focal adhesions (Woods and Couchman, 1994). Members of the Sdc 
family can form dimers or oligomers resistant to SDS treatment upon binding of specific 
ligands followed by phosphorylation of the cytoplasmic region (Pierce et al., 1992). In 
particular, recombinant Sdc-3 core protein forms stable non-covalent multimers through 
the transmembrane domain and the ectodomain flanking region (Asundi and Carey, 1995). 
Also, recombinant proteins of Sdc-2 and Sdc-4 form SDS-resistant multimers, even in the 
absence of the cytoplasmic domain (Longley et al., 1999; Oh et al., 1997a ; Oh et al., 
1997b). The formation of multimers can create specialised membrane domains able to 
mediate the interactions between cells and surrounding ECM by binding specific ligands 
and transmitting the signal to the cytosol or the cytoskeleton (Essner et al., 2006).  
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Figure  1-10 Structure of the Sdc family members. (a) Structure of the four vertebrate 
and two invertebrate Sdc; the transmembrane domain is represented by the black boxes 
while the lines represent regions for HS chains attachment. (b) alignment of Sdc amino 
acid sequences; the bars indicate identical residues. (c) structure of HS binding region and 
HS modification reactions, indicated in order of occurrence. Image taken from (Carey, 
1997). 
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1.4.5.1 Syndecan-1 
Sdc-1 is expressed really early during development and it is mainly found on epithelia and 
mesenchymal-cell condensations associated with tissue morphogenesis (Couchman, 2003). 
Defects in Sdc-1 expression lead to a phenomenon called epithelial-mesenchimal 
transition, where the cells of interest assume fibroblastic morphology (Bernfield et al., 
1992). This transition is correlated to tumorigenesis and severity of neck and cervical 
carcinoma (Anttonen et al., 1999; Rintala et al., 1999). It is possible that Sdc-1 acts 
regulating the cell-surface level of the tumour suppressor E-cadherin, since the loss of Sdc-
1 is associated with loss of E-cadherin (Leppa et al., 1996),  but the mechanism relating the 
two molecules is still unknown.  
Sdc-1 is also involved in cell-cell adhesion, in fact it can bind several members of the Ig 
super-family of cell-adhesion molecules (CAM), in particular PECAM-1 and N-CAM. 
Sdc-1 mediated adhesion has heterophilic nature, with a molecule of Sdc-1 on the cell 
surface binding a counter-receptor on an adjacent cell (Stanley et al., 1995). It has been 
shown that human myeloma cells loose the ability to adhere to each other after the loss of 
Sdc-1; normal levels of cell-cell adhesion can be restored by re-introducing Sdc-1 by cell 
transfection (Stanley et al., 1995); interestingly, cell-cell adhesion can also be restored by 
transfection with Sdc-4 cDNA, but not with re-introduction of other members of the Sdc 
family.  
1.4.5.2 Syndecan-2 
Sdc-2 is mainly expressed in mesenchymal tissue, but it is also found in liver and neuronal 
cells (Couchman, 2003); the expression of Sdc-2 is limited to sites of cell-cell and cell-
matrix interactions (David, 1993). Sdc-2 is the member of Sdc family with the highest 
expression in fibroblasts, even though its function is still not fully elucidated (David et al., 
1992). In particular Sdc-2 has been shown to be involved in signalling, cell-adhesion and 
angiogenesis (Beauvais and Rapraeger, 2004; Tkachenko et al., 2005), these abilities also 
link Sdc-2 to tumorigenesis. Sdc-2 has been found to be over-expressed in several cancers, 
such as lung and colon cancer, where it determines the establishment of a less adhesive 
phenotype and loss of contact inhibition, thus enhancing the metastatic potential (Gulyas 
and Hjerpe, 2003; Park et al., 2002). 
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The C1 domain of the cytoplasmic region interacts with proteins of the ER family, 
implicated in the organisation of the cortical actin cytoskeleton and in the activation of 
FAK, thus underlying the role of the receptor in cell adhesion and communication with the 
actin cytoskeleton (Granes et al., 2000). The C2 domain is also linked to communication 
with the cytoskeleton; in fact it binds Type II PDZ domain proteins involved in vesicle 
transport, synaptic transmission, axonal migration and development of cancer metastasis 
(Beauvais and Rapraeger, 2004; Essner et al., 2006). The V domain contains two residues 
(Ser197 and Ser198) which can be phosphorylated by activated protein kinase C γ (PKCγ); 
upon phosphorylation, Sdc-2 is able to mediate the response to vitellogenin 1 (Vg1), a 
member of the transforming growth factor β (TGFβ) family of signalling molecules 
involved in cell-cell communication (Kramer et al., 2002). Vg1-mediated signalling is of 
vital importance in the gastrulation process, where it regulates the formation of the right-
left axis leading to asymmetric heart and viscera development (Couchman, 2003). 
Summarising, there are several functions ascribed to Sdc-2, related to the expression in 
specific cell types and in the composition of the HS chains, which can in turn influence the 
ability to bind specific ligands (Essner et al., 2006). 
1.4.5.3 Syndecan-3 
The expression of Sdc-3 is predominantly related to neural cells, although a certain level of 
expression can also be detected in musculoskeletal tissue (Couchman, 2003). Sdc-3 has a 
really high expression in the early postnatal period, when it is involved in cell-matrix 
adhesion in the developing nervous system (Carey, 1997). In this process, Sdc-3 acts as a 
receptor for the growth factor pleiotrophin, whose expression is also correlated with the 
development of the central nervous system (Raulo et al., 1994); once bound to Sdc-3 
pleiotrophin promotes neurite outgrowth from embryonic or early post-natal cortical 
neurons. It has been demonstrated that the binding of pleiotrophin to Sdc-3 (Kd ≈ 0.4 nM) 
is mediated by the HS chains of the proteoglycan, and, in particular, by 2-O-sulphated 
iduronic acid residues contained in the chains. 
1.4.5.4 Syndecan-4 
Differently from the other members of the Sdc family, Sdc-4 is widely expressed through 
all the stages of the development and it is a constitutive component of focal adhesions (FA) 
of adhering cells, where it contributes to FA formation and cytoskeletal reorganisation 
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linked to cell spreading (Couchman et al., 2001; David et al., 1992). The role in FA 
formation is related to the presence of an intact V region in the cytoplasmic domain; this 
region in fact contains a core sequence (KKPIYKK) which binds phosphatidylinositol (4,5) 
bisphosphate (PIP2) (Couchman et al., 2002). This sequence is not present in other 
members of the family and Sdc-4 is the only Sdc binding phospholipids. After binding, 
PIP2 stabilises the cytoplasmic domain in dimeric form, and may also be involved in 
promoting the formation of higher order oligomers forming specialised microdomains in 
the plasma membrane (Oh et al., 1997a). The complex of Sdc-4 and PIP2 can then bind 
and activate PKCα, essential component of FA involved in the phosphorylation of 
cytoskeletal components (Couchman et al., 2001). C1 domain can also be phosphorylated 
at a specific Tyr residue (Horowitz and Simons, 1998), and this occurs in situations of 
growth inhibition; the kinase responsible for C1 phosphorylation is PKCγ, the same 
involved in the phosphorylation of Sdc-2 V domain; this seems to have an antagonistic 
effect on the activation of PKCα (Couchman, 2003). 
Another cytosolic partner of Sdc-4 is syndesmos, which requires both C1 and V region for 
the interaction; syndesmos acts as an adaptor protein for paxillin, a protein involved in FA 
formation (Baciu et al., 2000). There is also experimental evidence for Sdc-4 interaction 
with cytoskeletal components such as α-actinin, involved in the formation of actin bundles 
(Greene et al., 2003).  The signalling related to Sdc-4 seems to mediate the activation of 
the small GTPase RhoA (Saoncella et al., 1999) even though the mechanism is still not 
fully understood but the two main hypothesis consist in a direct interaction of PKCα with 
RhoA (Slater et al., 2001) or the separate, but equally important action of PKC family 
members and RhoA (Defilippi et al., 1997). Active RhoA can then regulate cytoskeletal 
reorganisation either via activating Rho kinases (ROCK), which lead to microfilament 
contraction promoted by myosin, or modulating actin polymerisation by regulating the 
activity of diaphanous (Bishop and Hall, 2000).  
When plated on fibronectin, primary fibroblasts interact with FN with 2 main cell surface 
receptor families: integrins and cell surface HSPG, in particular Sdc-4; the two signals are 
both necessary to regulate focal adhesions and stress fibres formation (Couchman et al., 
2001; Couchman and Woods, 1999). Integrin interaction with FN leads to the activation of 
several signalling molecules, including FAK; this is only sufficient for attachment and 
spreading. In order to have cytoskeletal and membrane reorganisation, to form stress fibres 
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and focal adhesion, an additional stimulus is needed, which comes from the heparin 
binding (HB) domain of FN interacting with Sdc-4 (Saoncella et al., 1999).  
1.4.6 Syndecan-4 in tissue injury and wound healing  
Tissue repair process following injury is a complex event which includes interaction of 
cells with the surrounding ECM -mainly mediated by β1 integrins and Sdc-4- leading to the 
formation of a new tissue. The importance of Sdc-4 in the wound healing process has been 
investigated in animal models; Sdc-4 -/- or Sdc-4 +/- mice resulted to have a reduced rate 
of wound healing compared to wild type mice (Echtermeyer et al., 2001). Mice with no or 
reduced expression of Sdc-4 in fact showed a reduced formation of granulation tissue, 
which represent the base for the migration of new cells repopulating the wounded area; this 
is linked to the delayed contraction of the wound (Echtermeyer et al., 2001). Moreover, the 
new tissue formed by Sdc-4 -/- and +/+ mice was less vascularised compared to the same 
tissue in wild type mice; the three groups showed a similar amount of blood vessels per 
unit area, but the decreased expression of Sdc-4 determined a reduction of their size 
(Echtermeyer et al., 2001). Elenius and co-workers have also reported that, after skin 
injury, Sdc-4 expression is transiently decreased in keratinocytes migrating into the wound, 
whereas it is increased in the keratinocytes proliferating at the wound margin and in the 
fibroblasts (Sdc-4) within the forming granulation tissue (Elenius et al., 1991). The 
induction seems to be induced by antimicrobial peptides (i.e. PR-39) released into the 
wound by inflammatory cells, in fact there is no increased expression in foetal skin, that 
heals without scarring and without extensive inflammation (Gallo et al., 1996).  
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Cell culture 
2.1.1.1 Reagents 
Dulbecco´s Modified Eagles Medium DMEM (12-614F), DMEM/HAM´s F12 medium 
(D6421) and MEM non-essential amino acids solution (M7145) were from Sigma-Aldrich. 
Penicillin/Streptomycin mix, L-Glutamine, and trypsin solution, were purchased from 
Cambrex bioscience Ltd. 
Heat-inactivated foetal calf serum (FCS) was purchased from BioSera. 
Fungizone, was from Invitrogen Corporation. 
2.1.1.2 Plastic ware 
All sterile plastic were supplied by Sarstedt, except for: 
- Cell scrapers and 8 well glass chamber slides (Lab-Tek II), Thermo Fisher Scientific. 
- Cryotube vials (Nalgene), SLS-Scientific Laboratory Supplies. 
2.1.2 Laboratory reagents 
2.1.2.1 Peptides 
RGD peptide (H-Gly-Arg-Gly-Asp-Thr-Pro-OH) and RAD peptide (H-Gly-Arg-Ala-Asp-
Thr-Pro-OH), purity ≥ 97%, were from Calbiochem. A 10 mg/ml stock solution was 
prepared in DMEM containing 2.5 mg/ml bovine serum albumine (BSA); aliquots were 
stored at -80°C.  
P3 peptide (WTATVVDQQDCTLSLQLTT) (Hang et al., 2005), purity ≥ 95%, was from 
Activotec. A 10 mg/ml stock solution was prepared in sterile distilled water; aliquots were 
stored at -80°C. 
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2.1.2.2 Enzymes 
Chondroitinase ABC (from Proteus vulgaris) and heparitinase (from Flavobacterium 
heparinum) were from Seikagaku Corporation. A 10 U/ml stock solution of chondroitinase 
ABC was prepared in 100mM Tris-HCl, pH 8; aliquots were stored at  -80°C. A 1 U/ml 
stock solution was prepared in 50 mM Tris, pH 7.4 containing 0.1% (w/v) BSA; aliquots 
were kept at -20°C. 
Dispase (from Bacillus polymyxa) was from Invitrogen Corporation. A 10 mg/ml stock 
solution was prepared in sterile PBS, filtered and kept at 4°C. 
Guinea pig liver transglutaminase-2 was from Sigma-Aldrich or Zedira GmbH. A 1 mg/ml 
stock solution was prepared in distilled water; aliquots were stored at -20°C. 
2.1.2.3 Antibodies 
Primary antibody Company 
Monoclonal mouse anti human fibronectin Sigma-Aldrich 
Monoclonal mouse anti human integrin β-1 (mab1965) Chemicon International Inc. 
Monoclonal mouse anti human vinculin (hVin-1) Sigma-Aldrich 
Monoclonal mouse anti transglutaminase 2 (Cub 7402) Abcam 
Monoclonal mouse anti transglutaminase 2 (TG100) Abcam 
Monoclonal mouse anti β-tubulin Sigma-Aldrich 
Polyclonal goat anti transglutaminase 2 (ab 10445) Abcam 
Polyclonal goat anti-type III collagen Southern Biotech. 
Polyclonal rabbit anti cyclophilin A Abcam 
Polyclonal rabbit anti focal adhesion kinase (p125),  Sigma-Aldrich 
Polyclonal rabbit anti focal adhesion kinase (pY397)  Abcam. 
Polyclonal rabbit anti phosphotyrosine BD biosciences 
Polyclonal rabbit anti syndecan-4 Zymed laboratories Inc 
Polyclonal rabbit anti syndecan-4 (H-140) Santa Cruz Biotechnology Inc 
Polyclonal rabbit anti transglutaminase 2 (ab2972) Abcam 
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Secondary antibody Company 
Goat anti-mouse IgG rhodamine RedTM-X-conjugated Invitrogen Corporation 
Polyclonal goat anti mouse Ig Horseradish Peroxidase DakoCytomation 
Goat anti rabbit IgG HRP-conjugated Sigma-Aldrich 
Sheep anti mouse IgG FITC-conjugated Sigma-Aldrich 
Goat anti mouse IgG AlexaFluor® 488 Invitrogen Corporation 
 
2.1.2.4 Molecular biology reagents 
2.1.2.4.1 Antibiotics 
Kanamycin and ampicillin were from Invitrogen Corporation. 
Tetracycline was from Sigma-Aldrich. 
G418 was from PAA laboratories GmbH. 
2.1.2.4.2 Cloning and Expression vectors 
pGEM®-3Zf (+) cloning vector was from Promega Corporation  
pSG5 expression vector was from Agilent Technology UK Limited 
pEGFP-N1 expression vector was from BdBioscience Clontech 
pcDNA™ 3.1(+) expression vector (invitrogen) was kindly donated by Prof. R Rees and 
Dr M. Mathieu, Nottingham Trent University, UK. 
2.1.2.4.3 PCR primers 
All DNA primers were provided by Sigma-Genosys (Sigma-Aldrich). 
Liofilized primers were resuspended in Tris-EDTA (TE) buffer (10 mM Tris-HCl, pH 7.5 
and 1 mM EDTA) at a concentration of 100 μM and stored at -20°C. These stock solutions 
were diluted in TE buffet at 20 μM concentration to generate working solutions used to 
prepare PCR reactions ( 2.2.10.12). 
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Target Primers pair (5’→3’), name and sequence AT (°C) 
Full length human TG2 cDNA pSG5S: atcagaattcatggccgaggagctggtcttagagagg 
pSG5AS: atcagaattccggcggggccaatgatgacattccgg 
56 
Mouse TG2 +/+ TGS1: tactccagcttcctgttctg 
TGA1: tcctgacctgagtcctcgtc 
56 
Mouse TG2 -/- TGN1: atcatctcgctcttgttgctc  
TGA1: tcctgacctgagtcctcgtc 
56 
Mouse Sdc-4 +/+ EX3S: atgacacggaggagcccaggc 
EX4AS: ccttacctgccaagacctcag 
61 
Mouse Sdc-4 -/- NeoS: atgacacggaggagcccaggc 
EX4AS: ccttacctgccaagacctcag 
68 
Mouse GAPDH GAPDHS: actccactcacggcaaattc 
GAPDHAS: ccttccacaatgccaaagtt 
55 
Table  2-1 Primers used for PCR reactions on genomic DNA. The annealing 
temperature (AT) used for PCR amplification is indicated for any primers pair. 
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Target Primers pair (5’→3’), name and sequence AT (°C) 
Mouse Sdc-1 mSdc-1FW: attctttctccccccacagcc 
mSdc-1RV: aataaggtctgctggggctctgaac 
56 
Mouse Sdc-2 mSdc-2FW: ctctccccttgctgtgactgac 
mSdc-2RV: agccccctaccttccctcctac 
56 
Mouse Sdc-4 mSdc-4FW: gggggcattctaagtccagtga 
mSdc-4RV: tatcccgctatccccctacattat 
56 
Human Sdc-4 hSdc-4FW: tgcaggaattcgccatggccc 
hSdc-4RV: gcgtagaactcattggtgggg 
54 
Mouse TG1 mTG1FW: tgagtcctctgatggcattg 
mTG1RV: tcgccaatctgtgcttctgt 
60 
Mouse TG2 mTG2FW: agtatgagcatgggcaacga 
mTG2RV: atacaggggatcggaaagtg 
60 
Mouse TG3 mTG3FW: tggcagtaggcaaagaagtc 
mTG3RV: cacatcaatcttaggctgc 
60 
Mouse TG5 mTG5FW: cttcccttcaacccagtgat 
mTG5RV: gagtgatgctggctttgtga 
60 
Mouse TG6 
 
mTG6FW: atatgtggactcttatggccg 
mTG6RV: tccacacttagcagtttcttca 
60 
Mouse TG7 
 
mTG7FW: catcgctgaggttgaagagac 
mTG7RV: ccttgtagcctttgatctcc 
60 
Mouse GAPDH mGAPDHFW: tggaaagctgtggcgtgat 
mGAPDHRV: ccctgttgctgtagccgtat 
55 
Table  2-2 Primers used for PCR reactions on cDNA. The annealing temperature (AT) 
used for PCR amplification is indicated for any primers pair. 
 
2.1.2.5 Chemicals 
Biotin cadaverine (N-(5-aminopentyl) biotinamide trifluoroacetic acid salt, Invitrogen 
Corporation. A 50 mM stock solution was prepared in DMSO and stored at 4°C. 
DAPI (4',6-diamidino-2-phenylindole), Sigma-Aldrich. A 1 mg/ml solution was prepared 
in H20, aliquots were stored at -80°C. 
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Fluorescein cadaverine, Sigma-Aldrich. A 1 mg/ml stock solution was prepared in 
dimethyl sulfoxide (DMSO); aliquots were kept at -80°C. 
Heparin (sodium salt from porcine intestinal mucosa, average molecular weight ~ 3 kDa), 
Sigma-Aldrich. A 20 mg/ml stock solution was prepared in H2O, aliquots were stored at -
20°C. 
Heparan sulphate (sodium salt from porcine intestinal mucosa, average molecular weight ~ 
12 kDa) MW, Celsus company. A 20 mg/ml stock solution was prepared in H2O, aliquots 
were stored at -20°C. 
TG inhibitor R283 was synthesized by R. Saint and I. Coutts, Nottingham Trent 
University. A 100mM stock solution was prepared in distilled water; aliquots were stored 
at -80°C.  
Surfen (bis-2-methyl-4-amino-quinolyl-6-carbamide) was kindly donated by Prof. J Esko 
(University of California, USA). A 30 mM stock solution was prepared in DMSO; aliquots 
were stored at -20°C.  
All general chemicals were obtained from Sigma-Aldrich unless otherwise stated.  
 
Chemical Company 
EZ-ECL Chemioluminescence detection kit Geneflow 
Protein G Agarose Insight Biotechnology Ltd 
Protein A Agarose Roche Diagnostics Ltd 
Vectashield mounting medum Vector Laboratories Ltd 
Vectashield mounting medum with propidium iodide Vector Laboratories Ltd 
Full-range Rainbow molecular weight markers Amersham Biosciences. 
Nitrocellulose for Western blotting, 0.22 μm Anachem 
Tissue-Tek O.C.T.™ compound Sakura Finetek Europe 
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2.1.3 Laboratory equipment 
Instrument Company 
3000 Biacore system and CM4 sensor chips,  GE Healthcare 
AE 6450 Atto Vertical Dual Mini Slab Kit,  Genetic research Instr. Ltd 
Biochrom30 Amino Acid Analyser Biochrom Ltd 
Bio-Rad mode 680 microplate reader Bio-Rad Laboratories Ltd. 
Bio-Rad Power Pack 300 Bio-Rad Laboratories Ltd 
Blood Tube rotator SB1 Jencons PLS 
Digital Net Camera DN100 Nikon Corporation 
Electrophoresis tank Multi SUB Mini Geneflow 
Eppendorf refrigerated centrifuge 5417R Eppendorf UK Ltd 
Fujifilm intelligent dark box Fujifilm Life Sciences 
Gene Genius Bioimaging System with UV Syngene 
Harrier 18/80 refrigerated centrifuge Sanyo Gallenkamp PCL 
Heating block QBT4 Grant Instruments Ltd 
Leica CLMS confocal laser microscope Leica 
Leica CM1850 UV cryostat Leica 
Neubauer hemocytometer  Hawksley 
Nucleofector Device (Amaxa) Lonza Cologne AG 
Optical inverted microscope Olympus CK2 Olympus 
Optima TLX-120 Ultracentrifuge Beckman Coulter 
Pellet Pestle Sigma-Aldrich 
Rotor-Gene™ 6000 Corbett Research UK 
Soniprep 150 sonicator MSE UK Ltd 
Termocycler TC-3000 Techne UK Ltd 
Walker class II microbiological safety cabinet Walker safety cabinets Ltd. 
Water bath SUB14 Grant Instruments Ltd 
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2.1.4 Companies 
Company Address 
Abcam Cambridge, UK 
AbD Serotech, Serotech Ltd Oxford, UK 
Activotec Cambrigde, UK 
Agilent Technology UK Limited  Santa Clara, Ca, USA 
Amersham Biosciences Bucks, UK. 
Anachem Luton, UK 
BdBioscience Clontech Oxford, UK 
Beckman Coulter High Wycombe, UK 
Biochrom Ltd Cambridge, UK 
Bio-Rad Laboratories Ltd. Hemel Hempstead, UK 
BioSera Ringmer, UK 
Calbiochem Darmstadt, Germany 
Cambrex bioscience Ltd. Wokingam, Berkshire, UK 
Celsus Inc. Cincinnati, Oh, USA 
Chemicon International Inc. Temecula, Ca, USA 
Corbett Research UK Eaton Socon, UK 
DakoCytomation Glostrup, Denmark 
Eppendorf UK Ltd Cambridge, UK 
Fujifilm Life Sciences Products Sheffield, UK 
GE Healthcare Bucks, UK 
Geneflow Fradley, UK 
Genetic Research Instr. Ltd Rayne Braintree, UK 
Grant Instruments Ltd Cambridge, UK 
Hawksley Lancing, UK 
Insight Biotechnology Ltd Wembley, UK 
Invitrogen Corporation Paisley, UK 
Jencons PLS Redhill, UK 
Leica Solms, Germany 
Lonza Cologne AG  Cologne, Germany 
MSE UK Ltd London, UK 
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Nikon Corporation Tokyo, Japan 
Olympus Watford, UK 
PAA laboratories GmbH Pasching Austria 
Promega Corporation Southampton, UK 
Roche Diagnostics Ltd Burgess Hill, UK 
Sakura Finetek Europe Zoeterwoude, The Netherlands 
Santa Cruz Biotechnology Inc Santa Cruz, Ca, USA 
Sanyo Gallenkamp PCL Leicester, UK 
Sarstedt  Leicester, UK 
Seikagaku Corporation Tokyo, Japan 
Sigma-Aldrich Poole, UK 
SLS-Scientific Laboratory Supplies Nottingham, UK 
Southern Biotech Birmingham, UK 
Syngene Cambrigde, UK 
Techne UK Ltd Newcastle, UK 
Thermo Fisher Scientific Loughborough, UK 
Upstate Lake Placid, NY, USA 
Vector Laboratories Ltd Peterborough, UK 
VWR International Lutterworth, UK 
Walker safety cabinets Ltd. Glossop, UK 
Zedira GmbH  Darmstadt, Germany 
Zymed laboratories Inc San Francisco, Ca, USA 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Cell lines 
Primary mouse dermal fibroblasts (MDF) were isolated from wild type (Sdc-4 +/+) and 
Sdc-4 null (Sdc-4 -/-) mice (Ishiguro et al., 2000) donated by Takashi Muramatsu, Nagoya 
University, Japan as described in paragraph  2.2.1.7.  
Primary mouse embryonic fibroblasts (MEF) from wild type (TG2 +/+) and TG2 null 
(TG2 -/-) mice (De Laurenzi and Melino, 2001) were donated by Gerry Melino, Leicester 
University, UK.  
Primary human osteoblasts (HOB) obtained from femoral heads  (Scotchford et al., 1998) 
were donated by S. Downes, University of Nottingham, UK. Human osteoblasts 
permanently transfected to over express TG2, clone 10 and 14 (HOB-TG2-10 and HOB-
TG2-14) (Verderio et al., 2001) were provided by Dr Elisabetta Verderio, Nottingham 
Trent University, UK. 
3T3 fibroblasts with tetracycline-regulated expression of TG2 (3T3-TG2) (Verderio et al., 
1998) were provided by Dr. Elisabetta Verderio, Nottingham Trent University, UK. 
2.2.1.2 Cell culture conditions 
MDF Sdc-4 +/+, MDF Sdc-4 -/-, MEF TG2 +/+ and MEF TG2 -/- were maintained in 
DMEM nutrient mixture F12 HAM supplemented with 10% (v/v) heat-inactivated FCS, 
2mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin and non essential 
amino acid mixture.  
HOB, HOB-TG2-10 and HOB-TG2-14 were maintained in Dulbecco's Modified Eagle's 
Medium (DMEM) supplemented as described above with exception for non essential 
aminoacid mixture, not added.  
3T3-TG2 cells were maintained in the same medium used for HOB further supplemented 
with 250 μg/ml xanthine, 10 μg/ml mycophenolic acid, 400 μg/ml G418, HAT supplement 
(Sigma-Aldrich) and 2 μg/ml tetracycline. In these conditions the cells express a low basal 
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level of TG2; to induce exogenous TG2 expression, cells were cultured in the absence of 
tetracycline for 72 hours. 
2.2.1.3 Sub-culture of cells 
Cells were sub-cultured at about 90% confluence; the cells were washed with serum-free 
culture medium and then incubated with 0.25% (w/v) trypsin in 5 mM EDTA in PBS, pH 
7.4 at 37°C. After complete detachment of the cells, trypsin was inactivated with serum 
containing culture medium (10% serum) and cells were collected by centrifugation at 300g 
x 5 minutes. Cell pellet was resuspended in complete culture medium and re-seeded. 
2.2.1.4 Cell counting 
Cell counting was performed using a hemocytometer (1 mm2 depth chamber). Two 
separate counts of 25 fields (0.04 mm2) were performed for every cell suspension using 
light microscopy at x 10 magnification. The final cell concentration, expressed as cell 
number/ml was calculated using the following formula: 
Cell concentration =  average cell number in 25 fields × 104 
2.2.1.5 Cryo-preservation of cells 
Confluent cell monolayers were trypsinised and collected as described in  2.2.1.3; the cell 
pellet was then resuspended in heat inactivated FCS containing 10% (v/v) dimethyl 
sulfoxide (DMSO). The cells were initially frozen at -70°C for 24 hours prior to long-term 
storage in liquid nitrogen. 
2.2.1.6 Resuscitation of cryo-preserved cells 
Vials of frozen cells were removed from liquid nitrogen storage and quickly thawed at 
37°C. The cell suspension was then carefully transferred into 25 cm2 tissue culture flask 
containing 5 ml complete growth medium and incubated for 12 hours before changing the 
medium. 
2.2.1.7 Isolation of primary dermal fibroblasts 
Primary fibroblasts were isolated from three months old C57BL/6J mice and Sdc-4 null 
mice (Ishiguro et al., 2000) following a method optimised by P. Kotsakis (Nottingham 
Trent University) (Kotsakis, 2005). The animals were sacrificed by neck dislocation, 
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2.2.1.8 Cell transfection 
Cell transfection was performed by electroporation using Nucleofector® Kit (Amaxa 
GmbH). Low passage cells were grown until 80-90% confluence level, trypsinized 
( 2.2.1.3) and divided in aliquots containing specific amounts of cells (Table  2-3). After 
centrifugation ( 2.2.1.3), the appropriate nucleofector solution (100 μl) and DNA (5 μg) 
were added to the cell pellet and the cells were transferred to the electroporation cuvette, 
that was then inserted in the Nucleofector.  
 
Cell type Cells Nucleofector solution Program 
MEF TG2 -/- 1 × 106 VPI-1006 (MEF starter kit) U23 
MDF Sdc-4 +/+ and Sdc-4 -/- 5 × 105 VPI-1002 (Basic kit for fibroblasts) A24 
Table  2-3 Parameters for cell transfection using Nucleofector Kit, Amaxa. 
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After performing the cell-specific electroporation, the cuvette was removed from the 
machine and the content was gently resuspended in 500 μl complete medium with serum 
before transferring to a 6 well plate well containing 3 ml complete medium with serum. 
Unless differently stated, the cells were incubated at 37 °C, 5% (v/v) CO2 for 48 hours 
before checking gene expression. 
The efficiency of transfection was estimated examining by fluorescence microscopy cells 
transfected with the control plasmid pmaxGFP® (Amaxa). Average efficiency was 80% for 
MEF and 60% for MDF.  
2.2.2 Preparation of matrices for cell adhesion  
Matrices of fibronectin (FN) and TG2-FN were prepared as described by Verderio et al. 
(2003).  
2.2.2.1 Fibronectin coating 
Tissue culture plastic surfaces or chamber slides were incubated for 16 hours at 4°C with 
the appropriate amount of 5 μg/ml human fibronectin (Sigma Aldrich) in 50 mM Tris-HCl, 
pH 7.4 (Tris buffer). 50 μl/well of the solution were used for 96 well plates, 110 μl/well for 
8 well chamber slides and 3 ml/dish for 5 cm diameter Petri dishes. The surfaces were then 
washed once with Tris buffer and blocked with 3% (w/v) BSA in 50 mM Tris-HCl for 1 
hour at room temperature. The surfaces were washed with Tris buffer and serum-free cell 
culture medium prior to cell seeding.  
2.2.2.2 Preparation of TG2-FN matrices 
Fibronectin coated surfaces were blocked as indicated in  2.2.2.1, then washed twice with 
50 mM Tris-HCl, pH 7.4 and incubated for 1 hour at 37°C with purified guinea pig liver 
TG2 (gpTG2, Sigma Aldrich) (20 μg/ml) in PBS, pH 7.4, containing 2 mM EDTA. 100 μl 
of the solution were used for 96 well plates, 220 μl for 8 well chamber slides and 6 ml for 
5 cm diameter Petri dishes. The gpTG2 solution was then removed and surfaces were 
washed twice with Tris buffer and once with serum-free medium before cell seeding. 
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2.2.3 Immunocytochemistry  
Cells were harvested and resuspended in complete medium with or without serum as 
indicated for every single experiment. The cells were then seeded on 8-well chamber slides 
(1.5 ×104 cells/ well) and incubated at 37°C, 5% CO2 for 3 hours, unless otherwise stated; 
the medium was removed and adherent cells were gently washed with PBS. Cells were 
fixed in 3.7% (w/v) paraformaldehide in PBS, pH 7.4 for 15 minutes at room temperature 
and washed three times with PBS. Permeabilization was performed by incubating the cells 
for 15 minutes at room temperature with 0.1% (v/v) Triton-X100 in PBS; after that, cells 
were washed again with PBS for 3 times. 
Non specific binding of antibodies was prevented by blocking with 3% (w/v) bovine serum 
albumin (BSA) in TBS for 1h at room temperature with gentle shaking; after blocking, 
cells were incubated overnight at 4oC in humidified chamber with the primary antibody 
diluted in blocking buffer. After washing 3 times for 5 minutes with TBS, the cells were 
incubated for 2 hours at 37oC in humidified chamber with the secondary antibody 
conjugated with a fluorescent dye (FITC or TRITC) diluted in blocking buffer. A second 
series of washes was performed, as after the incubation with primary antibody, and the 
slide was air dried and mounted with Vectashield fluorescence mounting media 
(containing or not propidium iodide for nuclei visualization).  
In selected experiments, nuclear staining was performed with 4',6-diamidino-2-
phenylindole (DAPI); after incubation with secondary antibody, cells were incubated for 3 
minutes with 1μg/ml DAPI in PBS. Cells were then washed as described above and 
coverslips were mounted with Vectashield fluorescent mounting media.   
2.2.4 Detection of actin stress fibres  
8-well chamber slides were coated with FN or TG2-FN as indicated in  2.2.2.1 and  2.2.2.2. 
Cells were serum-starved for 16 hours before the experiment, then harvested and 
resuspended in serum-free medium. In selected experiments, aliquots of 1.5 × 104 cells 
were pre-incubated for 10 minutes at 37°C with RGD or RAD peptide (100 μg/ml) or, in 
control samples, with serum-free medium only. The cells were seeded on the coated wells 
and incubated for 1 hour at 37°C, 5% CO2. The medium was removed and the cells were 
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2.2.5 Preparation of protein extracts for Western blotting 
2.2.5.1 Total protein extract 
Cell monolayers 90% confluent were washed twice with PBS and scraped in ice cold lysis 
buffer [20 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% (v/v) IGEPAL CA-630, 
0.5% (w/v) deoxycholic acid, 0.1% (w/v) SDS and protease inhibitor cocktail]. The 
homogenate was then sonicated on ice, 3 × 5 seconds, at amplitude 5, and then denatured 
as indicated in section  2.2.6.2.   
2.2.5.2 Cell fractionation 
Crude membrane fractions were prepared following the method described by Germack et 
al. (2006). Briefly, confluent cell monolayers were detached with 2mM EDTA in PBS in 
order to preserve cell surface proteins, collected by centrifugation and resuspended in lysis 
buffer (as described in  2.2.5.1). The homogenate was centrifuged for 2 minutes at  900g to 
eliminate whole cells and nuclei, and then ultracentrifuged for 30 minutes at 170,000g at a 
temperature of 4°C to separate the cytosolic cell fraction from the membrane fraction 
(pellet). The pellet was resuspended in lysis buffer and used as a crude membrane extract. 
2.2.5.3 Determination of protein concentration 
Protein estimation was performed using DC assay (Biorad) based on the Lowry method 
(Lowry et al., 1951). Standard solution of BSA (purity ≥ 96%) with a concentration of 0-1 
mg/ml were used to produce the calibration curve. 5 μl of sample or BSA standard, 25 μl 
of reagent A and 200 μl of reagent B were incubated in 96 well plate, in triplicate. If the 
protein extracts were prepared using a lysis buffer containing IGEPAL CA-630, reagent S 
was added to reagent A before the incubation (20 μl reagent S per 1 ml reagent A). After 
15 minutes incubation at room temperature, the absorbance of the plate was measured at 
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750 nm using a SpectraFluor 96 well plate reader. The calibration curve made with the 
BSA standards was used to derive concentration values for unknown samples.  
2.2.6 Denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
2.2.6.1 Preparation of polyacrylamide gels 
SDS PAGE was performed under reducing conditions using modification of the method 
described by Laemmli (1970) for use in vertical slabs gels. Polyacrylamide resolving gels 
(80×60×1.5 mm) were prepared as described in Table  2-4 and cast in the Atto minigel 
system, covered by a layer of distilled water to provide them with a flat upper surface and 
prevent contact with the air. 
The gels were let to polymerise for 30 min at room temperature, then the upper surface was 
washed with distilled water and the stacking gel was poured on top, together with the 10 
wells comb that forms the sample wells; the stacking gel was let to polymerize for 20 
minutes at room temperature. Composition of stacking gels is described in Table  2-5. 
Final % (w/v) acrylamide Stock solution 
8% 10% 12% 
Distilled H2O 6.99 ml 6.00 ml 5.01 ml 
30% (w/v) Acrylamide/Bis-acrylamide (29:1) 3.96 ml 4.95 ml 5.94 ml 
1.5 mM Tris HCl pH 8.8 3.75 ml 3.75 ml 3.75 ml 
10 % (w/v) SDS 0.15 ml 0.15 ml 0.15 ml 
10 % (w/v) Ammonium persulfate 0.05 ml 0.05 ml 0.05 ml 
TEMED 0.10 ml 0.10 ml 0.10 ml 
Table  2-4 Composition of SDS-PAGE resolving gels containing different acrylamide 
amounts. The amounts shown are enough to prepare two 6×8×0.15 cm gels for the Atto 
minigel system. 
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Final % (w/v) acrylamide Stock solution 
4% 5% 
Distilled H2O 3.56 ml 3.40 ml 
30% (w/v) Acrylamide/Bis-acrylamide (29:1) 0.67 ml 0.83 ml 
1 mM Tris HCl pH 6.8 0.63 ml 0.63 ml 
10 % (w/v) SDS 0.05 ml 0.05 ml 
10 % (w/v) Ammonium persulfate 0.05 ml 0.05 ml 
TEMED 0.01 ml 0.01 ml 
Table  2-5 Composition of SDS-PAGE stacking gels containing different acrylamide 
amounts. The amounts shown are enough to prepare two gels for the Atto minigel system.  
 
2.2.6.2 Separation of samples via SDS-PAGE 
Protein samples were diluted in 5× concentrated reducing electrophoresis buffer [300 mM 
Tris-HCl, pH 6.8; 50% (v/v) glycerol; 10% (w/v) SDS; 3.2% (v/v) β-mercaptoethanol; 
0.5% (w/v) bromophenol blue]. Samples were denaturated at 95°C for 5 minutes in heating 
block, cooled on ice and centrifuged for 10 seconds in a bench centrifuge to collect all the 
proteins. The samples were then loaded into the gel and separated at constant voltage of 
160 V in electrophoresis buffer at pH 8.3 [25 mM Tris, 192 mM glycine and 0.1 % (w/v) 
SDS]. Typically, 30-50 μg of proteins were loaded in each well. The current was stopped 
when the dye at the front ran out of the bottom of the gel. 
2.2.7 Western blotting and immunoprobing of proteins 
2.2.7.1 Western blotting 
Proteins separated by SDS-PAGE were transferred electrophoretically onto a nitrocellulose 
membrane by Western blotting using Atto Vertical Dual Mini Slab Kit wet system method. 
Four pieces of filter paper and one piece of nitrocellulose were cut to the same size as the 
gel and pre-saturated with electroblotting buffer [48.8 mM Tris, 39 mM glycine, 20 % 
(v/v) methanol, 0.0375 % (w/v) SDS] together with two fibre pads. The “sandwich” was 
assembled in the following order starting from the negative electrode: fibre pad, filter 
paper, polyacrylamide gel, nitrocellulose, filter paper, fibre pad. The sandwich was then 
Chapter 2. Materials and Methods 
 
 
54
submerged in a tank containing electroblotting buffer and an ice pack for the refrigeration 
and a constant current of 180 mA intensity was applied for 60 minutes. 
2.2.7.2 Membrane staining with red ponceau 
After the protein transfer, nitrocellulose membranes were immersed in 0.1 % (w/v) 
Ponceau S in 5 % (v/v) glacial acetic acid in dH2O for 30 seconds to reveal the total protein 
bands. The staining was washed away by rinsing the membranes in Tris buffered saline 
(TBS) (25 mM Tris-HCl, 150 mM NaCl and 2 mM KCl, pH 7.4). 
2.2.7.3 Immunoprobing  
After protein transfer, the membranes were incubated in blocking buffer [5 % (w/v) fat-
free powder milk in TBS buffer + 0.1% (v/v) Tween-20] for 1 hour at room temperature to 
avoid non-specific binding of antibodies. Blocked membranes were incubated overnight at 
4°C with the opportune dilution of primary antibodies (see Table  2-6) in blocking buffer.  
 
Primary antibody Dilution factor
Monoclonal mouse anti human fibronectin 1:1000 
Monoclonal mouse anti RhoGAP (p190) (clone D2D6), 1:500 
Monoclonal mouse anti β-tubulin 1:2000 
Polyclonal goat anti transglutaminase 2 (ab 10445) 1:1000 
Polyclonal rabbit anti focal adhesion kinase (p125) 1:2000 
Polyclonal rabbit anti phosphotyrosine    1:250 
Polyclonal rabbit anti syndecan-4 (Zymed Inc) 1:150 
Polyclonal rabbit anti Transglutaminase 2 (ab2972) 1:200 
Rabbit polyclonal anti cyclophilin A 1:1000 
Table  2-6 Dilution factors for primary antibodies used for protein immunodetection 
via Western blotting. 
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Following three washes of 10 minutes with TBS buffer + 0.1% (v/v) Tween-20 (TBST), 
the membranes were incubated for 2 hours at room temperature with the HRP-conjugated 
secondary antibody diluted in blocking buffer (see Table  2-7 for antibody dilutions), then 
they were washed with TBST. 
 
Secondary antibody HRP-conjugated Dilution factor
Polyclonal goat anti mouse Ig 1:5000
Goat anti rabbit IgG 1:5000
Rabbit anti goat IgG 1:5000
Table  2-7 Dilution factors for secondary antibodies used for protein immunodetection 
in Western blotting. 
 
2.2.7.4 Enhanced Chemiluminescence (ECL) development system 
ECL was performed using EZ-ECL kit (Geneflow) according to manufacturer’s 
instructions. Briefly, equal volumes of solution A and solution B were mixed to a final 
volume of 1 ml (for 8×6 cm2 nitrocellulose membrane), incubated in the dark for 5 minutes 
and then placed in contact with the membrane for 1 minute. ECL substrate was drained, the 
nitrocellulose was placed protein-side facing upwards onto a tray in the Fujifilm Intelligent 
dark box (Fujifilm Life Sciences Products) and exposed for a time varying from 10 
seconds to 30 minutes, depending on the protein analysed.  
2.2.7.5 Stripping and reprobing membranes 
Stripping procedure eliminates antibodies bound to nitrocellulose and permits monitoring 
the expression of different proteins from the same extracts. Membrane were submerged in 
stripping buffer [100 mM β-mercaptoethanol; 2% (w/v) SDS; 6.25 mM Tris-HCl, pH 6.7] 
and incubated at 50°C for 30 minutes. The membranes were then washed two times, for 10 
minutes, in a large amount of TBST, than blocked and re-probed as detailed in section 
 2.2.7.3. 
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2.2.7.6 Quantification of immunodetected proteins 
To allow for quantitative comparison of protein band intensity following Western blotting 
and immunoprobing, a process of manual band quantification was performed using the 
Aida Image Analyser v.4.03, according to the manufacturer’s guidelines. Equal sized 
boxes were drawn around bands to be quantified, and figures which represent the number 
of pixels in each box multiplied by the grey shade value of each pixel were generated for 
each band; a specific background signal level was subtracted from each band. 
2.2.8 Protein immunoprecipitation  
Confluent cell monolayers (typical cell number 3 × 106) were detached using 2 mM EDTA 
in PBS, collected by centrifugation and homogenized in ice cold hypotonic buffer (30 mM 
Tris HCl pH7.4, 5 mM MgCl2, 100 mM NaCl and 1 mM EDTA) supplemented with 
protease inhibitor cocktail (Sigma Aldrich). In selected experiments, cells were incubated 
for 1 hour at 37 °C with heparitinase (Seikagaku) (30 mU/ml) in serum free medium or, as 
a control, in serum free medium without heparitinase before homogenization. Cells were 
then lysed in ice-cold hypotonic 30 mM Tris-HCl buffer, pH 7.4, with protease inhibitors 
cocktail (Sigma-Aldrich), and after low speed centrifugation (800g, 10 minutes, to remove 
remaining whole cells and nuclei), crude plasma membranes were prepared as indicated in 
 2.2.5.2. Proteins were estimated using DC protein estimation kit (Biorad) as described in 
 2.2.5.3. Equal amounts of membrane proteins (500 μg) were then solubilised in 500 μl 
lysis buffer containing 1% (v/v) IGEPAL CA 630, 1% (v/v) Triton-X100, 0.5% (v/v) 
deoxycholic acid (DOC), protease inhibitors. The samples were pre-cleared through 1 hour 
incubation in rocking platform (Blood Tube rotator Sb1, with a constant speed of 33 rpm), 
at 4°C in the presence of 50 μl protein-G agarose suspension (Insight Biotechnology Ltd); 
after that, the samples were centrifuged at 10,000g for 1 minute to precipitate the protein-G 
agarose, and the cleared lysates were transferred to new tubes. The crude membrane 
lysates were then subjected to immunoprecipitation by incubation with 2 μg of rabbit anti-
Sdc-4 (Zymed) (against a Sdc-4-endopeptide) or anti-TG2 antibody TG100 (Abcam); in 
negative controls, the membrane preparations were incubated with 2 μg of rabbit anti-
gliadin antibody (Sigma-Aldrich) or without antibody. After 1 hour incubation in rocking 
platform at 4°C, 50 μl of protein-G agarose suspension were added to the samples and the 
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After the precipitation of the agarose beads by centrifuging the samples at 10,000g for 1 
minute, the denatured and reduced immunocomplexes were analysed by Western blotting. 
15 μl of the supernatant were separated by reducing SDS-PAGE on 10% polyacrylamide 
gel, transferred onto nitrocellulose membrane and immunoprobed with antibodies against 
either TG2, Sdc-4 or FN (as described in  2.2.7) Following incubation with the appropriate 
HRP-conjugated secondary antibody, bands were revealed by enhanced EZ-ECL 
chemiluminescence; densitometry of the bands was conducted by Aida ID/evaluation 3.44. 
2.2.9 Detection of TG activity 
2.2.9.1 Preparation of cell extracts for TG activity assay 
Cell homogenates and fractions for measurement of TG2 activity were prepared according 
to Balklava et al. (2002). Cells were washed with PBS and scraped in ice cold lysis buffer 
(0.25 M sucrose and 2 mM EDTA in Tris buffer containing protease inhibitor cocktail 
from Sigma Aldrich); the total cell homogenate was sonicated on ice, 3 × 5 seconds, at 
amplitude 5.  
Cell fractions were prepared by ultracentrifugation of the total homogenate (30 minutes at 
70,000g, 4°C); the supernatant was used as cytosolic fraction, whereas the pellet was 
resuspended in 50 μl of lysis buffer and used as crude membrane preparation.  
2.2.9.2 TG activity measurement 
Transglutaminase activity was assessed using a modification of the enzyme-linked sorbent 
assay (ELSA) based on incorporation of biotinylated cadaverine (BTC) into fibronectin 
described by (Jones et al., 1997). 
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Microtitre plates were coated with 100 μl/well 5mg/ml FN in 50 mM Tris-HCl (Tris 
buffer), pH 7.4 for 15 hours at 4°C. The plates were then washed with Tris buffer and 
blocked in 3% (w/v) BSA in Tris buffer for 1 hour at room temperature. 60 μg of total cell 
extracts or cell fractions were then incubated for 2 hours at 37°C in reaction buffer (5 mM 
CaCl2 [or 5 mM EDTA], 10 mM DTT and 0.1 mM BTC in Tris buffer) in a final volume 
of 100 μl; every sample was tested in triplicates. Together with the samples, standard 
quantities of gpTG2 (0-200 nM) were incubated in reaction buffer and used to produce a 
standard curve relating absorbance and transamidating activity.  
The reaction was terminated by two washes of the plate with PBS containing 10 mM 
EDTA, prior to other two washes with TBST and one with TBS. 100 μl/well of 1:5000 
dilution of extravidine peroxidise in blocking buffer were then added, and the plate was 
incubated at 37°C for 1 hour to reveal the covalently bound BTC. After removing the 
solution, the plate was washed with TBST/TBS as indicated above, and equilibrated with 
100 μl/well of sodium acetate buffer, pH 6, for 10 minutes. The plate was then incubated 
with developing solution (7.5% [w/v] 3,3′,5,5′-tetramethylbenzidine [TMB] in 0.05 M 
phosphate-citrate buffer, containing 0.014% [v/v] H2O2, pH 5.0), 100 μl/well. The 
development was stopped by adding 50 μl/well of 2.5N H2SO4 and the plate was then read 
using a microplate reader at 450 nm. Absorbance values obtained in presence of EDTA 
were subtracted to the ones recorded in presence of CaCl2 to eliminate background.  
If cell surface TG2 activity was measured, 2×104 cells/well (detached with 2 mM EDTA in 
PBS) were incubated in complete culture medium without serum (DMEM and DMEM 
F12-HAM contain 1.8 mM CaCl2) on FN-coated plates in presence of 0.1 mM BTC as 
indicated for cell homogenates. After blocking the reaction by washing with 10 mM EDTA 
in PBS, the cells were detached by incubating the plate with 100 μl/well of 0.1 % (w/v) 
deoxycholate in PBS for 20 minutes at room temperature, with gentle shaking. The plate 
was washed with TBST/TBS as indicated above and covalently incorporated BTC was 
detected as described for cell extracts.  
2.2.9.3 In situ TG activity assay 
The incorporation of FITC-cadaverine in fibronectin by living cells was previously 
developed to visualise TG2 activity in situ (Verderio et al., 1998). 
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Wild type and syndecan-4 null MDF were enzymatically detached, collected by 
centrifugation and resuspended in complete growth medium with serum (as described in 
 2.2.1.3). Cells were seeded in 8-well chamber slides (15,000 cells/well) in the presence of 
0.5 mM fluorescein isothiocyanate conjugated cadaverine (FITC-cadaverine) and 
incubated for 15 hours at 37°C, 5% CO2. In selected experiments, cells were additionally 
incubated with the active-site directed TG inhibitor R283 (200 μM) (Balklava et al., 2002) 
to confirm the specificity of the assay. At the end of the incubation, the medium was 
removed, the cells were washed gently with PBS and fixed in ice-cold methanol for 10 
minutes at -20°C; this fixation method is essential to remove the unspecifically bound 
fluorescent compound. After washing 4 times with PBS the samples were mounted with 
Vectashield mounting medium containing propidium iodide (for visualization of the 
nuclei) and the incorporation of FITC-cadaverine was visualised using a Leica CLMS 
confocal laser microscope equipped with an Argon/Krypton laser. Differences in 
fluorescence were evaluated measuring the intensity of the emission in 5 non overlapping 
images using Leica TC-SNT software (Leica). 
2.2.10 Molecular biology techniques 
Standard molecular biology methods were performed according to Sambrock and colleagues 
(Sambrook et al., 1989). When kits were used, the instructions of the manufacturers were 
followed. 
2.2.10.1 Transformation of bacteria with plasmid DNA 
Frozen Subcloning Efficiency DH5α E. coli competent cells (Invitrogen life technologies) 
were thawed on ice; 100 ng of plasmid DNA were mixed with 100 μl aliquots of cells and 
incubated for 30 minutes on ice. Uptake of DNA from the cells was induced by 20 seconds 
heat-shock in water bath at 37°C followed by 2 minutes incubation on ice. The cells were 
allowed to recover by the addition of 900 μl Luria Bertani (LB) medium [1% (w/v) 
bactotryptone, 0.5% (w/v) yeast extract and 1% (w/v) NaCl in H2O] and 1 hour incubation 
at 37°C, 225 rpm. The suspensions were then centrifuged at 1000 g for 1 minute and, after 
that, the cell pellet was gently resuspended in 200 μl of LB and plated in LB agar plates 
[LB medium containing 1.5 % (w/v) agar, that determines the solidification] containing the 
specific selective antibiotic (ampicillin was used at 75 μg/ml, kanamycin at 50 μg/ml). The 
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plates were incubated overnight (15 hours) at 37°C and they were examined on the 
following day for the formation of antibiotic-resistant colonies.  
2.2.10.2 Storage of bacteria colonies 
A single bacteria colony isolated from a fresh LB plate was used to inoculate 10 ml of 
selective LB medium; the cells were then incubated at 37°C in a shaking incubator (225 
rpm) for 12-16 hours. Glycerol stocks were prepared by mixing 810 μl of the bacterial 
culture and 190 μl of sterile 80% (v/v) glycerol in cryovials, that were then stored at  -
80°C.  
To retrieve a bacterial clone, the specific glycerol stock was taken out of the -80°C storage 
and a portion of it was scraped off using a sterile inoculating loop used to inoculate 3 ml 
LB medium containing the specific selective agent. This procedure was performed quickly, 
avoiding the thawing of the glycerol stock, which was then immediately transferred to -
80°C.  
2.2.10.3 Amplification and extraction of plasmid DNA 
Plasmid Mini preparations (minipreps) were prepared using Wizard® Plus SV Minipreps 
DNA purification system (Promega). A single bacterial colony isolated from a fresh LB 
plate (see  2.2.10.1) was used to inoculate 10 ml of LB medium containing the same 
antibiotic used for the selection. The cells were then incubated overnight (12-16 hours) at 
37°C in a shaking incubator (225 rpm). After that the bacteria were collected by 
centrifugation (10 minutes at 10,000 g) and lysed, and the plasmid DNA was extracted 
following the centrifugation protocol indicated by the manufacturer (yield was 
approximately 10 μg DNA). 
When higher amounts of plasmid DNA were required, MIDI kit (Qiagen) was used; in this 
case 5 ml of LB medium (containing selective antibiotic) were initially inoculated with the 
bacterial colony and incubated at 37°C in a shaking incubator (225 rpm) for 8 hours. The 
bacteria culture was then diluted 1:500 into 100 ml selective LB medium and incubated 
overnight 37°C in a shaking incubator (300 rpm). The bacteria were then harvested and 
plasmid DNA was purified following manufacturer’s instructions (yield was approximately 
100 μg DNA). 
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The plasmid DNA extracted was highly purified (ratio 260/280 ≥ 1.8), therefore it was 
directly used for cell transfection. 
2.2.10.4  Agarose gel electrophoresis of DNA 
Gels for electrophoresis were prepared dissolving agarose (typically 1% w/v) in Tris-
acetate-EDTA (TAE) buffer [40 mM Tris, pH 7.4; 0.114% (v/v) glacial acetic acid; 1 mM 
EDTA] and heating the solution in a microwave oven until the agarose was completely 
dissolved. After cooling, ethidium bromide (0.5 μg/ml) was added to the solution, which 
was poured into a casting plate with the appropriate comb. 50 ml of agarose gel were used 
for small casting plate (8 wells) and 120 ml were used for large plates (15 wells).  
2.2.10.5 Restriction enzyme digestion of plasmid DNA 
Restriction enzyme digestions were performed in 100 μl final volume containing: 15 μg 
DNA, 10 μl specific 10× digestion buffer, 5 μl of each 10 U/μl restriction enzyme 
(Promega), 1 μl 100× BSA solution, distilled water up to 100 μl. Digestion reaction was 
incubated for 1 hour in water bath at 37°C; 1 μl of the product was used for DNA 
electrophoresis (Paragraph  2.2.10.4) to check the efficiency of the reaction.  
2.2.10.6 Dephosphorylation of plasmid DNA 
Dephosphorylation prevents the re-circularization of vectors digested with a single 
restriction enzyme or with two enzymes that generate compatible ends, enhancing the 
efficiency of the ligation process. The reaction was performed by adding 11 μl of 10× 
dephosphorylation buffer and 1 μl of alkaline phosphatase (ALP) (Promega) to the 100 μl 
restriction product ( 2.2.10.5). Dephosphorylation was carried in water bath at 37°C for 30 
minutes, then another 1 μl of ALP was added and other 30 minutes of incubation were 
performed as above. 
2.2.10.7 Isolation of DNA from agarose gel 
After restriction enzymes digestion, vector and insert DNA was loaded into 0.7% agarose 
gel and the band of interest was excised using a scalpel keeping the gel on a UV 
transilluminator for no more than a minute, since UV light causes DNA damages. DNA 
was then purified from the band using Costar® SpinX® columns: the agarose band was 
placed in the columns and centrifuged for 10 minutes at 10,000g to separate the agarose 
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from the solution containing DNA. In order to concentrate it, DNA was then precipitated 
by adding 0.25 volumes of 10 M ammonium acetate and 2 volumes of 100 % ethanol and 
incubating 15 hours at -20°C (or 1 hour on dry ice). A DNA pellet was obtained by 
centrifugation at 10,000g for 20 minutes; the DNA was washed in 500 μl 70% (v/v) 
ethanol to eliminate residual salt, centrifuged at 10,000g for 10 minutes and the ethanol 
solution was removed. The pellet was allowed to air dry and it was then resuspended in 20 
μl sterile water. When the DNA was used for ligation, 1 μl of DNA was loaded on 0.7 % 
agarose gel together with quantitative DNA ladder (Invitrogen), which, by comparison, 
permits to quantify DNA fragments.  
2.2.10.8 Ligation  
Ligation was performed overnight at 16°C in a reaction volume of 10 μl; molar ratios 
insert/vector of 1:1, 1:3 and 3:1 were used, keeping constant the amount of vector (250 ng). 
The amount of insert to be used was calculated with the formula: 
ng insert = 
ng vector × size insert (base pairs) 
size vector (base pairs) 
× molar ratio insert/vector 
 
Specific amounts of insert and vector were mixed with 1 μl 10× ligation buffer, 0.8 μl (2.5 
U) T4 ligase (Promega) and distilled water up to the final volume. 
The total ligation product was used to transform an aliquot of E.coli competent cells as 
described in paragraph  2.2.10.1.  
2.2.10.9 RNA extraction 
RNA was extracted from primary cells using RNeasy kit (Quiagen) following 
manufacturer’s instructions. The RNeasy procedure represents a well-established 
technology for RNA purification. Briefly, after cell lysis, RNA was allowed to bind a silica 
membrane in presence of a high salt buffer containing RNases inhibitors; after eliminating 
cell-contaminants and salts through a series of washes, RNA was eluted from the silica 
membrane in RNase-free water. 
Aliquots of 1 × 106 cells were used for the extraction. To avoid RNA degradation, all the 
instruments and working surfaces were cleaned with RNaseZap® RNase decontamination 
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solution (Ambion) and rinsed with 0.1% diethylpyrocarbonate (DEPC)-treated water 
before use; the samples were digested with RNase-free DNase before reverse transcription 
to minimize the risk of DNA contamination. 
2.2.10.10 Quantification of nucleic acids 
Concentration of DNA and RNA samples was determined by using spectrophotometry. 
The samples were diluted (typically 1:50) in 10 mM Tris-HCl, pH 8.0 and placed in a 
quartz micro-cuvette; absorbance was measured at 260 and 280 nm to determine nucleotide 
concentration and grade of purity. When RNA was measured, the cuvette was washed with 
DEPC-treated water before use to prevent RNA degradation. Considering that at 260 nm 
an optical density of 1 corresponds to 50 μg/ml for DNA and 44 μg/ml for RNA, 
nucleotide concentrations were calculated following the formulas indicated below: 
Concentration of DNA sample = 50 μg/ml x A260 x dilution factor 
Concentration of RNA sample = 44 μg/ml x A260 x dilution factor 
2.2.10.11  Reverse transcriptase polymerase chain reaction (RT-PCR) 
RT-PCR was performed using SuperScript™ II Reverse Transcriptase (Invitrogen), enzyme 
that synthesizes first-strand cDNA starting from RNA template. A reaction containing 1 μl 
Oligo R15, 2 μg RNA, 4 μl dNTP mix and sterile water up to 12 μl was prepared in a 
nuclease-free microtube, heated at 65°C for 5 minutes and chilled on ice. 4 μl of 5× First-
Strand buffer and 2 μl of 0.1 mM DTT were added, the content of the tube was gently 
mixed and incubated at 42°C for 2 minutes before adding 1 μl (200 units) of SuperScript™ 
II RT and incubating at 42°C for 50 minutes. The reaction was inactivated by incubating it 
at 75°C for 15 minutes; 2 μl of the RT-PCR product were used for conventional PCR 
reactions  2.2.10.12) in a final 50 μl volume.  
2.2.10.12 Polymerase chain reaction (PCR) 
PCR was performed using GoTaq® Flexi DNA polymerase kit (Promega) following 
manufacturer’s instructions; reactions were performed in a final volume of 50 μl, using 1 
μg DNA.  When cDNA was used as template, 2 μl of RT reaction were used (see 
 2.2.10.11). PCR reactions were prepared in nuclease-free 200 μl tubes kept on ice. 
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5× Green GoTaq® Flexi buffer 10 μl 
25 mM MgCl2 3 μl 
5 mM dNTP mix  8 μl 
20 μM Forward primer 1.5 μl 
20 μM Reverse primer 1.5 μl 
GoTaq® Flexi DNA polymerase (5U/μl) 1 μl 
DNA (or cDNA) 1 μg (or 2 μl) 
Nuclease-free water up to 50 μl 
 
All the PCR programs used included a initial denaturation step of 5 minutes at 94°C 
followed by 30 cycles of denaturation (1 minute, 94°C), primer annealing (45 seconds, see 
Table  2-1 and Table  2-2 for specific annealing temperatures), elongation (72°C, 45 
seconds); a final elongation step (5 minutes, 72°C) was performed to complete the 
synthesis of all the DNA strands, then the samples were kept at 10°C. 
2.2.11 Subcloning of TG2 and Sdc-4 cDNA into mammalian expression vectors 
Full length TG2 cDNA was amplified by PCR from pSG5TG (Appendix 2) (Gentile et al., 
1992) using proof-reading Pwo-DNA polymerase (Roche) and the EcoRI-modified primers 
(5’→3’) pSG5S: atcagaattcatggccgaggagctggtcttagagagg (forward) and pSG5AS: 
atcagaattccggcggggccaatgatgacattccgg (reverse) listed in Table  2-1. The underlined bases 
represent EcoRI restriction sites; 4 additional bases were added after EcoRI sequence to 
ease the endonuclease digestion. The primers were designed with the purpose of keeping 
TG2 cDNA sequence in frame with EGFP coding region after insertion of TG2 cDNA into 
the mammalian expression vector pEGFP-N1. The PCR product and the vector were then 
digested with EcoRI, to generate compatible ends and ligated as indicated in  2.2.10.8. 
Plasmid DNA from transformed kanamycin-resistant E. coli was analysed for the presence 
and the correct orientation of TG2 cDNA by double restriction with EcoRV and XhoI 
(Figure  2-1). Plasmid DNA from clones containing circularised pEGFP-N1 only would 
generate a single fragment of 4733 bp, while purified plasmid DNA with correct TG2 
orientation (pEGFP-TG) was used for transfection of mammalian cells via electroporation 
as described in  2.2.1.8.  
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Figure  2-1 Screening of pEGFP-TG2 construct by double restriction with 
EcoRV/XhoI. The map of pEGFP-TG2 with correct and inverse orientation of TG2 cDNA 
is shown in (A) and (B), respectively. Position of restriction site is indicated next to each 
restriction enzyme. CMV, cytomegalovirus promoter; Kan/Neo, resistance to 
kanamycin/neomycin. (C) Electrophoretic separation of restriction products: 1 and 4, 1 kb 
DNA ladder (Promega); 2, uncut pEGFP-TG2; 3, pEGFP-TG2 digested with EcoRV and 
XhoI. 
 
Syndecan-4 cDNA was provided by Dr M. Bass (Manchester University, UK) at the 
EcoRI/SalI sites of the cloning vector pBluescript. The plasmid DNA was digested with 
EcoRI and SalI (as described in  2.2.10.5) to generate extremes compatible with the ones of 
the mammalian expression vector pcDNA 3.1 (+). Insert and vector were ligated as 
described in  2.2.10.8 to generate the construct pcDNAhS4 (Figure  2-2).  
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Figure  2-2 Screening of pcDNAhS4 construct by double restriction with EcoRI/XhoI. 
(A) Map of the construct, with indicated the restriction sites for EcoRI and XhoI. CMV, 
cytomegalovirus promoter; Amp, ampicillin resistance. (B) Electrophoretic separation of 
restriction products: 1, 1 kb DNA ladder (Promega); 2, uncut pcDNAhS4; 3-4-5, 
pcDNAhS4 digested with EcoRI, XhoI and EcoRI plus XhoI, respectively. 
 
2.2.11.1 Real time PCR 
In order to have a precise quantification of gene expression, cDNA samples ( 2.2.10.11) 
were analysed by real time PCR using iQ™ SYBR Green Supermix for qPCR (Biorad). 
All the reactions were prepared in triplicates in micro nuclease-free tubes.  
2× iQ™ SYBR Green Supermix 6.25 μl 
20 μM Forward primer 0.375 μl 
20 μM Reverse primer 0.375 μl 
cDNA template 1 μl 
Nuclease-free water up to 12.5 μl 
 
GAPDH was used as housekeeping gene in order to determine the relative expression of 
the genes of interest. The sequences of the primers used for real time PCR are listed in 
Table 2.1-2.                                                                                                                      
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An initial denaturation step of 3 minutes at 95°C was followed by 40 cycles of  
denaturation (94°C, 1 minute), annealing (60°, 1 minute) and elongation (72°C, 1 minute). 
For the preparation of melting curves, a ramp temperature from 58°C to 95°C was used.  
A mean cycle threshold (Ct) value was calculated for every gene of interest from the 
fluorescence data and the relative gene expression was calculated using the 2-ΔΔCT (delta-
delta Ct) method (Livak and Schmittgen, 2001); the threshold was arbitrarily determined 
for every reaction, in order to differentiate the fluorescence from the background. Ct is 
inversely proportional to the logarithmic scale of the initial quantity of template, hence a 
higher number of cycles (high Ct value) will be required to reach the threshold if the 
quantity of template is low. 
For each gene of interest, a normalized delta Ct (ΔCt) value, indicating the level of 
expression of the gene compared to the expression of GAPDH, was calculated as: 
ΔCt (normalised to GAPDH) =Ct (target gene) – Ct (GAPDH) 
From this value, delta-delta Ct (ΔΔCt) value, representing the difference of expression 
between the gene of interest and a calibrator, was calculated as: 
ΔΔCt= ΔCt- ΔCt (calibrator) 
The calibrator can be any of the target genes, and it is used as a reference to calculate the 
expression of the other genes of interest.  
For every gene of interest, the relative expression was calculated as 2-ΔΔCT.  
 
2.2.11.2 Mice genotyping 
Genomic DNA was extracted from mice for genotyping purposes before isolation of 
primary dermal fibroblasts ( 2.2.1.7). Ear biopsies were obtained from 1 month old mice 
and placed in 500 μl DNA extracting buffer (10 mM Tris HCl pH 8, 400 mM NaCl, 100 
mM EDTA, 0.6% [w/v] SDS and 0.4 mg/ml proteinase K). The samples were incubated in 
water bath at 55°C for 2 hours and then mixed by vortex to complete the solubilisation. To 
precipitate DNA, after adding 500 μl of isopropanol the samples were centrifuged at 
13,000 g for 10 minutes and the supernatant was discarded. The DNA pellet was 
resuspended in 30 μl Tris-EDTA (TE buffer), pH 8.0 and incubated at 65 °C for 15 
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2.2.12 Transglutaminase-2 binding studies to heparin/HS 
2.2.12.1 ELISA-based assay to measure TG2 binding to heparin and heparan sulfates 
2.2.12.1.1 Immobilisation of heparin and fibronectin for solid binding assay 
The ELISA-based assay was developed using BD™ heparin binding plates (BD 
Biosciences), specially treated with plasma polymerisation to immobilize a wide range of 
active and unmodified heparin and heparan sulfate (Mahoney et al., 2004). 
Low molecular weight heparin (4-6 kDa) or heparan sulfate (12 kDa) were dissolved in 
PBS at 1.2, 2.3 or 4.6 μM concentration and immobilized on heparin binding plate by 15 
hours incubation at room temperature. Fibronectin was dissolved in 50 mM Tris, pH 7.4 at 
a concentration of 5 μg/ml and immobilised on conventional microtiter plate by 15 hours 
incubation at 4°C. Plates were washed three times with PBS and incubated for 1 hour at 37 
°C with blocking solution (3% w/v BSA in PBS); after washing three times with PBS, the 
plates were ready to be used for solid binding assay. 
2.2.12.1.2 Solid binding assay 
Guinea pig liver TG2 (0-600 ng/well) was incubated on heparin/HS or FN coated-plate in 
blocking buffer containing either 2 mM EDTA or 2 mM CaCl2 for 2 hours at 37°C, in 
order to reach binding equilibrium. The plate was then washed with PBS as described 
above and incubated overnight with anti-TG2 antibody (Cub4701, Abcam; 0.2 μg/ml) of in 
blocking buffer at 4 °C. After washing with PBS, the plate was incubated with 1:5000 
dilution of goat anti mouse immunoglobulins-HRP (Sigma-Aldrich) in blocking buffer for 
2 hours at room temperature. The plate was developed by using 3,3’,5,5’ TMB liquid 
substrate system (Sigma-Aldrich; 200 μl/well) according to manufacturer’s instructions. 
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The color reaction was stopped by adding 0.5 M H2SO4 (50 μl/well) and read at 450 nm 
using a SpectraFluor 96 well plate reader. The strength of the binding was determined via 
GraphPrism software, which provided an approximate dissociation constant (Kd). The data 
were fitted to “one site specific binding model”, described by the equation Y=Bmax * X/ 
[Kd+X], where X is the concentration of the ligand, Y is the binding, Bmax is the 
maximum binding (in the same unit as Y) and Kd is expressed in the same unit as X. The 
equation is based on the consideration that at equilibrium only a small fraction of the 
ligand is bound to the substrate, so the free ligand concentration is very close to the ligand 
concentration added at the beginning. 
 
2.2.12.2 Surface Plasmon Resonance (SPR) 
SPR was performed at the “Institut de Biologie Structurale” CEA-CNRS-UJF, Grenoble, 
France, in a collaborative project with Dr. H. Lortat-Jacob, using a 3000 Biacore system. 
Size defined heparin (6 kDa), was biotinylated at its reducing end with Biotin-LC-
Hydrazide and immobilized on a Biacore sensorchip. For this purpose, two flow cells of a 
CM4 sensorchip were activated with 50 µL of 0.2 M N-ethyl-N'-(diethylaminopropyl)-
carbodiimide and 0.05 M N-hydroxysuccinimide, before injection of 50 µl of streptavidin 
(0.2 mg/ml in 10 mM acetate buffer pH 4.5). The remaining activated groups were blocked 
with 50 µl ethanolamine 1M, pH 8.5. Typically, this procedure permitted coupling of 
approximately 3500 resonance units (RU) of streptavidin. Biotinylated heparin (5 µg/ml) 
in HBS containing 0.3 M NaCl was then injected across one flow cell to obtain an 
immobilization level of 50 RU. The other one was left untreated and served as a negative 
control. For binding assays, 80 µl of purified TG2 (0-586 nM) diluted in HBS-EP buffer 
[0.01 M Hepes, pH 7.4; 0.15 M NaCl; 3 mM EDTA, 0.005 % (v/v) Surfactant P20] at 
25°C were simultaneously injected at a flow rate of 10 µl/min (kinetic mode) across the 
control and heparin surfaces, after which the formed complexes were washed with running 
buffer for 5 min. The sensorchip surface was regenerated with a 1 minute pulse of 0.025% 
(w/v) SDS followed by 5 minutes of 2 M NaCl in HBS-P buffer. Control sensorgrams were 
substracted on line from the heparin sensorgrams, and results analyzed using the Biaeval 
3.1 software. 
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2.2.12.3 Cell adhesion to heparin/HS-coated plates 
Heparin binding plates (BD Biosciences) were coated with 2.3 or 4.6 μM heparin or 1.2, 
2.3, 4.6 μM HS following manufacturer’s instructions, as described in section  2.2.12.1.1, 
then washed and blocked with 3 % (w/v) BSA in PBS for 1 hour at room temperature. 
Wild type and TG2 null mouse embryonic fibroblasts, serum-starved for 15 hours and 
allowed to adhere in serum-free medium for 1 hour at 37°C, 5% CO2 (1 × 104 cells/well). 
The medium was removed and the attached cells were washed with PBS and fixed in 3.7% 
(w/v) parafolmaldehyde in PBS for 15 minutes at room temperature. The excess fixative 
was washed away with 3 PBS washes, after that the fixed cells were permeabilized in 0.1% 
(v/v) Triton X-100 in PBS for 15 minutes at room temperature. After further washing with 
PBS, the fixed and permeabilised cells were stained with crystal violet solution (0.5% w/v 
crystal violet in 70% v/v ethanol), extensively washed with distilled water and allowed to 
air dry before microscope observation. For a precise quantification of cell adhesion, crystal 
violet stained cells were solubilised in 30% (v/v) acetic acid and the absorbance of the 
specimens was measured at 540 nm using a microplate reader (Biorad) as previously 
described (Balklava et al., 2002). 
2.2.13 Statistical analysis 
All experiments were undertaken at least three times unless specified. Data are expressed 
as means ± standard deviation (SD). Differences between data sets were determined by the 
Student’s t-test (two-tailed distribution, two-sample equal variance). When several data 
sets had to be compared to each other, One-way Anova was used to determine statistically 
significant differences. 
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Chapter 3: Outside-in role of TG2 in cell adhesion: implication of 
Sdc-4 
3.1 Introduction 
The process of cell adhesion and subsequent spreading requires specific interactions of 
cell-surface molecules with the adhesion substrate, followed by a signalling cascade which 
determines a re-organization of the cytoskeleton leading to the formation of focal 
adhesions (FA) and actin stress fibres (SF). Two main complementary signalling pathways 
originate from integrins and Sdc-4, as explained in Chapter 1, section 1.2.9.3 (Figure  3-1) 
(Bass et al., 2007; Morgan et al., 2007; Stephens et al., 2004). Cell attachment, mediated 
by integrins, involves FAK auto-phosphorylation at Tyr397, but complete activation of the 
kinase and phosphorylation of other FA components such as paxillin and vinculin is 
required for the subsequent spreading  (Wilcox-Adelman et al., 2002).  
Central to cell adhesion is the activation of FAK, occurring via phosphorylation of the 
enzyme. FAK is initially auto-phosphorylated (Tyr397) upon integrin clustering induced 
by cell-matrix contact; this process leads to the complete activation of FAK through further 
phosphorylation (Tyr 576 and Tyr 577) involving Src kinases. Activated FAK, together 
with driving the formation of FA, determines the regulation of the small GTPase RhoA, 
which, in turn, is involved in the formation of SF. FAK phosphorylation at Tyr 397 has 
been shown to be critical for the initial downregulation of RhoA at the beginning of the 
adhesion process (Ren et al., 1999), leading to efficient cell spreading. According to this, 
FAK null cell are characterised by RhoA hyper-activity (Ren et al., 2000). In the second 
phase of cell adhesion FAK contributes to RhoA activation determining full SF formation. 
Sdc-4 appears to have an important role in the full activation of FAK and cells defective in 
Sdc-4 have been shown to have impaired FAK activation and retarded cell migration 
(Gentile et al., 1992; Saoncella et al., 1999). Sdc-4-mediated activation of FAK occurs 
through the activation of PKCα which, in turn, activates Src kinases responsible for FAK 
phosphorylation (Simons and Horowitz, 2001). 
TG2 has been shown to have different roles in cell adhesion. Firstly, it can modify ECM 
components via its crosslinking activity thus enhancing the adhesive potential of the 
matrix; secondly, thanks to the GTP-binding potential, it can contribute to the signalling 
events involved in cytoskeleton re-organisation (Gentile et al., 1992; Stephens et al., 2004). 
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In particular, intracellular GTP-bound TG2 is suggested to be involved in the regulation of 
signal transduction pathway leading to the activation of PLP-Cδ1, which, in turn, regulates 
the activity of PKC, involved in FAK activation cascade (Nakaoka et al., 1994). 
Extracellular TG2, in complex with FN, is involved in a RGD-independent adhesion 
process which does not depend on its enzymatic activity and which complements integrin-
mediated adhesion (Stephens et al., 2004). This process relies on the presence of cell 
surface HS, and is impaired if the cells are treated with heparitinase (Verderio et al., 2003). 
Lack of TG2 determines impairment in the spreading process, in fact cells with defects in 
TG2 expression (via transfection of antisense RNA for TG2) were shown to form focal 
complexes at the base of actin filaments, but these complexes failed to mature into 
complete FA; moreover, TG2-deficient cells were shown to have an impairment in SF 
formation (Jones et al., 1997; Stephens et al., 2004). These TG2-related defects seem to be 
related to an impairment of FAK phosphorylation/activation. Indeed, even though TG2-
deficient cells had values of FAK-P (Y397) similar to control cells, they had significantly 
lower levels of FAK-P(Y576), implicated in FA and SF formation (Stephens et al., 2004). 
 
 
Figure  3-1 Signalling events leading to FA and SF formation upon cell adhesion to 
FN.  
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Given the signalling role of cytosolic TG2 and the role of TG2 associated to FN in RGD-
independent cell adhesion, which relies on cell surface HSPG (Verderio et al., 2003), it is 
possible that TG2 may be involved in FAK activation in the initial stages of cell adhesion 
in a co-operative way with the HSPG receptor Sdc-4.  
The aims of this chapter were (1) to investigate the specific role of extracellular TG2 in the 
cell adhesion process ad FAK activation and (2) to test the hypothesis that Sdc-4 may be 
involved in TG2-mediated RGD-independent cell adhesion. Primary embryonic fibroblasts 
with and without deletion of the gene codifying for TG2 were the chosen model for the 
investigation of the role of matrix TG2 in cell adhesion. Primary dermal fibroblasts with 
and without targeted deletion of Sdc-4 gene were utilised to test the involvement of Sdc-4 
in TG2-mediated RGD-independent cell adhesion. 
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3.2 Results 
3.2.1 TG2 localisation in primary fibroblasts 
Transglutaminase-2 localization was investigated in the early stages of cell adhesion on 
FN, in order to understand whether TG2 externalisation is an early event and hence it can 
contribute to initial cell adhesion/spreading on FN. Indirect immunofluorescent staining 
was performed in embryonic fibroblasts (MEF) from wild type mice, using MEF 
originated from TG2 null mice (De Laurenzi and Melino, 2001) as a negative control.  
 
 
Figure  3-2 Localization of TG2 in primary fibroblasts adhering on FN. Wild type 
(TG2+/+) and TG2 null (TG2-/-) MEF were allowed to adhere on FN-coated slides in 
medium containing serum for 20, 40 and 60 minutes (min). After fixing and permeabilising 
the cells, TG2 was detected by monoclonal anti-TG2 antibody Cub7402 (1:100) followed 
by FITC-labelled secondary antibody (1:100); nuclei were stained with propidium iodide. 
Images were acquired by confocal microscopy. The arrows point at dense areas of TG2 
localisation at the basal cell surface. The bar indicates 20 μm.  
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Cells were allowed to adhere on FN-coated slides in complete medium containing serum 
for 20, 40 and 60 minutes, then fixed, permeabilised and stained for TG2 (Figure  3-2). As 
shown in Figure  3-2, an increasing level of TG2 was detected at the periphery of wild type 
cells starting from the early stage of 20 minutes adhesion (arrows). At 40 minutes after 
seeding, TG2 appeared to be concentrated in punctuate structures at the cell periphery of 
TG2 +/+ fibroblasts, resembling cell-matrix adhesion points; this distribution was 
maintained at 60 minutes adhesion, with an intensification of the signal (pointed by 
arrows). TG2 also appeared to be localised intracellularly in wild type MEF, with a marked 
staining in the perinuclear area. A perinuclear staining was detected in TG2 -/- cells at 20, 
40 and 60 minutes adhesion; this staining could be non specific and/or due to another 
member of the TG family expressed in TG2 -/- MEF. 
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Figure  3-3 Extracellular TG activity in primary fibroblasts. Wild type (TG2 +/+) and 
TG2 null (TG2 -/-) MEF were allowed to adhere to FN for 20, 60 and 120 minutes in 
serum-free medium supplemented with biotinylated cadaverine. 2mM CaCl2 and 5 mM 
DTT were added to the culture medium to activate the TG-mediated incorporation of the 
amine substrate into DOC-insoluble FN matrix. n=3; ** indicates p<0.01.  
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The externalisation of TG2 at early stages of cell adhesion was also monitored by 
measuring its transamidation activity in fibroblasts adhering on FN-coated microplates 
(biotin-cadaverine incorporation into DOC insoluble FN matrix), an ELISA-type assay 
developed by (Jones et al., 1997). This assay, which is performed on whole cells in culture, 
measures the activity of externalised transglutaminases only; in addition, it is thought to be 
specific for the activity of TG2 (Verderio et al., 1998). However, TG2 null cells were used 
as a negative control to confirm the specificity of the assay for TG2. In agreement with the 
TG2 staining (Figure  3-2), in TG2 +/+ cells it was possible to detect extracellular TG 
activity starting from 20 minutes cell adhesion (Figure  3-3); the measured activity reached 
a maximum level at 60 minutes adhesion and then remained constant, as shown by the 
measurement at 120 minutes. The residual activity found in TG2 -/- cells, was significantly 
lower compared to that of TG2 +/+ cells at all the time points (p<0.01). By examining the 
expression of all the members of the TG family in wild type and TG2 -/- cells by RT-PCR, 
it was found that TG2 is the only member of the family expressed in wild type MEF. 
However, TG -/- MEF express TG1 (Figure  3-4); this is likely to be a compensatory event 
which may be responsible for the residual TG activity and was observed before by De 
Laurenzi and Melino (2001). 
 
 
 
Figure  3-4 RT-PCR-based study of TG family members in MEF.  cDNA preparation 
from wild type (TG2 +/+) and TG2 null (TG2 -/-) MEF were analysed for the presence of 
various member of the TG family. GAPDH amplification was used as a control for the 
cDNA quality. The primers used are listed in Table 2-2. Mk, 100 bp DNA ladder. 
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The distribution of TG2 in primary fibroblasts was also monitored by Western blotting. 
Crude membrane extracts and cytosolic fractions were prepared from TG2 +/+ and TG2 -/- 
MEF and analysed for the presence of TG2. The membrane fraction of wild type cells 
showed a 77 kDa immunoreactive band corresponding to the molecular weight of TG2 
(Figure  3-5, arrowheads) and, as expected, no immunoreactivity was detected in the crude 
membrane extracts of TG2 -/- cells (Figure  3-5). The cytosolic fraction of wild type cells 
showed the 77 kDa TG2 band (Figure  3-5, arrowhead) but, in addition to that, two lower 
molecular weight bands (approximately 67 kDa and 55 kDa) (Figure  3-5, arrows). The 
lower bands were also present in the cytosolic fraction of TG2 -/- cells, suggesting lack of 
specificity. Densitometric analysis showed that approximately 47% of the detected TG2 
was located in the membrane fraction and 53% in the cytosolic fraction of TG2 +/+ cells. 
 
 
 
Figure  3-5 TG2 distribution in MEF. TG2 was detected by Western blotting in 
membrane and cytosolic fractions from wild type (TG2 +/+) and TG2 null (TG2 -/-) MEF; 
25 μg proteins were loaded. TG2 was detected by polyclonal anti TG2 antibody ab10445 
followed by secondary antibody HRP-conjugated. MR indicates gpTG2 standard, 100 ng. 
Arrowhead, 77 kDa TG2; arrows, additional immunoreactive bands at 67 and 55 kDa.  
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3.2.2 Role of TG2 in the early stages of cell adhesion 
The early externalisation of TG2 during fibroblasts adhesion supports the idea of a specific 
role for matrix TG2 in FA and actin SF formation, opening events in the cell 
adhesion/spreading process. To investigate the role of externalised TG2, the formation of 
FA and actin SF was monitored in TG2 +/+ and TG2 -/- cells adhering on FN, and rescue 
experiments with either TG2 cDNA or extracellular TG2 were carried out. 
 
 
Figure  3-6 Lack of TG2 impairs vinculin FA formation. Staining of vinculin-containing 
FA in fixed and permeabilised wild type (TG2 +/+) and TG2 null (-/-) MEF after 45 
minutes adhesion on FN coated slides in serum-free medium. The cells were serum starved 
(0.1 % serum) for 16 hours before the experiment. Vinculin was detected with monoclonal 
anti human-vinculin antibody followed by incubation with secondary antibody conjugated 
with Red X Rhodamine. Images were acquired by fluorescent confocal microscopy. Three 
random fields per cell type are shown. The bar indicates 20 μm.  
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As shown in Figure  3-6, after 45 minutes of adhesion on FN wild type cells formed sharp 
vinculin-containing FA, distributed in defined sites at the cell surface; on the contrary, 
TG2 -/- cells showed diffused vinculin staining. The staining of actin SF via FITC-labelled 
phalloidin, which binds filamentous actin, revealed a dense network of mature actin fibres 
crossing the cell body of TG2 +/+ cells (Figure  3-7). Cells lacking TG2 failed to form a 
complete actin cytoskeleton, but they formed thin actin fibres which did not appear to end 
at FA as in wild type cells (Figure  3-7). These findings indicate that lack of TG2 leads to a 
disruption in SF formation. 
 
 
Figure  3-7 Lack of TG2 impairs actin SF formation. Staining of actin SF in wild type 
(TG2 +/+) and TG2 -/- MEF after 45 minutes adhesion on FN coated slides in serum-free 
medium. The cells were serum starved (0.1 % serum) for 16 hours before the experiment. 
Actin stress fibres were detected by incubating fixed and permeabilised cells with FITC-
labelled phalloidin. Images were acquired and presented as described in Figure  3-6. The 
bar indicates 20 μm.  
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Add-back experiments were carried out to confirm the role of TG2. TG2 cDNA was 
amplified by PCR from pSG5TG (Gentile et al. 463-74) using proof-reading DNA 
polymerase and EcoRI modified primers. The cDNA was cloned into the mammalian 
expression vector pEGFP-N1 in frame with the sequence codifying for the fluorescent 
protein EGFP (construct pEGFP-TG2, Figure 2-1). To verify the expression of EGFP-
tagged TG2 (where EGFP is localised at the C-terminal of TG2) and to make sure that the 
TG2 codified by pEGFP-TG2 plasmid was not altered by the conjugated EGFP, TG2 -/- 
fibroblasts were transfected with pEGFP-TG2 and the cell extracts were analysed by 
Western blotting with anti-TG2 antibody. The transfection was performed by 
electroporation using Nucleofector System (Amaxa), which in the system analysed gives a 
typical efficiency of ~80%. As shown in Figure  3-8.A, transfected cells expressed a level 
of TG2 comparable to cells transfected with the control plasmid pSG5-TG2 (shown in 
Appendix 2), which encodes for untagged TG2.  The molecular weight of the EGFP-TG2 
band (~ 100 kDa) was, as expected, higher than the one of TG2 (77 kDa), given the 
additional mass of EGFP (28 kDa). The negative control homogenate prepared from non 
transfected (NT) TG2 -/- cells, did not show a band (Figure  3-8. A). The same cell extracts 
were also analysed for TG2-dependent transamidation using a plate assay based on Jones 
et al. (1997). TG2 -/- cells transfected with pEGFP-TG2 showed an activity level 
comparable to the one of pSG5-TG2 transfected cells. Both extracts exhibited a 
significantly higher (p<0.001) transamidation level compared to non transfected cells 
Figure  3-8 B). These data indicate that the biochemical properties of TG2 were not 
changed by the conjugated protein EGFP. Therefore TG2 -/- MEF were transfected with 
the pEGFP-TG2 construct and the successfully transfected cells were identified by the 
EGFP fluorescence concomitant with TG2 expression. Re-introduction of TG2 via 
electroporation rescued to a large extent the formation of vinculin-containing FA in TG2 -
/- cells adhering on FN (Figure  3-9, arrows), confirming that lack of TG2 was responsible 
for the defects in FA formation.  
To investigate whether the externalised TG2 was responsible for the correct formation of 
vinculin-containing FA specifically, exogenous TG2 was provided to TG2 -/- fibroblasts 
by seeding them onto a matrix of TG2 immobilised on FN (TG2-FN) (Verderio et al. 
42604-14). As shown in Figure  3-10, TG2 -/- MEF seeded onto TG2-FN matrix displayed 
vinculin containing FA similarly to TG2 +/+ MEF adhering on FN, as pointed by the white 
arrows. TG2-/- MEF also formed better defined SF when seeded on TG2-FN compared to 
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Figure  3-8 Biochemical characterisation of pEGFP-TG2 construct. TG2 null MEF 
were transfected with pEGFP-TG2 or pSG5-TG2 plasmid (positive control); non 
transfected (NT) cells were used as negative control. Cell lysates (50 μg) were analysed by 
Western blotting with monoclonal anti TG2 antibody Cub7402 followed by HRP-
conjugated secondary antibody (A) or tested for transamidating activity (TG activity) 
(measured as Abs 450 nm) (B). The arrowhead points to 77 kDa TG2; the arrow points to 
TG2 fused to EGFP. *** indicates p<0.001. (C) Standard curve for TG activity measured 
on purified gplTG2, measured as absorbance at 450 nm.   
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Figure  3-9 Vinculin-containing FA formation is rescued by re-expression of TG2 cDNA. TG2 null cells (TG2 -/-) were transfected 
with the pEGFP-TG2 construct. After 48 hours, cells were allowed to adhere on FN coated slides for 45 minutes in serum-free medium. 
Untransfected wild type and TG2 -/- cells were also similarly seeded on FN as positive and negative controls. Transfected cells were 
identified by the expression of EGFP conjugated to TG2. Vinculin staining was performed as in Figure  3-6. The arrows point at restored 
FA. The bar indicates 20 μm. 
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Figure  3-10 FA formation of TG2 -/- MEF is rescued by extracellular TG2. TG2 null cells (TG2 -/-) were allowed to adhere for 45 
minutes on FN or TG2-FN coated slides for 45 minutes in serum-free medium. The cells were serum starved (0.1 % serum) for 16 hours 
before the experiment. Wild type cells adhering on FN are shown as positive control. Vinculin and actin SF were detected as in Figure  3-6 
and Figure  3-7, respectively. The arrows point at vinculin-containing FA; the arrow heads at SF ending at FA. The bar indicates 20 μm.  
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3.2.3 Matrix-Transglutaminase-2 has an RGD-independent role in FAK activation 
Next, the role of TG2 in focal adhesion kinase (FAK) activation was investigated, by 
measuring FAK phosphorylation at Tyr 397 (Y397) -the first residue to be phosphorylated 
upon extracellular ligand binding (Mitra et al., 2005)- in wild type and TG2 -/- MEF. FAK 
activation was measured at 45 minutes cell adhesion on FN in serum-free medium. Cells 
were serum-starved for 15 hours before the experiment, in order to exclude serum-induced 
effects on cell adhesion.  
 
 
Figure  3-11 Lack of TG2 impairs early FAK phosphorylation. Wild type (TG2 +/+) 
and TG2 null (TG2 -/-) MEF were serum starved for 15 hours and left to adhere on FN-
coated plates for 45 minutes in serum-free medium. The level of phosphorylated FAK in 
the cell extracts (50 μg) was determined by Western blotting using an anti phosphor-FAK 
(Y397) antibody followed by HRP-conjugated secondary antibody. For normalisation of 
the data, blots were stripped and re-probed with anti total FAK and anti β-tubulin 
antibodies. Three separate experiments were performed and a typical blot is shown. The 
mean values of FAK phosphorylation relative to total FAK are shown, normalised 
considering TG2 +/+ values as 1. * indicates p<0.05.  
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Following cell adhesion, cell homogenates were prepared and analysed by Western 
blotting using an antibody against phosphorylated FAK (Y397). In order to confirm equal 
loading, the membrane were stripped and re-probed with antibodies against total FAK and 
β-tubulin. A small but significantly lower level of FAK phosphorylation (-25%; p<0.05), 
calculated by densitometric analysis as ratio between P-FAK and the total FAK protein 
(125 kDa), was revealed in TG2 -/- MEF compared to TG2 +/+ MEF (Figure  3-11). This 
finding suggests that lack of TG2 impairs initial FAK signalling. 
FN-associated TG2 has been shown to support RGD-independent FAK-phosphorylation 
(Verderio et al., 2003). To determine if extracellular FN-bound TG2 was sufficient to 
restore FAK phosphorylation in TG2 -/- fibroblasts, TG2 -/- MEF were allowed to adhere 
on either FN or TG2-FN prior to analysis of FAK phosphorylation by Western blotting. 
BSA-coated wells were used as a negative control. As shown in Figure  3-12 A, the 
adhesion of TG2 null MEF on TG2-FN enhanced the level of FAK phosphorylation         
(+ 25%; p<0.05) compared to FN matrix.  
To investigate whether FAK phosphorylation driven by FN-bound TG2 was RGD-
independent, TG2 null MEF were allowed to adhere on TG2-FN in the presence of soluble 
RGD peptide, at a concentration which competes with integrin receptors for binding to the 
RGD cell-binding domain of FN (Verderio et al., 2003). Inactive RAD peptide was utilised 
as a negative control. As shown in Figure  3-12 B, in TG2 -/- MEF adhering on FN, FAK-P 
(Y397) level was further reduced in the presence of RGD peptide compared to RAD 
peptide (150 μg/ml). However, if TG2 null MEF were allowed to adhere on TG2-FN the 
phosphorylation level of FAK was significantly increased (p<0.01) in the presence of RGD 
pepide (Figure  3-12 B), confirming that matrix TG2 mediates RGD-independent FAK 
activation. As a negative control for the effect of TG2, cells were allowed to adhere on FN 
with a stoichiometric amount of BSA; unlike TG2-FN, BSA-FN did not reconstitute RGD-
independent FAK phosphorylation in TG2 -/- MEF (Figure  3-13).  
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Figure  3-12 Adhesion to FN-bound TG2 promotes FAK phosphorylation (Y397) in 
TG2 -/- MEF in a RGD-independent way. TG2 null (TG2 -/-) fibroblasts were serum 
starved for 15 hours and let to adhere on BSA, FN or TG2-FN coated plates for 45 minutes 
in serum-free medium (A); in selected experiments adhesion was performed in the presence 
of 150 μg/ml RGD peptide or control RAD peptide (B). Cell extracts were analysed by 
Western blotting as described in Figure  3-11; since a single cell line was used, β-tubulin 
was used for normalisation. Three separate experiments were performed and one typical 
blot is shown. The mean values of FAK phosphorylation in three experiments, relative to β-
tubulin, are displayed; * indicates p<0.05, ** indicates p<0.01. 
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Figure  3-13 Adhesion to FN-bound BSA does not induce RGD-independent FAK 
phosphorylation (Y397). TG2 null (TG2 -/-) fibroblasts were serum starved for 15 hours 
and let to adhere to either FN or BSA-FN coated plates for 45 minutes in serum-free 
medium, in the presence or absence of 150 μg/ml RAD or RGD peptide. Cell extracts were 
analysed by Western blotting as indicated in Figure  3-11; β-tubulin was used as a control 
for equal loading.  
 
3.2.4 Importance of Sdc-4 in RGD-independent FAK phosphorylation induced by 
matrix TG2 
The presence of cell-surface heparan sulphate (HS) chains, such as the ones of heparan 
sulphate proteoglycan (HSPG), has been shown to be essential in the RGD-independent 
cell-adhesion process mediated by matrix TG2 (Verderio et al., 2003). Therefore, after 
demonstrating the role of matrix TG2 in RGD-independent FAK activation, the hypothesis 
of the involvement of HSPG Sdc-4 in outside-in signalling induced by matrix TG2 was 
tested. To this aim, primary dermal fibroblasts were isolated from mice lacking Sdc-4 
(MDF Sdc-4 -/-) (Ishiguro et al., 2000) as described in Chapter 2 (2.2.1.7). Control Sdc-4 
+/+ MDF were isolated from wild type C57BL/6 mice. Firstly, the ability of Sdc-4 null 
MDF to support TG2-mediated RGD-independent cell adhesion was investigated. Wild 
type and Sdc-4 null MDF were allowed to adhere to either FN or TG2-FN in the presence 
or absence of RGD peptide before measuring the level of FAK phosphorylation (Y397) by 
Western blotting. As shown in Figure  3-14, matrix TG2 failed to mediate RGD-
independent FAK activation in Sdc-4 -/- MDF compared to wild type MDF, suggesting the 
involvement of Sdc-4 in the mechanism. Interestingly, a small but significant reduction of 
FAK-P was associated with Sdc-4 deletion at 45 minutes cell adhesion.  
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Figure  3-14 Co-operation of Sdc-4 and TG2 in RGD-independent FAK 
phosphorylation. Wild type (Sdc-4 +/+) and Sdc-4 -/- fibroblasts were serum starved for 
15 hours and let to adhere on FN or TG2-FN coated plates for 45 minutes in serum-free 
medium; in selected experiments adhesion was performed in the presence of 150 μg/ml 
RGD peptide. Cell extracts were analysed by Western blotting as indicated in Figure  3-11; 
FAK phosphorylation is expressed as ratio between P-FAK (Y397) and total FAK. β-
tubulin was used as a control for protein equal loading. n=3; * indicates p<0.05, ** 
indicates p<0.01. 
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In order to investigate the specificity of action of Sdc-4 in extracellular TG2-mediated 
adhesion, a construct expressing human Sdc-4 (pcDNAhS4) was created by cloning human 
Sdc-4 cDNA (hS4) into the mammalian expression vector pcDNA 3.1. Preparation of the 
construct is described in the Material and Methods section, paragraph 2.2.11. The vector 
was used to add back Sdc-4 to Sdc-4 -/- cells by cell electroporation. As illustrated in 
Figure  3-15, RT-PCR of human Sdc-4 (hS4) showed that Sdc-4 -/- cells transfected with 
pcDNAhS4 expressed human Sdc-4 at 48 hours from cell transfection. The negative 
controls, represented by both non transfected (NT) Sdc-4 -/- MDF and Sdc-4 -/- MDF 
transfected with pcDNA, did not show expression of any Sdc-4. As expected, wild type 
MDF showed expression of endogenous murine Sdc-4 (mS4) instead of hS4.  
 
 
Figure  3-15 Controls on the expression of pcDNAhS4 vector in Sdc-4 -/- cells. RNA 
was extracted from wild type (Sdc-4 +/+) and Sdc-4 -/- cells (untransfected and 
transfected with pcDNAhS4 or pcDNA) and analysed for the presence of mouse and human 
Sdc-4 (mS4 and hS4) by RT-PCR. GAPDH expression was used as a positive control. Mk, 
molecular weight markers (100 bp DNA ladder). Primers’ sequences are shown in Table 
2-2. 
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At this stage, Sdc-4 null MDF with added back Sdc-4 were tested for RGD-independent 
FAK-phosphorylation mediated by TG2. As shown in Figure  3-16, the re-introduction of 
Sdc-4 via pcDNAhS4 largely restored RGD-independent FAK activation induced by cell 
adhesion to TG2-FN, which was lost in Sdc-4 -/- MDF transfected with the empty vector. 
Sdc-4 null cells transfected with the vector only (pcDNA) showed the same profile of FAK 
phosphorylation previously observed in non transfected Sdc-4 -/- cells (Figure  3-14). This 
result confirms that Sdc-4 is implicated in TG2-mediated outside-in signalling leading to 
FAK phosphorylation (Y397) in a RGD-independent way. 
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Figure  3-16 Add-back of Sdc-4 rescues TG2-mediated RGD-independent FAK 
phosphorylation in Sdc-4 -/- MDF. Sdc-4 -/- fibroblasts were transfected with either 
pcDNAhS4 or pcDNA. After 48 hours, cells were serum starved for 15 hours and let to 
adhere on FN or TG2-FN coated plates for 45 minutes in serum-free medium; in selected 
experiments adhesion was performed in the presence of 150 μg/ml RGD peptide. Cell 
extracts were analysed as indicated for FAK-P(Y397) by Western blotting as indicated in 
Figure  3-11; FAK phosphorylation was expressed as ratio between P-FAK and β-tubulin. 
n=3; ** indicates p<0.01. 
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It was noted that the rescue of Sdc-4 (pcDNAhS4) in Sdc-4 -/- MDF did not increase the 
level of FAK-P on FN compared to cells transfected with pcDNA vector (Figure  3-16). 
This suggests that the decrease in FAK-P observed in Sdc-4 null cells (Figure  3-14) may 
not be due to the lack of Sdc-4. Alternatively, the added back Sdc-4 could not be enough to 
re-stimulate FAK-P.  
The involvement of Sdc-4 in RGD-independent adhesion was also investigated by 
monitoring actin SF formation. Staining with FITC-phalloidin revealed that the absence of 
Sdc-4 does not inhibit SF formation, even though Sdc-4 -/- cells displayed thinner SF 
compared to wild type cells when adhering on FN (Figure  3-17). The actin cytoskeleton of 
both wild type and Sdc-4 null cells was disrupted when the cells were allowed to adhere on 
FN in the presence of RGD peptide, and it was not possible to identify correctly formed 
SF. When wild type MDF were plated on FN-bound TG2 in the presence of RGD peptide 
they still formed SF which were morphologically similar to those formed on FN in the 
absence of RGD peptide (Figure  3-17). This finding agrees with previous data showing 
that matrix TG2 supports RGD-independent SF formation (Verderio et al., 2003). 
However, Sdc-4 null MDF failed to form actin SF when plated on TG2-FN in the presence 
of RGD peptide, suggesting the important role of Sdc-4 in TG2-mediated RGD-
independent cell adhesion. 
Examination of SF formation in Sdc-4 -/- cells transfected with pcDNAhS4 revealed that 
the re-introduction of Sdc-4 can restore actin SF formation in Sdc-4 -/- fibroblasts adhering 
on TG2-FN in the presence of RGD peptide, as shown by the white arrows in Figure  3-18 
A. The specificity of Sdc-4 effect was demonstrated by the absence of RGD-independent 
SF formation in Sdc-4 -/- cells transfected with pcDNA vector only (Figure  3-18 A). The 
level of SF formation was also quantified in non transfected (NT) Sdc-4 -/- cells and Sdc-4 
-/- cells transfected with either pcDNAhS4 or pcDNA demonstrating that re-introduction 
of Sdc-4 significantly increased (p<0.01) SF formation in RGD-independent cell adhesion 
on TG2-FN (Figure  3-18 B). As previously shown in the selection of pictures presented in 
Figure  3-17 and Figure  3-18 A, the transfection with pcDNA vector did not affect the 
formation of SF in Sdc-4 null cells and (Figure  3-18 B). These results indicate that it was 
the specific re-introduction of Sdc-4 that drove the RGD-independent formation of SF 
when cells were plated on TG2-bound FN, since SF were not formed in untransfected Sdc-
4 null MDF or in Sdc-4 null MDF transfected with pcDNA vector (Figure  3-18 B).  
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Figure  3-17 Co-operative role of Sdc-4 and TG2 in SF formation during RGD-
independent cell adhesion. Wild type (Sdc-4 +/+) and Sdc-4 -/- cells were plated on FN 
or TG2-FN in the presence or absence of RGD peptide (150 μg/ml). Cells were allowed to 
adhere for 45 minutes in serum-free medium. Actin SF were detected as described for 
Figure  3-6. The bar indicates 20 μm. 
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Figure  3-18 Re-introduction of Sdc-4 in Sdc-4 -/- MDF restores TG2-mediated RGD-
independent SF formation. A) Sdc-4 -/- cells transfected with pcDNAhS4 or pcDNA only 
were seeded on FN or TG2-FN in the presence or absence of RGD peptide (150 μg/ml). 
Cells were allowed to adhere for 45 minutes in serum-free medium. Actin SF were detected 
as described for Figure  3-6. The white arrows point at the restored SF in Sdc-4 -/- cells 
after re-introduction of Sdc-4. The bar indicates 20 μm. B) SF formation was quantified in 
three separate experiments by image analysis (three non-ovrlapping fields per 
experiment). Mean % of cells with SF (± SD) is plotted. ** indicates p<0.01. 
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3.3 Discussion 
In this study the role of extracellular TG2 in the early stages of cell adhesion on FN was 
analysed for the first time using a cell system of primary fibroblasts derived from wild type 
and TG2 null mice (De Laurenzi and Melino, 2001). The availability of embryonic 
fibroblasts isolated from mice where TG2 was disrupted by homologous recombination 
(De Laurenzi and Melino, 2001) provided a useful control for both the specificity of TG2 
detection and for studying the role of TG2 in cell adhesion.  
The first set of experiments addressed the issue of whether TG2 was externalised and how 
early in the cell adhesion process. Extracellular TG2 was detected by both 
immunocytochemistry and measurement of cell-surface TG activity; both experiments 
were performed in a time course fashion, analysing TG2 externalisation at 20, 40 and 60 
minutes cell-adhesion on FN-coated plates. In agreement with a possible role for TG2 in 
early cell adhesion, it was possible to detect TG2 antigen starting from 20 minutes of 
adhesion to FN. TG2 was mainly localised in cell-matrix adhesion structures at the cell 
periphery. TG2 was also detected in the cytosol, concentrated in the perinuclear area; the 
diffused cytosolic signal was absent in TG2 -/- cells, however the perinuclear staining was 
also present in TG2 null cells, suggesting its non specificity. The results obtained by 
immunocytochemistry were confirmed by measurement of cell-surface TG activity by 
incorporation of biotinylated cadaverine onto FN. Transamidating activity was detectable 
starting from 20 minutes adhesion, and it reached a plateau at 40 minutes adhesion, 
supporting the idea of a role for TG in the early stages of cell adhesion. In order to 
determine which part of the cell-surface transamidation activity measured was attributable 
to TG2, a study of expression of the different members of the TG family was performed on 
wild type and TG2 null primary fibroblasts. The study revealed that TG2 is the member 
with the highest expression level in primary fibroblasts; the only other member expressed 
is TG1, which is localised intracellularly (Mehta, 2005; Zhang et al., 2009), but its level is 
significantly lower. However, in TG2 -/- cells the level of TG1 was found to be 
significantly increased (possibly for compensatory effect). This finding was previously 
described  by (De Laurenzi and Melino, 2001), who also did not report a parallel increase 
in transamidation activity. The conclusion is that the activity measured in the considered 
cell system is mainly due to TG2.  
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TG2 has been mainly described as a cytosolic enzyme (Fesus and Piacentini, 2002), and 
this was often seen in disagreement with TG2 externalisation and involvement in cell 
adhesion. The analysis of TG2 distribution by Western blotting presented in this study has 
revealed that in our cell system the enzyme has a comparable level in the cytosol and in the 
cell membrane, together with being externalised and localised at cell-matrix adhesions. To 
my knowledge, this is the first study showing TG2 distribution in primary fibroblasts. TG2 
concentration at the cell surface and in the cell membrane, at matrix adhesion sites, is 
consistent with its role in cell-matrix interactions. 
In the present study, the formation of FA and SF during cell adhesion on FN has been 
monitored in the presence and absence of TG2. Lack of TG2 inhibited the formation of 
correct FA and SF compared to wild type cells, as previously shown in cells with inhibited 
TG2 expression via antisense RNA (Jones et al., 1997; Stephens et al., 2004). TG2 was re-
introduced in TG2 null cells by either transfecting them with a pEGFP-TG2 construct or by 
seeding TG2 null cells on a TG2-FN matrix. The enhanced TG2 level largely rescued the 
formation of FA and stress fibers in both cases, confirming the essential role of 
extracellular TG2 in the early adhesion process. 
Previously, FN-bound TG2 has been shown to contribute to RGD-independent cell 
adhesion on FN, leading to RGD-independent formation of SF (Verderio et al., 2003). 
TG2-FN has also been shown to promote RGD-independent FAK phosphorylation (Y397) 
in human osteoblasts (Verderio et al., 2003). Having identified a specific role for 
extracellular TG2 in early cell adhesion, the outside-in signalling events induced by TG2 
were also investigated. The first outcome was that the absence of TG2 causes a decreased 
level of FAK-P at Tyr 397, which is likely to be responsible for altered FA and SF 
formation, since extracellular TG2 compensated both the defects in FAK-P and that of FA 
formation. Although increased expression of TG2 has been linked to FAK phosphorylation 
(Akimov and Belkin, 2003), FAK-P (Y397) was previously shown to be unaltered in 
fibroblasts where TG2 was silenced by antisense RNA (Stephens et al., 2004), even though 
these cells presented alterations in FA and SF formation. The differences in FAK-P (Y397) 
measured in the present study results from the analysis of primary cell lines of fibroblasts, 
contrary to previous experiments where TG2 effects on cell adhesion were measured on 
immortalised clones of fibroblasts were TG2 expression was altered by stable cell 
transfection with TG2 antisense RNA (Stephens et al., 2004). Thus, the results presented 
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here are more indicative of the possible role of TG2 in physiological systems of adhering 
fibroblasts.  
In this study, it was confirmed that TG2-mediated FAK phosphorylation is RGD-
independent. This finding suggests a role for externalised TG2 in situations of cell stress or 
wound healing, when FN matrix is fragmented (Davis et al., 2000) and the ordinary cell 
adhesion mechanism mediated by integrin binding to FN is not sufficient to sustain full cell 
adhesion/spreading (Jeong et al., 2001). A previous study performed in human osteoblasts 
has shown that the role of TG2 in mediating RGD-independent cell adhesion relies on the 
presence of cell surface HS, as the process is inhibited by pre-treating cells with 
heparitinase (Verderio et al., 2003). Cell surface HSPG mainly consist of glypicans and 
syndecans, each of the families containing members with specific tissue and development-
related expression. In the current study, Sdc-4 was chosen as a candidate HSPG-receptor 
for mediating the RGD-independent extracellular TG2 role since, contrary to the other 
syndecans, it is a widespread component of FA and it has an active role in mediating the 
cell spreading events (Echtermeyer et al., 1999). The role of Sdc-4 was investigated by 
studying TG2-induced SF formation and FAK phosphorylation in primary dermal 
fibroblasts isolated from wild type and Sdc-4 null mice (Ishiguro et al., 2000). It emerged 
that the presence of Sdc-4 is essential for TG2-mediated events in RGD-independent cell 
adhesion, and the essential role of Sdc-4 was confirmed by rescue experiments performed 
by transfecting Sdc-4 null cells with pcDNAhS4. Interestingly, Sdc-4 deletion did not 
result into a significant reduction in SF formation. This is in agreement with previous 
reports where it was shown that Sdc-4 null cells can form FA on FN (Bass et al., 2007; 
Ishiguro et al., 2000) and only when the heparin-binding fragment of FN is missing from 
the cell surface, then Sdc-4 deletion affects cell spreading (Ishiguro et al., 2000).  
Since both TG2 and Sdc-4 have been involved in cell spreading events, it was important to 
clarify whether the action of TG2 and Sdc-4 is synergistic or simply additive. Since no 
increase in RGD-independent cell spreading (Figure  3-18), SF assembly (Figure  3-17) and 
FAK-P (Figure  3-14) was observed in Sdc-4 null cells plated on TG2-FN matrix compared 
to FN, these findings suggest that the effect of TG2 is not simply additive to that of Sdc-4 
but synergistic (both molecules are required to mediate RGD-independent cell adhesion). 
The results of this study have identified Sdc-4 as a possible receptor in RGD-independent 
cell adhesion mediated by TG2, a process which is likely to occur in situations of 
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Chapter 4: Investigation on TG2 binding to Sdc-4 
4.1 Introduction 
4.1.1 Interactions of proteins with Heparin/HS 
Given the structure of heparin/HS (general introduction, paragraph 1.2), strong ionic 
interactions can take place between basic side chains of protein bound Arg, Lys and His 
and negatively charged sulphate groups (Fromm et al., 1997). There are also other types of 
interactions taking place between heparin/HS and partner molecules: van der Waals forces, 
hydrogen bonds and hydrophobic interactions with the carbohydrate backbone (Gandhi and 
Mancera, 2008). Affinity of protein-heparin binding can be enhanced by polar amino acids 
which provide minimal steric constraints and good flexibility, thus facilitating the 
interaction with GAG chains (Caldwell et al., 1996). 
X-Ray crystallography studies have provided several information on heparin-binding, such 
as protein fold, periodicity of basic amino acids and sulphate clusters, and sulphation level 
required for protein-GAG interaction (Hileman et al., 1998). These studies have also 
permitted the identification of amino acids consensus sequences involved in heparin-
binding. From comparison of several heparin-binding sites, it has emerged that the typical 
sequences XBBXBX, XBBBXXBX or XBBBXXBBBXXBBX (where B is Lys or Arg 
and X is a “hydropathic residue”, most commonly Asn, Ser, Ala, Gly, Ileu, Leu and Tyr) 
are involved in heparin/HS-binding (Cardin and Weintraub, 1989; Sobel et al., 1992). 
Examples of heparin-binding domains and corresponding predicted secondary structures 
have been reviewed by Hileman et al. (1998) and are shown in Figure  4-1. These binding 
sites can also be formed by residues which are distant in the amino acid sequence, but are 
brought in spatial proximity by the protein folding, and the binding usually involves a 
portion of 6-12 monosaccharides in the GAG chain. The distribution of sulphated groups in 
GAG chains can determine the structure of GAG-binding sites on the protein surface by 
neutralising inhibitory charge repulsion of residues present in a specific spatial 
arrangement (Sibille et al., 2006). The relative proportion of N- and O-sulphated groups in 
heparin and HS, together with the presence of N-linked acetyl groups, can also influence 
the interaction with proteins (Kuschert et al., 1999). 
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Figure  4-1 Heparin binding proteins with predicted secondary structure. Heparin 
binding regions and predicted secondary structure of different proteins are shown 
(Hileman et al., 1998). 
4.1.2 TG2 affinity for heparin 
TG2 has been known to have a certain affinity for heparin for a long time; in fact Signorini 
et al. (1988) have developed a method for the purification of TG2 from human 
erythrocytes involving heparin-Sepharose affinity chromatography as the last step. 
Interestingly, amino acid analysis of TG2 from human erythrocytes has shown that the 
enzyme has a lower proportion of basic amino acids compared to TG2 from guinea pig 
liver (Signorini et al., 1988), thus suggesting that the latter enzyme, which is used in the 
present investigation, could present higher affinity for negatively charged heparin and HS. 
More recently Gambetti et al. (2005) described that binding of TG2 to heparin does not 
affect TG2 accessibility to substrates of transamidation reaction, but it protects the enzyme 
from thermal unfolding and proteolytic degradation, enhancing the potential cross-linking 
activity of the enzyme. However, the binding affinity of TG2 for heparin and the kinetics 
of the interaction have never been addressed. As illustrated in Figure  4-1, ECM 
glycoproteins as fibronectin, vitronectin and laminin, known to be TG2 substrates 
(Nardacci et al., 2003; Sane et al., 1988) are heparin binding proteins (Hileman et al., 
1998). Sane and colleagues (1990) have demonstrated that TG2-mediated transamidation 
activity on vitronectin can be increased by the presence of highly sulphated GAG chains, 
suggesting that heparin could enhance TG2 accessibility to its substrates either by 
immobilising it on the cell surface or by increasing the concentration of available 
substrates in particular spatial disposition. 
The aim of this chapter was to measure for the first time the affinity of TG2 for heparin 
and HS employing in vitro systems and cells in culture. 
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4.2  Results 
4.2.1 Affinity of TG2 for heparin/HS 
The first step to test the interaction of TG2 with GAG chains was the development of an 
ELISA-based solid binding assay aimed to study the affinity of TG2 for heparin/HS. For 
this study, heparin-binding microtiter plates previously developed by (Mahoney et al., 
2004) were utilised. Since the ELISA detection of TG2 bound to heparin was conducted as 
previously described for the detection of TG2 bound to FN (Verderio et al., 2003), control 
binding studies were firstly performed on either immobilised FN or, as a control, BSA. 
TG2 was allowed to bind immobilized molecules in the presence of the Ca2+ chelator 
EDTA (2 mM) to prevent TG2 auto-transamidation, after that, bound TG2 was detected by 
ELISA using the monoclonal anti-TG2 antibody Cub7402. Under these settings, TG2 
showed a dose-dependent binding to FN (Figure  4-2). Since the binding was saturable, it 
was also possible to obtain some information on the strength of TG2 binding to FN,even 
though there was variability in estimated dissociation constant between separated 
experiments. The best fitting (R2=0.8820) of the absorbance data was obtained using the 
“one site specific binding” model of GraphPad Prism. The estimated dissociation constant 
for TG2 bound to FN was approximately 20 nM when calculated from three independent 
experiments, confirming high affinity binding. 
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Figure  4-2 TG2 binding to immobilised FN. In this controlexperiment TG2 (0-212 nM) 
was allowed to bind immobilised FN (5 µg/ml) or, as a negative control, BSA (5 µg/ml) in 
the presence of 2 mM EDTA. Binding was performed at 37°C for 2 hours. Kd for FN was 
19.47±6.92 nm. n=3.  
 
 
The same approach was then used for binding studies of TG2 to heparin and HS. Heparin, 
representative for the sulphated protein-binding regions of heparan sulphate, was initially 
used as a model for the HS chains of Sdc-4, given the structural similarity and the ready 
availability. As shown in Figure  4-3, TG2 displayed a saturable concentration-dependent 
binding to low molecular weight heparin (4-6 kDa); as for the binding to FN, the best 
fitting was obtained applying a one site specific binding model (R2=0.9785). The estimated 
affinity of TG2 for heparin was in the low nM range, with a Kd of approximately 20 nM 
(23.20±1.84 nM) estimated from three independent experiments, similar to the value 
obtained for FN-binding. 
Since the binding of TG2 to HS chains in physiological conditions occurs in presence of 
Ca2+, the ELISA was also performed in a buffer containing 2 mM Ca2+ (Figure  4-3); under 
this condition, the binding was still saturable and fitted with a model of one site specific 
binding (R2= 0.9722). However, the affinity of TG2 for heparin in the presence of Ca2+ 
(approximate Kd = 40 nM estimated from three independent experiments) resulted slightly 
lower than the one measured in the presence of EDTA. It has to be considered that this Kd 
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is an estimated value and, although lower than the value measured for the binding in the 
presence of EDTA, it is still in the low nM range. In order to see whether it was the Ca2+-
bound conformation of TG2, as opposed to the GTP-bound conformation, to be responsible 
for the lower affinity for heparin, the experiment was also conducted in the presence of 
GTPγS, a non hydrolysable form of GTP. Even in this condition the affinity of TG2 for 
heparin was slightly lower than when measured in the presence of EDTA only, with a Kd 
of approximately 40 nM  (39.75±11.63 nM) estimated fromthree independent experiments 
(Figure  4-3). In this case the fitting with the one site specific binding model was not as 
good as for the other conditions (R2= 0.86). This finding, however, suggests that the lower 
Kd measured with Ca2+ compared to that measured with EDTA does not depend on the 
Ca2+-induced conformation of TG2.  
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Figure  4-3 TG2 binding to heparin. TG2 (0-212 nM) was allowed to bind immobilised 
heparin (4.6 µM) or, as a negative control, BSA (5 µg/ml) in the presence of either 2 mM 
EDTA, 2 mM Ca2+, or 2 mM EDTA plus 150 μM GTPγS at 37°C for 2 hours. Kd values 
were 23.20±1.84 nM, 40.33±3.75 nM and 39.75±11.63 nM, respectively. n=3.  
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Since the decreased TG2 binding to heparin in the presence of Ca2+ could also be due to 
the formation of Ca2+-dependent TG2 oligomers via TG2 auto-crosslinking activity, the 
binding reaction was monitored at the end of the 2 hours incubation time by analyzing the 
reagents through Western blotting using anti-TG2 antibody. As shown in Figure  4-4 
(arrowheads), the presence of Ca2+ was accompanied by the formation of TG2 oligomers 
generated by auto-crosslinking activity of the enzyme. The presence of TG2 oligomers was 
absent in the control (TG2 not incubated at 37°C) and it was significantly lower in TG2 
incubated in the presence of either EDTA or EDTA plus GTPγS. However, the formation 
of TG2 oligomers did not seem to reduce the amount of free monomeric TG2 in a 
considerable way (Figure  4-4, arrow) suggesting that it may not significantly affect TG2 
binding to heparin.. 
 
 
 
Figure  4-4 Western blot analysis of TG2-heparin binding reaction. The TG2-heparin 
binding reaction was performed in a test tube in identical conditions to the solid binding 
assay (Figure  4-3). After the 2 hours incubation at 37°C, the reagents were analysed by 
Western blotting using monoclonal anti-TG2 antibody TG100.  Secondary antibody was 
goat anti mouse-HRP. The arrow indicates the TG2 monomer (77-80 kDa) and the arrow 
heads indicate TG2 oligomers (approximately 155, and 310 kDa). 
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The decreased binding in the presence of Ca2+ could also be a consequence of an 
interaction of positively charged ions with heparin. For this reason, TG2-heparin binding 
was also studied in the presence of ions of similar properties such as Mg2+ and K+. As 
illustrated in Figure  4-5, by performing the assay in the presence of either 2 mM Ca2+, 2 
mM Mg2+ or 4 mM K+, the Kd values were, respectively, 40.33±3.70 nM, 43.05±5.96 nM 
and 54.85±7.57 nM; the best fitting model for all the conditions was the one site specific 
binding (R2 values were 0.9722, 0.9563 and 0.9762, respectively). Since the Kd were not 
significantly different, these results indicated that the decreased TG2-heparin affinity 
recorded in the presence of Ca2+ compared to EDTA could be a consequence of ionic 
interference in TG2 binding to heparin rather than Ca2+-dependent conformational change 
of the enzyme or Ca2+-induced oligomerisation. 
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Figure  4-5 Interference of positively charged ions on TG2-binding to immobilised 
heparin. TG2 (0-212 nM) was allowed to bind immobilised heparin (4.6 μM) or, as a 
negative control, BSA (5 µg/ml), in the presence of either 2 mM EDTA, 2 mM Ca2+, 2 mM 
Mg2+ or 4 mM K+. Binding was performed at 37°C for 2 hours. n=3. Kd values for Mg2+ 
and K+ were 43.05±5.96 nM and 54.85±7.57 nM, respectively. TG2 binding in the 
presence of EDTA and Ca2+ is the same previously shown in Figure  4-3, with Kd values of 
23.20±1.84 nM and 40.33±3.75 nM, respectively.  
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Since the GAG chains of HSPG are mainly HS, and heparin is a highly sulphated form of 
HS, the ELISA-based assay was repeated in the same way using equimolar concentrations 
of purified HS. Figure  4-6 shows that TG2 displayed a dose-dependent binding to HS (4.6 
µM), as previously recorded using heparin. Analogously to the TG2 binding studies to 
heparin, the best fit of the TG2 binding curve to HS was obtained using a one site specific 
binding model (R2= 0.9394), and the binding was saturable. The calculated Kd was 
19.47±2.76 nM, indicating high affinity of TG2 for HS. 
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Figure  4-6 Binding of TG2 to HS. TG2 (0-212 nM) was allowed to bind immobilised HS 
(4.6 µM) or, as a negative control, BSA (5 µg/ml) in the presence of 2 mM EDTA for 2 
hours at 37°C as shown in Figure  4-3. Kd for HS was 17.03±2.76 nM. n=3.  
 
 
After showing that TG2 binds either heparin or HS with similar high affinity, the 
interaction of TG2 with heparin was further investigated in real time by using surface 
plasmon resonance (SPR). For this study heparin was immobilised on a Biacore 
sensorchip, thus mimicking the cell surface presentation of HSPG, and TG2 was perfused 
above this surface in a buffer containing 2 mM EDTA. Injection of a range of TG2 
concentrations (51-586 nM) over a sensorchip activated with 50 RU of heparin gave rise to 
the binding curves shown in Figure  4-7. The data were fitted with the Langmuir 1:1 model, 
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which explains the simplest way an analyte (A) (TG2) can interact with an immobilised 
ligand (B), in our case heparin (A+B ? AB).  
The fitting of the data with the Langmuir model returned a χ2 value (which describes the 
closeness of the fit) of 4.5; fitting the data with other binding models did not improve the 
closeness (data not shown). Following data fitting, it was possible to calculate: 
koff (rate of dissociation) = 4.95 × 10-4 s-1 and 
kon (rate of association) = 5.5 × 103 M-1 s-1 
leading to an average Kd (Koff/Kon) of 92.7 ± 4.7 nM. 
Within the limit of the χ2 this finding confirmed a nM-range affinity of TG2 for HS, as 
shown by the solid binding assay.  
 
 
 
 
Figure  4-7 SPR analysis of TG2 affinity for heparin. TG2 (51-586 nM) was injected over 
a heparin activated surface for 8 min at a flow rate of 10 µl/min, after which running 
buffer was injected, and the response in RU was recorded as a function of time. 
Sensorgrams were analysed with Biaeval 3.1 software. 
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4.2.2 Cell-surface TG2 interacts with heparin and HS chains 
After establishing a strong affinity of purified gpl TG2 for heparin and heparan sulphate, 
the affinity of endogenous cell-surface TG2 for heparin/HS was explored. Since wild type 
MEF externalise TG2 starting from early stages of cell-adhesion (see Chapter 3), reaching 
a peak of externalisation after 1 hour post-seeding, they were used as a source of cell-
surface TG2. The TG2-heparin binding was investigated by monitoring the cell-attachment 
to heparin/HS of wild type MEF compared to the one of TG2 null MEF. 
As shown in Figure  4-8, cells presenting TG2 at the cell surface (TG2 +/+) had a 
significantly higher level of adhesion on both heparin and heparan sulphate compared to 
TG2 -/- cells (p<0.001). Wild type cells showed a ≈60 % level of adhesion to wells coated 
with 2.3 μM heparin and ≈100% adhesion to wells coated with 4.6 μM heparin. When the 
adhesion of wild type MEF was performed on HS-coated plates, there was ≈65% adhesion 
on 1.3 μM HS and ≈100% adhesion on both 2.3 and 4.6 μM HS. Cells lacking TG2 (TG2 -
/-) cells displayed a significantly lower adhesion level (20-30%) compared to wild type 
cells on heparin/HS, suggesting that TG2 is critical for heparin/HS binding. Both TG2 +/+ 
and TG2 -/- cells displayed a similar level of cell adhesion on control FN, although 
differences in the spreading level were noticeable, with wild type cells showing a more 
homogeneous distribution and a flatter morphology (Figure  4-8). The level of cell adhesion 
on BSA-coated plates was significantly lower for both the cell lines compared to FN, and 
was estimated to be lower than 10% compared to the positive FN control.   
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Figure  4-8 Cell adhesion studies on heparin/HS-coated plates. Wild type (TG2 +/+) and 
TG2 -/- MEF were serum-starved and allowed to adhere on plates coated with either 
heparin (2.3 or 4.6 μM) or HS (1.2, 2.3 or 4.6 μM) for 1 hour in serum-free medium. 
Plates coated with BSA or FN (5 μg/ml) were used as negative and positive control, 
respectively. Adherent cells were quantified and normalised considering cell adhesion of 
TG2 +/+ cells on FN as 100%. The bar indicates 20 μm. n=3. *** indicates p<0.001.  
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4.2.3 Direct co-association of TG2 and HS chains of Sdc-4 at the cell surface 
After establishing the association of TG2 to GAG chains through affinity measurements, 
the biological significance of this binding was investigated by co-immunoprecipitation 
studies of TG2 and Sdc-4. Sdc-4 was chosen among the others HSPG given its significant 
role in TG2-mediated RGD-independent cell adhesion, as shown in Chapter 3. Given the 
transmembrane localization of Sdc-4, co-immunoprecipitation experiments were 
performed on crude membrane preparations. It was decided to undertake the co-
immunoprecipitation experiments using a cell line particularly rich in both HSPG and 
TG2; for this reason human osteoblasts (HOB) (Scotchford et al., 1998) were chosen, since 
they are rich in HSPG (Gronthos et al., 1997) and express cell-surface TG2 (Heath et al., 
2001; Verderio et al., 2001). Moreover, stably transfected HOB over-expressing human 
TG2 (HOB-TG14) (Verderio et al., 2001) were available for the study.  
As a preliminary study, the expression of Sdc-4 was tested in membrane extracts from 
HOB cells by Western blotting. In order to distinguish the glycosylated forms from the 
core protein of Sdc-4, untreated extracts were compared to heparitinase-treated extracts. 
Heparitinase catalyses the cleavage of α-N-acetyl-D-glucosaminide linkage (either 6-
sulphated or non-sulphated) in heparan sulphate, reducing or eliminating the glycosylation 
level of the Sdc-4 core protein. Western blotting analysis revealed a strong band at ~200 
kDa and other high molecular weight bands in the untreated sample (Figure  4-9, asterisk); 
these bands were markedly reduced after heparitinase treatment, indicating their 
glycosylated nature. Heparitinase treatment also resulted in the intensification of the band 
at ~44 kDa, which should correspond to Sdc-4 core protein SDS-insoluble homodimer 
(Echtermeyer et al., 1999; Longley et al., 1999) (Figure  4-9, arrow). 
Next, membrane extracts obtained from HOB and HOB-TG14 cells were 
immunoprecipitated with anti-Sdc-4 antibody and analysed by Western blotting for the 
presence of TG2. As shown in Figure  4-10 A (arrow head), a band of 77 kDa, 
corresponding to TG2 was detected in both HOB and HOB-TG14 Sdc-4-
immunoprecipitates (S4), which was not detected in the negative controls, represented by 
immunoprecipitation with beads only (B) and with anti gliadin antibody (Gl); this finding 
suggests association of TG2 with Sdc-4.  
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The above described immunoprecipitates were also examined for the presence of Sdc-4, to 
test the efficiency and the specificity of the immunoprecipitation process. As shown in 
Figure  4-10 B, Sdc-4 immunoprecipitates displayed high molecular weight bands 
corresponding to the glycosylated core protein of Sdc-4 (in particular a band of ~200 kDa, 
indicated by the asterisk) together with a large band of 35-45 kDa which may include Sdc-
4 core protein homodimer and other glycosylated Sdc-4 isoforms. The band of 50-55 kDa, 
detected in both immunoprecipitates with anti-gliadin and anti-Sdc-4 antibody corresponds 
to the heavy chain (Hc) of the rabbit antibody used for the immunoprecipitation, reacting 
with anti-rabbit IgG secondary antibody (Figure  4-10 B, Hc).  
To verify the association of TG2 and Sdc-4, membrane extracts from HOB and HOB-
TG14 were also immunoprecipitated with anti-TG2 antibody and analysed by Western 
blotting for the presence of Sdc-4. As shown in Figure  4-11 A (left panel), both 
glycosylated Sdc-4 (asterisk) and other lower Mr Sdc-4 oligomers were detected in the 
TG2-immunoprecipitates. The Sdc-4 band profile in TG2 immunoprecipitates was 
analogue to the one detected in membrane protein extracts from HOB cells (Figure  4-9). 
To verify the identity of the bands detected by the anti Sdc-4 antibody, the TG2-
immunoprecipitates were treated with heparitinase before Western blotting (Figure  4-11 A, 
right panel). Treatment of TG2-immunoprecipitates with heparitinase determined the loss 
of high molecular weight bands and the intensification of the band corresponding to Sdc-4 
core protein homodimer (Figure  4-11 A, right panel, arrow). This time the antibody heavy 
chain was not detectable, since the antibody used for immunoprecipitation was a mouse 
monoclonal and the secondary antibody used for the Western blotting was an anti-rabbit 
IgG from mouse. Control Western blotting for TG2 revealed that TG2 was correctly 
immunoprecipitated in both HOB and HOB-TG14 extracts (Figure  4-11 B, arrow head). 
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Figure  4-9 Sdc-4 detection in total membrane extract from HOB. 30 μg of untreated or 
heparitinase (Hep)-treated membrane protein extract from HOB were separated by 
reducing SDS-PAGE (10% polyacrylamide gel) and analysed by Western blotting.. Sdc-4 
was detected by anti-Sdc-4 antibody followed by secondary antibody, HRP-conjugated. 
The arrow points at Sdc-4 core protein dimers (~44 kDa). The asterisk indicates the 
predominant band of glycosylated Sdc-4 (~200 kDa). Positions of molecular weight 
markers are shown on the right hand side of the blot. 
 
 
 
 
 
 
 
Formatted: Font: Symbol
Deleted: (Zymed) 
Chapter 4:  Investigation on TG2 binding to S4 
 
 113
 
Figure  4-10 TG2 detection in Sdc-4 immunoprecipitates from HOB and HOB-TG14. 
Membrane preparations (500 µg) from HOB and HOB over-expressing human TG2 (HOB-
TG14) were immunoprecipitated with anti-Sdc-4 antibody [S4] (2µg) and after that the  
immunoprecipitates were subjected to Western blot analysis for TG2 (A) and, as a control, 
for Sdc-4 (B). Control immunoprecipitations were performed with beads only [B] and anti 
gliadin antibody [Gl] (2 μg). Hc represents the heavy chain of the antibody used for 
immunoprecipitation. * , glycosylated Sdc-4 (~200 kDa); arrow head, TG2 (~77 kDa). 
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Figure  4-11 Sdc-4 detection in TG2 immunoprecipitates from HOB and HOB-TG14. 
Membrane preparations (500 µg) from HOB and HOB overexpressing human TG2 (HOB-
TG14) were immunoprecipitated with anti-TG2 antibody (2µg) and after that the  
immunoprecipitates were subjected to Western blot analysis for Sdc-4 (A) and, as a 
control, for TG2 (B) before and after heparitinase (Hep) treatment. * , glycosylated Sdc-4 
(~200 kDa); arrow, Sdc-4 core protein dimer (~44 kDa); arrow head, TG2 (~77 kDa). 
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To investigate whether TG2-Sdc-4 association was also present in the fibroblast cell type, a 
Swiss 3T3 cell line (clone TG3) with tetracyline-regulated inducible expression of TG2 
was used (Verderio et al., 1998). A band corresponding to TG2 (~77 kDa) was present in 
the Sdc-4-immunoprecipitates (S4) from TG3 Swiss 3T3 cells + tet (expressing 
endogenous level of TG2), which intensified in the Sdc-4 immunoprecipitates from cells 
overexpressing TG2 (TG3 Swiss 3T3 – tet) (Figure  4-12). A faint TG2 band could also be 
detected in the control immunoprecipitation performed by incubating the protein 
preparation with protein G agarose only, indicating aspecific binding to protein G agarose 
beads. However, the intensity of aspecific binding was much lower compared to the 
intensity of TG2 bands in Sdc-4 immunoprecipitates. 
  
 
 
 
Figure  4-12 TG2 detection in Sdc-4 immunoprecipitates from Swiss 3T3 cells with 
inducible expression of TG2. Membrane preparations (500 µg) from  Swiss 3T3 cells 
control (+tet) or with induced TG2 expression (-tet) were immunoprecipitated with anti 
Sdc-4 antibody (S4) (2 µg) or with protein G agarose beads (-) and analysed by Western 
blotting with anti TG2 antibody. The band corresponding to TG2 is indicated by the arrow 
head. 
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The experiments described in section  4.2.1 demonstrated the binding affinity of TG2 for 
heparin and heparan sulphate. To investigate if TG2 associates with Sdc-4 via binding of 
Sdc-4 HS chains, the cell suspensions of HOB and Swiss 3T3 cellswere incubated with 
protease-free heparitinase (to selectively clear HS chains) prior to immunoprecipitation of 
Sdc-4 using an antibody directed against the core protein.  
 
 
 
Figure  4-13 Immunoprecipitation of TG2 and Sdc-4 largely relies on Sdc-4 HS chains 
(1). Membrane extracts prepared from HOB and HOB overexpressing human TG2 (HOB-
TG14) were digested or not with heparitinase (Hep) (30 mU/ml) to remove HS chains. The 
membrane preparations (500 µg) were then immunoprecipitated with anti Sdc-4 antibody 
(S4) (2 µg) and analysed by Western blotting against TG2. Three independent experiments 
and their densitometric analysis are shown (data are expressed as the mean ± SD); data 
were normalised considering HOB-TG14 value without Hep as 1. gpTG2 (200 ng) was 
used as a control and for normalisation of data. * indicates p<0.05; ** indicates p<0.002. 
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The removal of HS significantly reduced the amount of TG2 associated with Sdc-4 in both 
HOB and HOB-TG14 cells (Figure  4-13) and Swiss 3T3 cells by a 40-50% value (Figure 
 4-14). This range is in agreement with the effect of heparitinase treatment on HOB cells, 
that, if measured by flow cytometry, shows a digestion level of HS chains of ~ 50% 
(previous work by E. Verderio, Nottingham Trent University).  
These results give information on the way TG2 interacts with Sdc-4, which largely occurs 
through the HS chains of Sdc-4. 
 
 
 
Figure  4-14 Immunoprecipitation of TG2 and Sdc-4 largely relies on Sdc-4 HS chains 
(2). Membrane extracts were prepared from Swiss 3T3 cells control (+tet) digested or not 
with heparitinase (Hep) (30 mU/ml). Membrane preparations (500 µg) were 
immunoprecipitated with anti Sdc-4 antibody (S4) (2 µg) and analysed by Western blotting 
against TG2. Densitometric analysis of two independent experiments is shown; data are 
normalised considering sample –Hep equal to 1. ** indicates p<0.002 
Deleted: n
Chapter 4: Characterization of Transglutaminase-2 binding to Sdc-4 
 118
4.2.4 Binding of TG2 to Sdc-4 is not mediated by fibronectin 
Fibronectin is known to interact with HS chains of Sdc-4 through its high affinity Hep II 
binding domain (Woods et al., 2000); since FN has also elevated affinity for TG2, it was 
important to demonstrate that the binding of TG2 to the HS chains of Sdc-4 at the cell 
surface  was direct and not mediated by FN. For this purpose TG2 binding to FN was 
inhibited by using a peptide (P3 peptide, Hang et al., 2005) which mimics FN binding site 
within TG2, and thus binds FN in competition with TG2 (Figure  4-15). 
 
 
 
 
 
Figure  4-15 Scheme of triangular association of TG2, Sdc-4 and FN. The triangular 
association of the three molecules is shown, together with the inhibitory action of P3 
peptide (Hang et al., 2005), which interferes with TG2 binding to FN by mimicking FN 
binding region of TG2. 
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In order to confirm the inhibitory action of P3 peptide on TG2 binding to FN, a plate assay 
was performed, measuring the binding of TG2 to FN in the presence of increasing 
concentrations (0-150 μM) of P3 peptide (Figure  4-16). The FN-binding of TG2 at both 20 
nM and 50 nM was significantly reduced if 100 µM P3 peptide was present; this result 
validated the use of 100 µM P3 peptide in subsequent immunoprecipitation experiments to 
interfere with TG2-FN association. 
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Figure  4-16 Inhibition of TG2 binding to FN using P3 peptide. Inhibition of TG2-FN 
binding, assayed by ELISA using 20 nM and 50 nM purified gpTG2 allowed to bind FN-
coated microtiter plates (5 µg/ml) for 1 hour  in the presence of increasing concentrations 
of P3 peptide (0-150 µM). Data (mean absorbance values ± SD from three independent 
experiments) have been normalised considering the binding of 50 nM TG2 to FN in the 
absence of P3 peptide equal to 1. 
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At this stage HOB cells were plated on a FN matrix pre-incubated with P3 peptide (100 
µM) in order to saturate the TG2 binding sites on FN; after one hour, both adherent and not 
adherent cells were collected and membrane preparations were subjected to 
immunoprecipitation with anti Sdc-4 antibody followed by Western blotting against TG2 
and FN (Figure  4-17). The pre-incubation of FN with P3 peptide did not reduce the amount 
of TG2 co-immunoprecipitated with Sdc-4 (Figure  4-17, top panel), suggesting that the 
binding is direct and not mediated by FN. As a control, FN was also detected in the Sdc-4 
immunoprecipitates, showing that the amount of FN associated with Sdc-4 was not 
reduced by the action of P3 peptide (Figure  4-17, bottom panel) (densitometric values for 
FN with and without P3 peptide were 1.2±0.2 and 1.0±0.1, respectively; p=0.32).  
 
 
 
Figure  4-17 Immunoprecipitation of TG2 and Sdc-4 in the presence of competitive 
concentrations of P3 peptide. HOB cells were let to adhere on FN matrices pre-incubated 
(+) or not (-) with P3 peptide (Hang et al., 2005) (100 µM) before preparation of 
membrane extracts. Membrane preparations (500 µg) were immunoprecipitated with anti-
Sdc-4 antibody (S4) (2 µg) and analysed by Western blotting against TG2 and FN. The 
arrow heads point at TG2 (top panel) and FN (bottom panel). 
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4.2.5 Visualisation of TG2-Sdc-4 association by fluorescence microscopy 
Association of TG2 with Sdc-4 was further investigated by using indirect double 
fluorescent labelling of HOB allowed to adhere for 2 hours on tissue culture plastic in 
serum-containing medium. A combination of secondary antibody conjugated to different 
fluorescent dyes was chosen in order to avoid overlapping emission signals, and to make 
sure that any co-staining of TG2 and Sdc-4 was effectively due to co-localisation of the 
two molecules. To this purpose, the primary antibodies mouse anti-TG2 and rabbit anti-
Sdc-4 were revealed by sheep anti mouse IgG FITC and donkey anti rabbit IgG 
AlexaFluor568, respectively. As shown in Figure  4-18, the two molecules appeared to co-
localise, in particular at the cell borders and in correspondence of cell-cell contacts, as 
pointed by the arrows. 
 
 
Figure  4-18 Co-localisation of TG2 and Sdc-4 in HOB. Fixed and permeabilised HOB 
were stained with anti-TG2 and anti-Sdc-4 antibodies and revealed with anti mouse-FITC 
and anti rabbit-AlexaFluor 568 secondary antibodies, respectively. Images were acquired 
by laser confocal microscopy and represent sections of the cellular basal surface. Two 
different fields are shown. The arrows point at areas of co-localisation. The bar indicates 
20 μm.  
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4.3 Discussion 
After showing the involvement of Sdc-4 in TG2 mediated RGD-independent adhesion 
(Chapter 3), in the present chapter the investigation was focused on the physical interaction 
between TG2 and Sdc-4. Solid binding assays were developed to measure for the first time 
the affinity of purified TG2 for heparin and HS. A strong binding affinity was measured, 
with a Kd of ≈20 nM. Considering that so far FN has been considered the main 
extracellular binding partner for TG2, this value is surprisingly high if compared to the 
measured affinity of TG2 to the 42 kDa gelatin binding domain of FN, which was 
estimated as 8-10 nM (Jeong et al., 1995; Radek et al., 1993) and, more recently, using 
SPR, as 180 nM (Hang et al., 2005). Since the estimated affinity of TG2 for HS measured 
in this thesis is similar to the measured affinity of TG2 for FN, the results shown in this 
thesis show that FN may not been the only extracellular high-affinity binding partner for 
TG2, expecially in cell systems with a high expression of HSPG. 
It was of interest that the estimated affinity of TG2 for heparin and HS was slightly lower 
in the presence of physiological extracellular concentration of Ca2+ compared to EDTA, 
even though both affinities were in the low nM range.   Given that TG2 is catalytically 
active outside the cell and Ca2+ changes TG2 conformation (Li et al., 2002), TG2 auto-
crosslinking was considered at first as an interfering factor on heparin-binding. Western 
blot analysis in reducing conditions showed that even though a certain amount of TG2 is 
present in oligomeric form in the presence of Ca2+, the majority of the enzyme is still in 
monomeric form, so auto-crosslinking can not be the cause of the reduced binding to 
heparin in the presence of Ca2+. The presence of Ca2+ is not supposed to interfere with 
heparin and HS binding to the plates used for the assay (Mahoney et al., 2004), but, given 
its positive charge, Ca2+ could interfere with negatively charged heparin and HS, thus 
potentially lowering the binding of TG2 (Rudd et al., 2007). Solid binding assays were also 
performed in the presence of positive ions with similar properties to Ca2+. The apparent 
affinity of TG2 for heparin was not significantly different in the presence of either Ca2+, 
Mg2+ or K+. This suggests that the slightly lower binding recorded in the presence of Ca2+ 
compared to EDTA was not due to a change in conformation of the enzyme, but more 
likely to altered heparin accessibility (Rudd et al., 2007).  
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A lower apparent binding affinity of TG2 to heparin was also measured in the presence of 
GTPγS (150 μM); however, there is no documented evidence of GTP/GDP interaction 
with heparin/HS. Therefore, it can not be excluded that a lower binding of TG2 to 
heparin/HS in the presence of GTPγS could be the consequence of the GTP-induced 
conformation of the enzyme (Lorand and Graham, 2003; Smethurst and Griffin, 1996), 
which may have a lower affinity for heparin/HS. 
The estimated affinity of TG2 for HS obtained with solid binding assay was confirmed by 
monitoring TG2 binding to heparin with SPR. Here the binding was measured in real time 
and not at equilibrium, after 2 hours of TG2 interaction with heparin, as in the solid-
binding assay. The estimated Kd in this case was ≈ 90 nM, a value of similar rage to what 
obtained with solid binding, although suggesting a slightlylower affinity. It has to be 
mentioned that the χ2 value obtained for this analysis (indicating the goodness of the 
fitting) was 4.5, a value higher than the limit normally considered for a meaningful fitting 
(χ2= 2). Therefore the SPR result can be regarded as indicative of a high affinity but with 
some limitations due to the complexity of the system.  
At least one of the heparin-binding motif described by Cardin and Weintraub (1989), 
XBBXB (see  4.1.1) can be found in human TG2 (position 261-265), and appears to be 
accessible on the enzyme surface (personal communication by Lortat-Jacob, Institut De 
Biologie Structurale, Grenoble). Interestingly this domain is not only conserved in TG2 
from different species (rat, mouse, human, guinea pig) (Figure  4-19) but it is also specific 
for TG2, since it is not present in TG1, TG3, TG5, TG6, TG7 and FXIIIa so it may be a 
good candidate for the specific interaction of TG2 with HSPG (Verderio et al., 2008). 
Next, to find out if cell-surface TG2 as opposite to purified TG2 could interact with 
immobilized heparin/HS, and thus support the physiological relevance of the binding, the 
adhesion of wild type MEF to heparin/HS was compared to that of TG2 null MEF. As 
shown in Chapter 3, wild type MEF display cell-surface TG2. The study revealed that the 
presence of cell surface TG2 is essential for the interaction of primary fibroblasts with 
heparin/HS. Interestingly, the absence of cell surface TG2 did not alter cell adhesion to 
immobilized FN, in accordance with the fact that TG2 inhibition via antisense RNA affects 
cell spreading but not cell attachment on FN (Stephens et al., 2004). 
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Figure  4-19 Putative heparin-binding site conserved in TG2 from different species 
(Verderio et al., 2008). Multiple sequence alignment (ClustalW) of rat, mouse, human and 
guinea pig liver TG2, showing a conserved putative heparin-binding site based on the 
motif XBBXB, where X is an hydropathic amino acid and B is either Arg (R) or Lys (K). 
N=fully conserved; N= non conserved; N=conserved; N=similar. 
 
Co-immunoprecipitation studies performed on cell membrane preparations from different 
cell lines (osteoblasts and fibroblasts) revealed that TG2 and Sdc-4 are physically 
associated at the cell surface, and that this association is largely mediated by HS chains of 
Sdc-4, since it was significantly reduced by heparitinase cleavage of HS chains. The 
physical association was confirmed by dual labeling, revealing an overlapping signal for 
TG2 and Sdc-4 in correspondence of cell-cell contacts and at the cell surface. The TG2-
Sdc-4 association resulted to be direct and not mediated by the mutual interaction of TG2 
and Sdc-4 with the high affinity partner FN, since the level of TG2 co-precipitated with 
Sdc-4 was not altered by a previously characterized peptide that inhibits the binding of FN 
to the N-terminal β-sandwich domain of TG2 (Hang et al., 2005).  
A recent study has shown that the extracellular domain of α5β1 integrins is able to bind 
heparin/HS (Faye et al., 2009). Since TG2 has been shown to have a high affinity for this 
class of integrins (Akimov et al., 2000), the reciprocal binding of α5β1 integrins to HS 
chains could mediate the association of TG2 to heparin/HS. However, in the study by Faye 
and colleagues (2009), the interaction of integrins with heparin/HS was performed using 
purified molecules, which may interact in a different way compared to a cell system. The 
study also shows no difference in cell attachment on immobilized α5β1 integrins 
(measured by SPR) between control chinese hamster ovary (CHO) cells and CHO cells 
which do not present sulfated GAG at the cell surface (Faye et al., 2009), thus confirming 
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the hypothesis that the interaction between integrins and Sdc-4 may not occur under 
physiological conditions.  
In conclusion, this study has revealed for the first time that TG2 has high affinity for 
heparin/HS, that the association is direct and physiologically relevant.  
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Chapter 5: Role of Sdc-4 in the trafficking and cell-surface 
localization of TG2 
5.1 Introduction 
5.1.1 Insight on TG2 cell-surface trafficking 
Since TG2 is a multifunctional enzyme whose action can lead to permanent protein 
modifications, and since TG2 influences intracellular signalling, its cell-surface trafficking 
needs to be highly regulated. Several mechanisms have been proposed as regulators of cell-
surface/ECM adhesion-related TG2 functions. Belkin and colleagues have suggested a 
model of TG2 release involving proteolysis of cell-surface TG2, mediated by membrane-
anchored and soluble metalloproteases (Belkin et al., 2001; Belkin et al., 2004). Another 
model describes inside-out regulation of TG2-mediated cell-matrix adhesion by the Ras-
Raf-MEK1-ERK1 signalling pathway (Akimov and Belkin, 2003). More recently, a novel 
mechanism of TG2 regulation has been proposed, involving TG2 internalisation and 
degradation in the lysosomes (Zemskov et al., 2007). This process is mediated by the low 
density lipoprotein receptor-related protein 1 (Zemskov et al., 2007) and seems to be 
related to TG2 association to the binding partners FN and β1/β3 integrins, which are also 
internalised in an analogous way.  
The mechanism of TG2 externalisation remains tobe elucidated as numerous evidence 
justify a possible unconventional export. In fact, TG2 lacks of a hydrophobic leader 
sequence or the post-translational modifications, which would indicate processing by 
endoplasmic reticulum and Golgi apparatus leading to externalisation (Lorand and 
Graham, 2003). Interestingly, even though TG2 shows important extracellular functions, it 
presents some characteristics typical of cytosolic proteins, such as the absence of disulfide 
bridges and the lack of glycosylation (Ikura et al., 1989), thus strengthening the idea of 
non-conventional secretion. A common feature of TG2 and Factor XIIIa, both secreted 
members members of the TG family, is the modification of the N-terminal domain by 
removal of the terminal Met and acetylation of the adjacent Ala (Ikura et al., 1989; 
Takahashi et al., 1986). This modification could represent a signal for TG2 externalisation. 
So far, it has been shown that TG2 externalisation is affected by the conformation of the 
Cys-containing active site and by the N-terminal FN-binding β-sandwich domain 
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(Balklava et al., 2002; Gaudry et al., 1999). More recently,  transamidating activity was 
shown not to affect TG2 secretion, since the process was shown to occur even in the 
presence of the TG inhibitor R283 (Telci et al., 2009). Although TG2 externalisation is 
enhanced by situations of cell-stress (Lorand and Graham, 2003; Thomazy and Fesus, 
1989), this process does not seem to be a passive event following cell damage, since it 
occurs in the absence of leakage of intracellular components, when the cells are still viable 
(Skill et al., 2004).  
Work by Peng et al. (1999) has demonstrated that TG2 is also translocated in the nucleous, 
and this process is mediated  by importin α-3, a nuclear transport protein (Lorand and 
Graham, 2003). 
5.1.2 Possible role of HS in mediating the cell-surface biological action of TG2. 
Recent evidence have ascribed a role to HSPG in both membrane secretion and 
endocytosis (MacArthur et al., 2007), raising the hypothesis of the current study, that 
HSPG could influence cell trafficking of TG2 through the high affinity binding of TG2 for 
HS. 
HSPGs are specialised glycoproteins with a core protein linked to one or more HS 
glycosoaminoglycan chains, which are linear polysaccharides consisting of alternating N-
acetylated or N-sulphated glucosamine units, and uronic acids (Bishop et al. 2007). The 
assembly of HS chains on core proteins, which is catalysed by enzymes of the Golgi, leads 
to a wide structural heterogenicity (e.g. chain size and length, extent of sulphation, spatial 
distribution of negatively charged groups). Interestingly, adhesive ECM glycoproteins such 
as FN and vitronectin, and growth factors such as midkine, which all serve as substrates for 
TG2 transamidation, are also heparin-binding proteins (Table 4-1). In some cases, the 
TG2-mediated protein transamidation can be even augmented by GAGs such as heparin 
(Sane et al., 1990), suggesting that heparin could help immobilise TG2 on these target 
substrates. 
The aim of this chapter is to test the possible influence of TG2 binding to HS on its cell-
surface localisation and activity. 
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5.2 Results 
5.2.1 Role of Sdc-4 in the cell-surface localisation of TG2 in primary fibroblasts 
Given the association of TG2 and Sdc-4 at the cell surface, proven by co-
immunoprecipitation and double immunofluorescence (Chapter 4), a set of experiments 
was carried out in order to determine whether Sdc-4 was involved in TG2 extracellular 
localisation.  
In a first set of experiments, TG2 was detected by indirect immuofluorescence on fixed 
and permeabilised mouse dermal fibroblasts expressing or not Sdc-4 (Sdc-4 +/+ or Sdc-4   
-/-) adhering on FN-coated slides and visualised by confocal microscopy. As shown in 
Figure  5-1 (arrows), TG2 was found to be predominantly located in patches at the cell 
periphery of wild type cells, where contacts between cells and the ECM take place. A 
similar TG2 staining was detected in FN-adhering MEF (Chapter 3, 3.2.1). A diffused 
cytosolic signal was also present, and a marked perinuclear signal, which was, however, 
also visible in cells lacking TG2 (Chapter 3, Figure 3-1). In the absence of Sdc-4, TG2 
appeared to be mainly located in the cytosol, and its presence at the cell periphery was 
negligible (Figure  5-1). This aspect has been further investigated in Chapter 3. In order to 
gain more insights on the cellular localisation of TG2, firstly wild type and Sdc-4 -/- cells 
were further visualised by double phase contrast microscopy and ordinary confocal 
microscopy. Pictures taken at the basal cell surface confirmed that TG2 is predominantly 
located at cell-matrix adhesions in wild type cells (Figure  5-2, arrows) and that in the 
absence of Sdc-4 TG2 is mostly localised in the cytosol/perinuclear area (Figure  5-2). TG2 
was also co-stained with actin stress fibres, in order to visualise the location of TG2 in 
relation to the actin cytoskeleton. As shown in  Figure  5-3 (arrowheads), in wild type MDF 
anti-TG2 antibody stained peripheral cell structures at the basal surface, most of which 
appeared to be connected with the end of actin stress fibres; TG2 was also localised in the 
pericellular matrix, as indicated by the small arrows. As previously shown, TG2 staining 
was restricted to the perinuclear and cytosolic regions of Sdc-4 null cells ( Figure  5-3).  
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Figure  5-1 TG2 staining in wild type and Sdc-4 null MDF. Wild type (Sdc-4 +/+) and 
Sdc-4 -/- MDF were allowed to adhere for 2 hours in complete serum-containing medium.  
TG2 was detected in fixed and permeabilised cells by monoclonal anti-TG2 antibody 
Cub7402 and revealed by FITC-conjugated secondary antibody. Two representative fields 
are shown. The arrows point at TG2 at the cell periphery in Sdc-4 +/+ cells. The bar 
corresponds to 20 μm.  
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Figure  5-2 Visualisation of TG2 by dual phase contrast confocal microscopy. TG2 was 
detected in wild type (Sdc-4 +/+) and Sdc-4 -/- MDF as described in Figure  5-1. Cells 
were visualised with fluorescent confocal microscopy (left panel) and phase-contrast 
microscopy (right panel). Nuclei were stained with DAPI.  The arrows point at TG2 
localised at cell-matrix adhesions in Sdc-4 +/+ cells. The bar corresponds to 20 μm.  
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 Figure  5-3 Co-staining of TG2 and SF in wild type and Sdc-4 null MDF. TG2 and SF were detected in fixed and permeabilised Sdc-4 
+/+ and Sdc-4 -/- MDF after 2 hours adhesion in complete serum-containing medium as described in Figure  5-1. Cells were stained with 
anti-TG2 antibody Cub7402 followed by 488Alexafluor-conjugated secondary antibody. SF were detected by TRITC-conjugated 
phalloidin. Nuclei were stained with DAPI. The arrowheads point at TG2 at cell-matrix adhesions. The small arrows point at TG2 in the 
pericellular matrix. The bar corresponds to 20 μm. 
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TG2 and actin stress fibres co-staining was also performed on MDF adhering on FN-
coated slides, in order to simulate cell adhesion on a mature extracellular matrix. As shown 
in Figure 5-4, the same pattern of TG2 previously observed in cells adhering on uncoated 
slides (Figure 5-3) was produced in both wild type and Sdc-4 -/- fibroblasts. However, a 
noticeable difference could be spotted in S4 +/+ cells, where TG2 was present in diffuse 
patches at cell-matrix contacts (Figure 5-4, pointed by arrows) as if those were the sites 
from where TG2 is released into the ECM. 
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Figure  5-4 TG2 localisation in wild type and Sdc-4 null MDF adhering on FN. TG2 and stress fibres were detected in wild type (Sdc-4 
+/+) and Sdc-4 -/- MDF allowed to adhere on FN for 2 hours in complete serum-containing medium. All the stainings were performed as 
described in  Figure  5-3.  The arrows point at TG2 at cell-matrix adhesion. The bar corresponds to 20 μm. 
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The data shown so far suggest that TG2 is predominantly located at cell-matrix adhesions 
and that the absence of Sdc-4 alters the pattern of TG2 localisation. The association of TG2 
and Sdc-4 in MDF was also examined by double immunostaining, as previously done in 
osteoblasts (Chapter 4, paragraph 4.2.5). The results (Figure  5-5) showed that TG2 and 
Sdc-4 co-localise at cell-matrix adhesions, as pointed by the arrows. Only a faded Sdc-4 
signal was detected in Sdc-4 -/- cells, confirming the specificity of the antibody used for 
the staining. As previously shown in Figure  5-1 to 5-3, TG2 was absent from cell adhesion 
structures in cells lacking Sdc-4 (Figure  5-5).  
 
 
Figure  5-5 Co-staining of TG2 and Sdc-4 in MDF. The staining was performed on fixed 
and permeabilised wild Sdc-4 +/+ and Sdc-4 null -/- MDF after 2 hours adhesion in 
complete serum-containing medium. Sdc-4 was detected by rabbit anti-syndecan-4 
antibody and TG2 was detected by mouse anti-TG2 antibody Cub7402; secondary 
antibodies were goat anti rabbit IgG Alexafluor488 and goat anti mouse IgG Rhodamine 
RedX, respectively. The arrows point at cell-matrix adhesion sites where TG2 and Sdc-4 
co-localise. The bar indicates 20 μm.  
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Next, the cellular distribution of TG2 distribution in wild type MDF compared to Sdc-4 
null MDF was studied by Western blotting. Equal amounts of crude membrane (M) and 
cytosolic (C) fractions prepared from wild type and Sdc-4 -/- cells were separated by 
reducing SDS-PAGE and analysed by Western blotting for the presence of TG2. Protein 
equiloading was verified by probing blots of membrane extracts with antibody towards 
Na+/K+ATPase (a membrane marker) and the blots of cytosolic extracts with antibody 
against β-tubulin (a cytosolic marker) (Figure  5-6).  
As shown in Figure  5-6, TG2 antigen was significantly higher (p<0.05) in membrane 
fractions from wild type MDF compared to S4 -/- MDF; on the contrary, Sdc-4 -/- 
cytosolic extracts presented a significantly higher level of TG2 compared to wild type cells 
(p<0.05). There was not a significant difference in the total level of TG2 in wild type and 
Sdc-4 -/- cells when calculated as the sum of M and C (Figure  5-6).  
After studying the cellular distribution of TG2 by immunofluorescence and Western 
blotting, the distribution of TG2 activity in different cell compartments was also studied by 
measuring Ca2+-dependent transamidation (TG activity) in membrane and cytosolic cell 
extracts from wild type and Sdc-4 null dermal fibroblasts.  
 
 
 
 
Chapter 5: Effect of Sdc-4 in trafficking and cell-surface localisation of TG2 
 
 
Figure  5-6 Analysis of TG2 distribution in cell compartments of wild type and Sdc-4 
null MDF. The distribution of TG2 in crude membrane (M) and cytosol (C) of Sdc-4 +/+ 
and Sdc-4 -/- fibroblasts was analysed by Western blotting. Proteins (50 μg) were 
separated by reducing SDS-PAGE (10% polyacrylamide gel) and immunoblotted with anti-
TG2 polyclonal antibody Ab10445. The equiloading was verified on a parallel blot of 
membrane and cytosolic extracts using, respectively, anti Na+/K+ ATPase and anti β-
Tubulin (β-Tub). The arrow heads point at TG2 (77 kDa), Na+/K+ ATPase (113 kDa) and 
β-tub (55 kDa). Densitometric analysis of three independent blots is shown in the 
histogram below the blots; data were normalised considering Sdc-4 +/+ M equal to 1. * 
indicates p<0.05. There was no significant difference between the total (M+C) level of 
TG2 in Sdc-4 +/+ and Sdc-4 -/- cells (p>0.05).   
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Figure  5-7 Cellular distribution of TG activity in wild type and Sdc-4 null MDF. Sdc-
4 +/+ and Sdc-4 -/- fibroblasts were fractionated into membrane (M) and cytosolic (C) 
fractions. TG activity was measured in the cell fractions through incorporation of 
biotinylated cadaverine into FN. The histogram shows the mean values ± SD of three 
independent experiments performed in triplicate. Data (Abs 450 nm) were normalised 
considering Sdc-4 +/+ M fraction equal to 1.  * indicates p<0.05. There was no significant 
difference between the total (M+C) activity level of Sdc-4 +/+ and Sdc-4 -/- cells (p>0.05). 
 
 
In wild type cells, TG2 activity was predominantly present in the membrane fraction; on 
the contrary, Sdc-4 null cells exhibited a higher level of TG2 activity in the cytosolic 
fraction compared to the membrane fraction. Considering the total level of TG activity as 
the sum of membrane plus cytosol activity, no significant differences were measured 
between wild type and Sdc-4 null cells (p>0.05) (Figure  5-7). This finding was consistent 
with the cell distribution of TG2 detected by Western blotting (Figure  5-6). As a further 
control, the specificity for TG2 of the total TG activity assay used in this study (Balklava 
et al., 2002) was confirmed by testing cell extracts lacking TG2. The results (Figure  5-8) 
showed that the Ca2+-dependent transamidation was close to zero in TG2 null MEF and 
was significantly lower than the signal measured in wild type MEF (p<0.01), indicating 
that the TG activity is predominantly due to TG2. 
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Figure  5-8 Total TG activity measurement in wild type and TG2 null MEF. TG 
activity was measured on total cell lysates from TG2 +/+ and TG2 null (-/-) MEF. Data 
presented are the mean values (Abs 450 nm ± SD) of 3 independent experiments performed 
in triplicates. **  indicates p<0.01. 
  
 
Next, the analysis of TG2 cellular distribution was completed by examining the level of 
secreted TG2. TG2 is known to be secreted and to bind ECM components, however it is 
not easily found free in the culture medium (Balklava et al., 2002; Gaudry et al., 1999). 
Therefore, the level of extracellular TG2 was analysed by using a immunofluorescence-
based protocol designed to specifically detect matrix-bound TG2 (Verderio et al., 1998). 
TG2 was detected by incubating wild type and Sdc-4 null cells with anti-TG2 antibody 
before cell fixation, as described in the Material and Methods section; the cells were then 
fixed and the primary antibody was detected by FITC-conjugated secondary antibody. The 
resulting staining showed a much lower level of matrix TG2 in cells lacking Sdc-4 
compared to wild type (Figure  5-9). Quantitative analysis of matrix-TG2 revealed that the 
difference between wild type and Sdc-4 -/- cells was statistically significant (p<0.01), thus 
suggesting a role for Sdc-4 in TG2 externalisation. 
At this stage, a series of controls on TG2 expression was performed in order to make sure 
that the differences in TG2 expression/externalisation between wild type and Sdc-4 null 
cells were due to the presence/absence of Sdc-4 rather than to different TG2 expression in 
the two cell lines. Firstly, RNA was extracted from wild type and Sdc-4 null cells, retro-
transcribed into cDNA and analysed by real-time PCR for the expression of TG2 and 
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Figure  5-9 Matrix-TG2 distribution in wild type and Sdc-4 null cells.  Matrix TG2 was 
detected in Sdc-4 +/+ and Sdc-4 null -/- MDF by culturing them in the presence of anti-
TG2 antibody Cub7402 for 2 hours before cell fixation and incubation with FITC-
conjugated secondary antibody. Nuclei were stained with DAPI, The bar indicates 20 μm.  
The average fluorescence of 5 random fields was quantified with Leica TCSNT image 
processing and represents matrix TG2 signal per number of nuclei; data were normalised 
considering Sdc-4 +/+ matrix TG2 as 100. n=5. ** indicates p<0.01.  
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Figure  5-10 Analysis of TG2 expression in primary fibroblasts. (A) TG2 expression 
was analysed by real time PCR in extracts from Sdc-4 +/+ and Sdc-4 -/- MDF; analysis 
was performed in triplicate. Values presented in the histogram are the mean changes of 
TG2 expression versus control GAPDH expression (2-ΔΔ Ct). (B) Real-time PCR products 
were analysed by gel electrophoresis. MW, 1 kb DNA ladder. (C) Western blot analysis of 
TG2 expression in total cell extracts (30 μg) from Sdc-4 +/+ and Sdc-4 -/- MDF. TG2 was 
detected by anti TG2 antibody Ab10445. (D) TG activity was measured in total cell 
extracts from Sdc-4 +/+ and Sdc-4 -/- MDF as incorporation of biotinylated cadaverine 
into FN. The histogram shows the mean ± SD of three independent performed in triplicate; 
data were normalised considering Sdc-4 +/+ activity (Abs 450 nm) as 1.  
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5.2.2 Sdc-4 influences TG2 activity at the cell-surface. 
The biological significance of the altered TG2 distribution at the cell surface was analysed 
in terms of TG2 transamidation activity, the main TG2 activity that takes place in the 
extracellular environment. To test this, the effects caused by interference with the heparan 
sulphate (HS) chains of HS proteoglycans, in particular those of Sdc-4, were studied. Two 
different approaches were used to interfere with HS chains, the first was heparitinase 
digestion, and the second consisted in the cell-treatment with surfen (bis-2-methyl-4-
amino-quinolyl-6-carbamide), an antagonist of HS function (Schuksz et al., 2008). To test 
the consequences of lack of Sdc-4 on TG2 activity, Sdc-4 null MDF were also used. 
Measurement of extracellular TG transamidation was carried out by using a previously 
developed assay involving biotinylated-cadaverine incorporation into FN by whole cells in 
serum-free culture medium (Jones et al., 1997). The transamidation level of wild type cells 
was significantly lowered by treating the cells with heparitinase or surfen, indicating that 
an interference with cell surface HS chains is correlated with a decreased cell-surface TG2 
activity (Figure  5-11). The IC50 value for surfen-mediated cell-surface TG activity 
inhibition was calculated from the titration curve showed in Figure  5-12, and corresponded 
to 6.8 μM surfen. To rule out an effect of surfen on the transamidation potential of TG2, 
the activity of purified gpTG2 was tested in the presence of surfen (6 and 12 μM). The 
presence of surfen did not determine a significant change in TG2 transamidation compared 
to the untreated control (p>0.05) (Figure  5-13). This confirms that the effect on cell-
surface TG2 activity is due to surfen antagonism for HS chains function. 
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Figure  5-11 Cell surface HS affect extracellular TG2 activity of MDF adhering on FN. 
Cell-surface TG activity was measured in Sdc-4 +/+ and Sdc-4 -/- MDF through the 
incorporation of BTC into FN. Where indicated, cells were pre-treated with heparitinase 
(Hep, 30mU/ml), surfen (12 μM) or medium only for 1 hour at 37°C; afterwards cells were 
seeded on FN in the presence of either Hep or surfen. The histogram shows the mean 
values ± SD of 3 independent experiments performed in triplicate; data were normalised 
considering activity of untreated Sdc-4 +/+ cells as 1. **, p<0.01. 
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Figure  5-12 Titration of TG2-activity inhibition by surfen. Dose response curve of TG2 
activity in the presence of increasing concentrations of surfen (1-14 μM). Cell-surface TG 
activity of wild type MDF was measured through the incorporation of biotinylated 
cadaverine into FN.  The mean ± SD of two independent experiments performed in 
triplicate is shown; data presented are normalised considering TG activity in the absence 
of surfen as 100. The calculated IC50 was 6.8 μM.  
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Figure  5-13 Dose-response curves of TG2 in the presence of surfen. TG activity of 
purified gpTG2 (0-8.5 nM) was measured through the incorporation of biotinylated 
cadaverine into FN in the absence (control) or presence of surfen (6 or 12 μM). The data 
shown are the mean Abs 450 nm ± SD of three independent experiments performed in 
triplicate. Differences were not statistically significant (p>0.05).   
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A significantly lower level of cell-surface TG2 activity was also measured in Sdc-4 null 
cells compared to wild type (p<0.01) (Figure  5-11). However, as noticed in Figure  5-10, 
the total level of TG2 expression and activity was unchanged between the two cell lines, 
thus confirming that the differences noticed on cell-surface activity were not due to 
different enzyme levels. The treatment of wild type fibroblasts with heparitinase and surfen 
determined a lower transamidation activity compared to Sdc-4 null cells Figure  5-11. 
Moreover, interference with HS chains significantly reduced the TG activity of Sdc-4 -/- 
cells (Figure  5-11). Together, these data indicate that HS are important for the 
transamidation activity of TG2 at the cell-surface. They also show that even though Sdc-4 
appears to be the main player in determining TG2 cell-surface transamidation activity, 
other HSPG are likely to be involved in TG2 presentation at the cell-surface.  
To confirm that the observed changes in TG2 were related to the lack of Sdc-4, a series of 
add-back experiment was performed. The re-introduction of Sdc-4 in Sdc-4 null cells using 
pcDNAhS4 determined a total rescue of cell-surface TG2 transamidation (Figure  5-14), 
which, as noticed for wild type and non transfected Sdc-4 null cells, was significantly 
reduced by treating the cells with heparitinase or surfen. 
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Figure  5-14 Sdc-4 rescues the level of extracellular TG2 activity in primary 
fibroblasts. Cell-surface TG2 activity was measured in Sdc-4 -/- MDF with added back 
Sdc-4 through transfection with pcDNAhS4; TG2 activity was measured as described in 
Figure  5-11.  Wild type fibroblasts (Sdc-4 +/+) are shown as a control. The histogram 
shows the mean values ± SD of three independent experiments performed in triplicate; 
data were normalised considering activity of untreated S4 +/+ cells as 1. **, p<0.01. 
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Since the assay used to measure cell-surface transamidation activity is based on the 
incorporation of biotinylated cadaverine into FN and presupposes cell-FN contacts taking 
place, the effect of either surfen or lack of Sdc-4 on cell adhesion on FN was tested. This 
was important to determine if the decreased transamidation was really due to interference 
with TG2 presentation or simply to a reduced cell-contact with the substrate. For the 
adhesion assay, cells in suspension were incubated for 1 hour at 37°C in serum-free 
medium with or without surfen (6 or 12 μM). The cells were then seeded onto FN-coated 
plates for 2 hours as in the cell-surface TG activity protocol (Jones et al., 1997). BSA 
coated plates were used as negative control for cell adhesion. As shown in Figure  5-, the 
presence of surfen neither interfered with the level of cell-adhesion on FN, nor with the 
morphology of adhering cells. Quantitative analysis (Figure  5-, histogram) revealed that 
there was no significant difference in cell adhesion on FN between wild type and Sdc-4 
null cells (p>0.05), as well as between untreated wild type cells and cells treated with 
surfen (p>0.05), thus confirming the suitability of theTG2 assay. 
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Figure  5-15 Analysis on surfen effect on cell-adhesion on FN. Sdc-4 +/+ or Sdc-4 -/- 
MDF were incubated for 1 hour at 37°C in serum-free medium with surfen (6 or 12 μM) or 
in serum-free medium only prior to seeding on BSA or FN coated microplates (in the 
absence or presence of surfen, as indicated). After 2 hours adhesion, cells were stained 
with crystal violet and cell adhesion was quantified spectrophotometrically after dissolving 
the attached cells in acetic acid. Absorbance data were normalised considering attachment 
of Sdc-4 +/+ cells in the absence of surfen as 100. Values are the mean ± SD of three 
independent experiments.  The bar indicates 20 μm. There was not a significant difference 
in cell adhesion on FN between untreated and surfen- treated cells (p>0.05).  
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The extracellular transamidation activity of TG2 was also measured by an in situ assay 
based on the incorporation of FITC-cadaverine into endogenous cellular substrates. The 
fluorescent substrate permeates the cells, however it has been previously shown to be 
predominantly incorporated in extracellular substrates, given the high Ca2+/GTP ratio in 
the extracellular environment (Balklava et al., 2002; Verderio et al., 1998). Cells were 
incubated for 15 hours in complete serum-containing medium supplemented or not FITC-
cadaverine before being fixed and analysed by confocal microscopy. In negative controls, 
either an active-site inhibitor of TG activity (R283, 200 μM) (Balklava et al., 2002), or no 
FITC-cadaverine were added. In Figure  5-16 representative pictures of wild type and Sdc-4 
null cells incubated in the different conditions are shown; the fluorescent amine was found 
to be predominantly cross-linked in cell-matrix glutaminyl substrates and in the 
pericellular matrix of wild type fibroblasts. Quantification of the average fluorescent signal 
per cell showed that the absence of Sdc-4 determined a significantly lower level of 
extracellular TG activity compared to wild type cells (p<0.01) (Figure  5-16). The 
specificity of TG-mediated incorporation was proven by the almost total inhibition of the 
reaction by TG inhibitor R283 (Figure  5-16) (Balklava et al., 2002). The specificity of the 
in situ assay for TG2 was tested by using TG2-null MEF as shown in Figure  5-17; no 
FITC-cadaverine incorporation was detected in TG2 null cells compared to wild type cells.  
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Figure  5-16 In situ measurement of extracellular TG2 activity. In situ TG activity of 
Sdc-4 +/+ and Sdc-4 null -/- MDF was visualised by the incorporation of FITC-labelled 
cadaverine into endogenous substrates. R283 (200 μM), a specific TG inhibitor, was used 
as a control for the reaction. Nuclei were stained with propidium iodide. The bar indicates 
20 μm. The average fluorescence/cell of 5 random fields (as those shown in the image) was 
quantified with Leica TCSNT image processing; data ± SD are presented in the histogram. 
* indicates p<0.01.  
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Figure  5-17 Validation of FITC-cadaverine incorporation as TG2 activity assay for 
primary fibroblasts. In situ TG activity of TG2 +/+ and TG2 -/- MEF was visualised by 
the incorporation of FITC-labelled cadaverine into endogenous substrates. The bar 
indicates 20 μm. 
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At this stage it was important to test whether heparin and HS had a direct effect on TG 
transamidation activity to investigate whether the effect of HSPG, and in particular that of 
Sdc-4, was also due to an action on TG2 enzymatic activity. To this purpose, the enzymatic 
assay was performed on purified TG2 (0-8.5 nM) in the presence of 2.3 or 4.6 μM heparin 
(same concentrations used for the solid-binding assay showed in Chapter 3). The results, 
shown in Figure  5-18, indicated that at these concentrations heparin does not affect the 
enzymatic activity of TG2 per se, since no differences were recorded between TG2 assayed 
with or without the presence of heparin. Therefore, this finding suggests that HS affects the 
biological activity of TG2 indirectly by altering its cell-surface localisation. 
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Figure  5-18 Study of heparin-binding effect on TG2 activity. TG activity of purified 
TG2 (0-8.5 nM) was measured through the incorporation of biotinylated cadaverine into 
FN in the absence (control) or presence of heparin (2.3 or 4.6 μM). The data shown are 
the mean Abs 450 nm ± SD of three independent experiments performed in triplicate. 
Differences were not statistically significant (p>0.05).   
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5.3 Discussion 
The experiments presented in this chapter were aimed to investigate the role of Sdc-4 on 
the cell-surface trafficking of TG2 in primary fibroblasts.   
The physical association of TG2 and Sdc-4 at the cell surface was confirmed by co-
staining of the two molecules in large peripheral cell-matrix adhesions. These structures, 
which determine the cell shape, have been reported by Longley et al. (1999) and Zamir and 
Geiger (2001). The absence of Sdc-4 determined a drastic reduction of the amount of TG2 
present at these cell-surface structures, and a parallel accumulation of TG2 in the cytosol.. 
Interestingly, when the staining was performed on cells adhering on FN, the patches 
corresponding to TG2 staining became larger, as if the TG2 was externalised from these 
cell-matrix contacts. Western blot analysis and TG2 activity assays performed on 
membrane and cytosolic fractions confirmed that in the absence of Sdc-4 TG2 is mostly 
retained intracellularly. This finding suggests a possible role for Sdc-4 in the cell-surface 
trafficking of TG2 and it is supported by the observation that heparin/HS does not 
influence the Ca2+-dependent transamidation activity of purified TG2.  
The results of the previous chapter showed a direct interaction of TG2 and Sdc-4 mediated 
by the HS chains of Sdc-4. The results of this chapter support this data, as lack of Sdc-4 is 
shown to lower cell-surface TG2, which is rescued by adding back Sdc-4. However, since 
perturbation of all cell-surface HS chains by either heparitinase or surfen (Schuksz et al., 
2008), determined an even lower cell surface activity in Sdc-4 null cells, it is possible that 
Sdc-4 may not the only HSPG receptor involved in the trafficking of TG2. A possible 
candidate for this role is Sdc-2, the Sdc family member with the highest expression at cell-
matrix contact points in fibroblasts (David et al., 1992; David, 1993).  
The role of HSPG in the externalization of unconventionally secreted proteins has been 
suggested and HSPG are essential factors in the export of FGF-2, (Zehe et al., 2006). It is 
therefore  possible that the HS chains of Sdc-4 and other HSPG may be involved in the 
externalization of TG2 in a similar way. 
However, HS are also involved in endocytosis of extracellular components (MacArthur et 
al., 2007), therefore they could affect the cell-surface trafficking of TG2 influencing its 
internalization. This possibility is particularly intriguing, since Zemskov and colleagues 
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(2007) have demonstrated that internalization of TG2 requires the endocytic receptor 
LRP1, and this receptor has been shown to act in concert with HSPG  (Mahley and Ji, 
1999). Although the possible double action of HSPG receptors in externalization and 
internalization of TG2 can not be excluded, even though the model used for the 
investigation presented in this thesis (Sdc-4 null cells) is not adequate to clarify the effect 
of lack of Sdc-4 in TG2 internalisation since these cells are not able to externalize TG2.  
In conclusion, this study has shown for the first time that cell-surface HSPG like Sdc-4 
influence the activity of extracellular TG2 by driving its location at cell-matrix adhesions.  
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Chapter 6: Physiological significance of Transglutaminase-2 
binding to Syndecan-4 in kidney fibrosis 
6.1 Introduction 
6.1.1 TG2 and kidney fibrosis 
Since kidneys are organs constantly subjected to injuries, they are regarded a good model 
for studying wound repair. There are several factors responsible for kidney insults, such as 
drugs, dietary compounds, environmental factors and diseases. Under normal conditions 
the repair processes take place without being noticed, but when the insult becomes chronic 
(eg glomerulosclerosis, diabetic nephropathy) or the repair process is aberrant, the diseased 
condition becomes evident (El Nahas et al., 1997; Verderio et al., 2004). This abnormal 
state is characterized by a continuous remodelling process, which leads to kidney scarring 
and fibrosis and carries on until the kidney looses functionality. In particular, a non-
resolving inflammatory response takes place, together with fibroblasts proliferation and 
over expression/accumulation of ECM components, leading to loss of functionality and 
destruction of the kidney (Johnson et al., 2002; Johnson et al., 2003; Johnson et al., 1997).  
Despite being the main factor in determining renal failure, the matrix accumulation and the 
changes in cells-ECM interaction typical of this process are only partially understood and 
their improved understanding would support the development of new selective therapies.  
Experimental studies on the association of TG2 with progressive kidney fibrosis have 
shown a considerable increase in TG2 expression and externalisation. Extracellularly, 
given the high Ca2+ and low GTP/GDP concentrations, TG2 catalyses the formation of ε-
(γ-glutamyl) lysine crosslinks, characteristic of kidney fibrosis (El Nahas et al., 2004; 
Johnson et al., 1997; Johnson et al., 1999). It is possible to distinguish different stages in 
the development of renal conditions where TG2 is invoved. In the initial stage, there is an 
increased level of TG-mediated cross-links in the expanding ECM; this process seems to 
be correlated with either the externalisation of existing TG2, or to the involvement of other 
members of the TG family, since the overall renal TG level remains constant (Skill et al., 
2001). With the progression of the disease state, TG2 levels increase in tubular epithelial 
and mesangial cells (El Nahas et al., 2004; Johnson et al., 2004; Johnson et al., 2003). This 
new pool of TG2 is released in the ECM, where it further contributes to the crosslinking of 
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ECM proteins. In vitro studies have shown a marked reduction in matrix accumulation 
when TG2 activity is blocked, thus confirming the direct role of the enzyme on the 
development of fibrotic diseases (Skill et al., 2004). As a consequence, understanding of 
the regulation of TG2 externalisation and activity is important in the development of an 
effective therapy against kidney fibrosis. 
6.1.2 Sdc-4 and renal diseases 
The role played by Sdc-4 in the regulation of cell-matrix interactions and the variety of 
ligands that the HS chains can bind, determine the involvement of Sdc-4 in several types of 
diseases. In particular, given the high expression of Sdc-4 in kidney, compared to other 
tissues/organs, its role in the development of renal diseases is of particular interest. 
Kidneys isolated from Sdc-4 deficient mice are functionally and structurally normal 
(Ishiguro et al., 2000), but they react differently from wild type kidneys if exposed to 
artificial stress or diseases. For example, induction of obstructive nephropathy via 
intraperitoneal injection of κ-carrageenan (polysaccharide which accumulates in the 
collecting ducts) leads to high mortality in Sdc-4 null mice but not in wild type mice 
(Ishiguro et al., 2001). Kidneys from Sdc-4 -/- mice injected wit κ-carrageenan showed a 
high level of dilation of the renal tubules and of the inner medulla, where the compound 
was accumulated and determined obstruction of the collecting ducts. This obstruction led 
to high level of blood urea nitrogen in Sdc-4 -/- mice, which was responsible of the higher 
mortality compared to wild type animals. It has been suggested a role for Sdc-4 in 
preventing carrageenan accumulation in the collecting ducts, but the mechanism behind it 
is still unknown.  
It has been demonstrated that Sdc-4 is up-regulated in progressive proliferative kidney 
diseases, such as IgA nephropathy, but not in non-proliferative diseases such as thin-
membrane nephropathy (Yung et al., 2001). Sdc-4 was increased at both the mRNA and 
protein level, and interestingly, there was a correlated up-regulation of microfilament-
associated proteins such as vinculin, α-actinin and paxillin. These proteins, in particular α-
actinin, have been shown to form stable complexes with Sdc-4 in vitro, thus suggesting a 
possible role for Sdc-4 in cytoskeletal reorganisation which occurs during the development 
of proliferative diseases (Yung et al., 2001).  
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As reported in paragraph  6.1.1, TGFβ1 is an important factor in the wound healing process 
and fibrotic response, and TG2 plays a role in the regulation of TGFβ1 activation (Nunes 
et al., 1997; Telci et al., 2009; Verderio et al., 1999). Sdc-4 has been shown to be an 
essential factor in mediating cytoskeletal re-organisation in response to TGFβ1 (Chen et 
al., 2005). These data, together with the in vitro evidence of the essential role of cell 
surface HS for TG2-mediated RGD-independent cell adhesion (Verderio et al., 2003) 
suggest a possible connection between TG2 (which is also over-expressed in kidney 
fibrosis) and Sdc-4 signalling in the development of fibrotic diseases.  
6.1.3 TG2 and HSPG in kidney fibrosis 
Chronic kidney diseases lead to kidney fibrosis, characterised by accumulation of ECM 
components, fibroblasts proliferation and tubular atrophy (Johnson et al., 2003; Johnson et 
al., 1997); this process ultimately determines kidney failure. TG2, which has a high 
expression level in several kidney cell types (tubular epithelial cells and mesangial cells) 
plays an important role in the development of kidney fibrosis, as demonstrated by in vivo 
studies on experimental renal scarring models (Johnson et al., 1999). TG2 involvement in 
kidney fibrosis requires externalisation and translocation to the ECM, and it has been 
demonstrated that the level of extracellular TG2 is significantly increased in biopsies from 
fibrotic kidneys (Johnson et al., 2003). However, it is still unclear how TG2 is translocated 
to the cell-surface and ECM, as previously mentioned (Chapter 1, paragraph 1.2.9.6.3). In 
the previous chapters new evidence have been provided for the high affinity of TG2 and 
cell-surface HSPG in vitro, which has a significant impact on cell-surface trafficking of 
TG2. Therefore, HSPG may act as modulators of TG2 extracellular functions also in vivo.  
HSPG are key components of the tubular basement membrane and play an essential role 
for the proliferation of renal fibroblasts by facilitating the interaction of FGF with its cell-
surface receptor (Clayton et al., 2001). Moreover, cell-surface HSPG have been shown to 
participate to the unconventional mechanism of FGF translocation through the plasma 
membrane, mediated by FGF binding of HS chains of the receptors (Zehe et al., 2006). 
HSPG are upregulated in chronic kidney diseases characterised by tissue fibrosis (Fisher et 
al., 2009). These cell surface receptors have been implicated in kidney fibrosis by creating 
gradients of pro-fibrotic factors. Given the length and flexibility of their HS chains they 
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could also present the bound pro-fibrotic factors to cell types that do not secrete them, thus 
amplifying the response of those HS-binding molecules. 
The results presented in this thesis so far have highlighted a role for Sdc-4 in the regulation 
of cell-surface TG2 localisation and biological activity. Given the importance of TG2 
activity as a pro-fibrotic factor in the establishment of scarring and fibrosis, the analysis of 
the co-operation between Sdc-4 and TG2 was investigated in vivo. Unilateral ureteral 
obstruction (UUO) was used as an experimental model of kidney fibrosis, firstly to assess 
the role of Sdc-4 in the development of kidney fibrotic disease, and secondly to investigate 
whether TG2 and Sdc-4 cooperate in this process. 
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6.2 Materials and Methods 
6.2.1 Experiment design 
The minimum number of animals to use for the in vivo study was determined using an 
online power calculator (http://www.stat.ubc.ca/~rollin/stats/ssize/n2.html). The 
parameters used for the algorithm (μ 78 vs 36, σ19, Power 0.99, α 0.05) were derived from 
a previous study on the effect of lack of TG2 in unilateral ureteral obstrtruction (UUO) 
development (Mohammed et al., 2006). The power calculator returned a value of 8, for that 
reason 8 or more (wild type or Sdc- null) animals were chosen for each time point 
considered as shown in Table  6-1. Both kidneys from control animals (untreated) were 
analysed. UUO was typically induced in the left kidney and the right kidney from animals 
with UUO induction was also analysed (it is indicated as untreated kidney in UUO). 
 
Time point Sdc-4 +/+ control Sdc-4 +/+ UUO Sdc-4 -/- control Sdc-4 -/- UUO 
7 days 8 8 10 8 
14 days 8 8 8 10 
21 days 8 8 8 10 
Table  6-1 Experimental design for in vivo study on Sdc-4 and TG2 contribution to 
kidney fibrosis. The table shows the number of animals used in every experimental group.  
 
6.2.2 Induction of UUO 
Experimental unilateral ureteric obstruction (UUO) was performed by the Department of 
Histopathology, Northern General Hospital (Sheffield) in wild type and Sdc-4 -/- mice 
(Ishiguro et al. 5249-52). Anaesthesia was induced with 5% fluorothane and maintained by 
2% fluorothane during all the surgical process. The procedure consisted in the ligation of 
the left ureter of each animal with a legating clip (Hemoclip Plus, Weck Closure Systems), 
which was placed one-third of the way down the ureter from the pole of the kidney 
(Ophascharoensuk et al., 1998). The peritoneum was flooded with ADEPT (4 % Icodextrin 
solution), in order to prevent post-surgical adhesions prior to closing. The muscle wall was 
closed with single cross-over stitching using dissolvable stitches. After UUO was 
Chapter 6: Physiological significance of TG2 binding to Sdc4 in tissue fibrosis 
 159
performed, all mice were provided with Buprenorphine (10 mg/kg) for 40 hours for 
analgesic purpose. The mice were allowed to recover and were given free access to food 
and water.  At days 7, 14 and 21, the kidneys (n≥8) were retrieved, weighed and then 
sectioned into four equal parts to be used for the different analytical techniques. All 
procedures were carried out under license according to regulations laid down by Her 
Majesty’s Government, United Kingdom (Animals Scientific Procedures Act, 1986). 
6.2.3 Preparation of kidney paraffin sections 
Paraffin sections were prepared by the Department of Histopathology, Northern General 
Hospital (Sheffield). Kidneys were fixed in neutral buffered formalin then embedded in 
paraffin and, after solidification, cut at a thickness of 4 μm.  
6.2.4 Preparation of kidney cryosections 
Cryosections were prepared from kidney tissues stored in liquid N2. Tissues were mounted 
on tissue holders using Tissue-Tek O.C.T.™, a compound made of water soluble glycols 
and resins, providing an excellent specimen for cryostat sectioning at temperatures ≤ -
10°C. After embedding, the tissues were placed inside the cryostat, at a temperature of -
16°C, for 20 minutes, in order for the embedding resin to solidify completely and for the 
tissue to reach the same temperature of the cryostat chamber. After that, 14 mm thick 
sections were cut and, with the help of a fine brush, placed on Superfrost® Plus microscope 
slides, suitable for tissue staining procedures and microscopy. Cryosections were 
immediately used for in situ enzymatic activity assay ( 6.2.8).  
6.2.5 Masson’s trichrome staining on kidney tissues 
Masson’s trichrome staining was performed by the Department of Histopathology, 
Northern General Hospital (Sheffield) to stain in blue/green any collagen present and in 
red/pink nuclei, fibers, erythrocytes and elastin. Paraffin sections were de-waxed in xylene 
for 10 minutes, serially re-hydrated in 100%, 95% and 75% (v/v) ethanol, and then washed 
in distilled water prior to staining in Weigert's iron hematoxylin working solution [0.5% 
(w/v) hematoxylin, 47.5% (v/v) ethanol, 0.6% (w/v) ferric chloride, 0.5% (v/v) 
concentrated hydrochloric acid] for 10 minutes. Sections were rinsed in distilled water, 
stained in Biebrich scarlet-acid fuchsin solution [0.9% (w/v) biebrich scarlet, 0.1% (w/v) 
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6.2.6 Multiphase image analysis 
Multiphase analysis consents to quantify the percentage of coverage of a specific colour in 
a specific image. The analysis was performed using Analysis™ 3.2 software (Soft Imaging 
Systems, Germany), considering 10 images of non overlapping regions for each kidney 
sample. For each image, a distinct phase was allocated to a defined colour shade, 
representing a specific component of the tissue (i.e. one phase was representative of the 
blue/green colour of collagen after Masson’s Trichrome staining). The phases were 
allocated in order to have a minimum total phase coverage of  95%. 
6.2.7 Measurement of Hydroxyproline by Amino Acid Analyser. 
Kidney tissue was homogenised in four times its volume of homogenising buffer (50 mM 
Tris HCl, pH 7.4 containing 0.25 M sucrose, 10 mM EDTA and proteases inhibitor 
cocktail) using a motor-driven pellet pestle (Sigma Aldrich). Total proteins were assessed 
as described in Chapter 2 (section 2.2.5.3) after dissolving 10 μl of the homogenate in 10 
μl homogenation buffer supplemented with 0.2% (w/v) SDS in order to solubilise all the 
proteins present.1.4 mg of proteins from the homogenate were hydrolysed in 1.5 ml of 6M 
HCl at 110°C for 18 hours. The samples were then freeze-dried for 8 hours and 
resuspended in 200 μl lithium citrate loading buffer (0.2 M, pH 2.2) for amino acid 
analysis. 40 ml of the preparation were loaded onto a Biochrom30 Amino Acid Analyser 
(available at Sheffield University) using a partial fill loop. The fractionation was 
performed using 96361 LiHP control program and analysis package, and the readings of 
Ninhydrin derivatised peaks at 440nm were recorded. The estimated hydroxyproline 
Chapter 6: Physiological significance of TG2 binding to Sdc4 in tissue fibrosis 
 161
concentration in the volume loaded was calculated by reference to the 10 nmol/20 μl 
Biochrom calibration standard.    
6.2.8 Detection of in situ TG activity in kidney tissues  
Determination of in situ TG activity was performed on kidney cryosections with a 
thickness of 14 μm. Unfixed sections were rehydrated in reconstitution buffer [5% (v/v) 
donkey serum; 10 mM EDTA; 0.1 (v/v) Triton X-100 in 50 mM Tris-HCl, pH 7.4 
containing protease inhibitor cocktail] for 30 minutes at room temperature, then washed 
twice with washing buffer [10 mM EDTA in PBS containing protease inhibitor cocktail]. 
Kidney sections were incubated for 1 hour at 37°C in reaction buffer containing the TG 
substrate Texas Red cadaverine [5 mM CaCl2; 5 mM DTT, 0.1 mM Texas Red cadaverine 
in 50 mM Tris-HCl, pH 7.4 containing protease inhibitor cocktail]. The TexasRed 
fluorochrome was specifically chosen instead of FITC used in the original protocol, which 
emits at a frequence similar to the auto-fluorescence of kidney tissue. In negative controls, 
10 mM EDTA was used instead of 5 mM CaCl2 in the reaction buffer. After the 
incubation, sections were washed 3 times with washing buffer, fixed in ice cold acetone for 
5 minutes at -20°C and air dried. Slides were mounted with Vectashield fluorescence 
mounting media and visualised using Leica TCS-NT confocal microscope. The level of TG 
in situ activity was determined subtracting the fluorescence level of negative control (10 
mM EDTA) to the level of samples containing CaCl2. Non overlapping fields of the same 
size were quantified for each kidney sample using the Leica oonfocal image analysis 
software. Data were expressed as TexasRed emission versus auto-fluorescent emission.  
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6.3 Results 
6.3.1 Lack of Sdc- is protective against the development of kidney fibrosis 
Impaired kidney function results from remodelling in the kidney and excess ECM 
deposition, leading to renal fibrosis. Wild type and Sdc-4 null mice were subjected to UUO 
as described in section  6.2.2. Masson’s trichrome staining was used to assess the overall 
level of scarring in normal and fibrotic kidney tissue harvested at 7, 14 and 21 days after 
the induction of UUO. The scarring level, represented by accumulation of collagen (blue 
staining), was quantified by using multiphase image analysis, as described in section  6.2.6; 
for each sample the scarring index was expressed as the average ratio of blue signal to red 
signal (non collagen staining) in order to correct the values for the area of tissue analysed.  
As shown in Figure  6-1 normal kidney sections from both wt and Sdc-4 -/- mice showed 
almost absence of blue/green colour and a tight association of tubules (index of renal 
functionality) in the cortical region of the kidneys. No differences were registered in the 
scarring level, with a measured value of 0.015±0.004 for Sdc-4 +/+ and 0.016±0.006 for 
Sdc-4 -/- kidneys (Figure  6-2). There was a progressive accumulation of tubulo-interstitial 
collagen in both Sdc-4 +/+ and Sdc-4 -/- kidneys after the induction of UUO, reaching the 
maximum level at 21 days post UUO induction. The induced fibrosis also disrupted the 
association of tubules, with the creation of gaps among them filled by ECM components. 
Starting from day 7 after UUO induction, it was possible to detect collagen deposition in 
the tubulointerstitial space and in the area surrounding the glomeruli (Bowman’s capsule) 
in kidneys from wild type mice.  At the same time point, sections taken from Sdc-4 -/- 
mice showed a significantly lower amount of collagen deposition compared to the sections 
from wild type mice (p<0.05), and the association between the tubules did not appear to be 
altered. The scarring index was 0.117±0.059 for the wild type and 0.030±0.012 for the 
Sdc-4 null kidneys (Figure  6-2). 
At 14 days after the induction of UUO the blue signal indicating collagen deposition was 
more diffused compared to the previous time point in wild type cells (0.221±0.081), and 
the association between tubules also started to be compromised (Figure  6-1). The scarring 
index was also increased in Sdc-4 -/- kidney tissues (0.133±0.058), but in these samples 
the tubular structure was maintained. Even though wild type kidneys displayed a higher 
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The trend observed after 21 days of UUO was consistent with what observed at the 
previous time points, with a higher level of collagen deposition in wild type kidneys 
compared to Sdc-4 -/- kidneys (Figure  6-1). At this time point the structure of Sdc-4 null 
kidneys was also altered, with an accumulation of blue-stained collagen in the tubulo-
interstitial space compromising the contact between tubules. The scarring index values 
calculated at 21 days were 0.3167±0.171 for Sdc-4 +/+ tissues and 0.133±0.087 for Sdc-4  
-/- tissues (p<0.05). 
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Figure  6-1 Extracellular matrix accumulation after induction of kidney fibrosis-Masson’s Trichrome staining. Paraffin sections 
from normal and UUO (7, 14 and 21 days) kidneys from Sdc-4 +/+ and Sdc-4 -/- mice were stained to evaluate renal scarring. Collagen is 
stained in blue/green; nuclei, fibers and elastin in red/pink. White arrow: glomerulus; asterisk: tubular lumen; black arrow: peritubular 
space. The bar indicates 50 μm. 
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Figure  6-2 Quantification of scarring index in normal and fibrotic (UUO) kidneys. 
The data represent the average values obtained from multiphase analysis of 4 to 10 
kidneys from Sdc-4 +/+ and Sdc-4  -/- mice at 7, 14 and 21 days after UUO induction; 
scarring index of normal kidneys is shown as a control. 10 images taken from non-
overlapping fields were analysed for each kidney sample. Average scarring index ± SD is 
shown. * indicates p ≤ 0.05. Normal kidneys, n=48. UUO kidneys, n=8. 
 
To have a clearer idea of the localisation of the collagen staining, kidney sections were 
analysed at 400X magnification and separate pictures were taken for proximal tubules and 
glomeruli. Figure  6-3 displays collagen accumulation in the proximal tubules of the kidney 
cortex. It is possible to see that, with the progression of the disease, there is an expansion 
of the matrix surrounding the tubules, with a loss of the compact structure observed in 
normal tissue. As presented in Figure  6-1, the blue staining appeared to be higher in wild 
type kidneys compared to Sdc-4 -/-. A similar analysis was performed on the glomeruli, the 
functional units of the kidney (Figure  6-4). A progressive collagen accumulation is evident 
in the space surrounding the glomerulus (Bowman’s capsule), indicating 
glomerulosclerosis, characteristic of renal fibrotic diseases.  
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Figure  6-3 Collagen accumulation in the proximal tubules after UUO induction. Progressive collagen accumulation was monitored 
after UUO induction (7, 14 and 21 days) in the proximal tubules of Sdc-4 +/+ and Sdc-4 -/- kidneys. Collagen was detected using 
Masson’s trichrome staining. The bars correspond to 50 μm. 
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Figure  6-4 Collagen accumulation in the glomeruli after UUO induction. Progressive collagen accumulation was monitored after UUO 
induction (7, 14 and 21 days) in the periglomerular area of Sdc-4 +/+ and Sdc-4 -/- kidneys. Collagen was detected using Masson’s 
trichrome staining. The bars correspond to 50 μm.  
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The scarring index was also assessed in untreated kidneys of animals which had UUO 
induced in the left kidney, in order to determine if compensatory effects were taking place. 
The results presented in Figure  6-5 show that at the three time points considered there was 
not a significant difference between kidneys from normal mice and untreated kidneys from 
UUO mice (p>0.05) even though a general increase in scarring index could be measured in 
untreated kidneys from UUO mice at the higher stages of UUO development (Figure  6-5). 
 
 
Figure  6-5 Quantification of scarring index in the untreated kidneys of mice with 
UUO induction. Scarring index was quantified as described in Figure  6-2. Normal 
kidneys (n=16) and untreated kidneys from UUO mice (n=8) were compared at every time 
point (7, 14 and 21 days) for wild type and Sdc-4 mice. 
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The effect of the gender in the development of kidney fibrosis was investigated by 
analysing separately the scarring index values relative to male and female individuals. 
Normal kidneys from either wild type (Figure  6-6 A) or Sdc-4 null (Figure  6-6 B) 
displayed similar values of scarring index at the three time points considered and no 
significant differences were detected between male (M, shown in blue) and female (F, 
shown in red) samples.  
 
 
 
Figure  6-6 Effect of gender on scarring index of normal kidneys. Kidney scarring index 
(quantified with Masson’s trichrome staining) was compared between normal male (M, 
blue) and female (F, red) at 7, 14 and 2 days. Quantification of wild type samples is shown 
in A, Sdc-4 null samples is presented in B.  
 
 
 
Wild type kidneys affected by UUO showed a progressive increase in scarring index, but 
no significant differences could be identified between males and females at the three time 
points considered (Figure  6-7 A). Sdc-4 null samples displayed a lower level of scarring 
index compared to wild type samples, as already shown in Figure  6-1, but, as wild type 
samples, there was no difference between male and females at the three time points 
considered (Figure  6-7 B). 
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Figure  6-7 Effect of gender on scarring index on kidneys subjected to UUO. Kidney 
scarring index (quantified with Masson’s trichrome stainig) was compared between UUO 
male (M, blue) and female (F, red) at 7, 14 and 21 days. Quantification of wild type 
samples is shown in A, Sdc-4 null samples are presented in B. 
 
 
Collagen accumulation during UUO was also monitored by measuring the level of 
hydroxy-Pro, a major component of collagen. Hydroxy-Pro gives a more precise 
measurement of collagen deposition compared to Masson’s trichrome staining, which can 
be altered by urine infiltration in kidneys subjected to UUO. As shown in Figure  6-8, a 
significantly higher value of the hydroxyl-Pro was detected in wild type samples after 21 
days UUO compared to Sdc-4 null samples. No significant differences were measured 
between wild type and Sdc-4 null normal samples. The analysis validated what previously 
determined with Masson’s trichrome quantification. 
In conclusion, these data have shown that Sdc-4 is involved in the development of 
experimental renal fibrosis. Since previous work has shown that TG2 is also implicated in 
this process, we next tested whether the interaction of TG2 with Sdc-4 could affect TG2 
activity also in vivo.  
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Figure  6-8 Hydroxy-Pro quantification in normal and fibrotic kidneys. The total level 
of hydroxyproline was quantified in normal and UUO (21 days) kidney homogenates from 
Sdc-4 +/+ and Sdc-4 -/- mice, as described in section  6.2.7. **, p<0.01. n≥3. Normal 
kidneys, n=24. UUO kidneys, n=8 
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6.3.2 Lack of Sdc-4 leads to lower in situ Transglutaminase activity 
In situ TG activity was assayed on kidneys from wild type and Sdc-4 null mice through the 
incorporation of Texas Red labelled cadaverine into unfixed cryosections, either normal or 
post UUO.  Since the TG-reaction is Ca2+-dependent, reaction buffer containing EDTA 
was used as a negative control. The green auto-fluorescence of the kidney tissue was used 
as a normaliser for the area of tissue considered (kidney cortical area).  
As shown in Figure  6-9 and Figure  6-10, TG in situ activity was hardly detectable in 
normal kidneys from wild type and Sdc-4 -/- mice. At 7 days after the induction of UUO 
there was a clear distribution of TG activity in the space surrounding the tubules of wild 
type kidneys, as pointed by the arrow in Figure  6-9. The signal measured in Sdc-4 -/- 
kidneys at the same time point was significantly lower (p<0.05), as shown in Figure  6-10 
and quantified in the histogram of Figure  6-11. At 14 days after UUO induction, the 
peritubular signal was increased in wild type kidneys compared to the previous time point 
(Figure  6-9 and Figure  6-11), with a pattern analogue to the collagen distribution measured 
with Masson’s trichrome (Figure  6-1). At the same time, a similar pattern of TG activity 
was detected in Sdc-4 null kidneys, as pointed by the arrow in Figure  6-10, even though 
the activity level was significantly lower (p<0.01) than what measured in wild type 
kidneys. TG in situ activity was still significantly higher (p<0.05) in wild type kidneys 
compared to Sdc-4 null kidneys at 21 days UUO. At this late time point post UUO, the 
kidney integrity was also compromised, so it was difficult to have a clear idea of TG 
activity localisation (Figure  6-9). 
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Figure  6-9 Measurement of TG activity in situ in normal and fibrotic (UUO) kidneys 
from wild type mice. TG activity was measured in cryosections produced from normal 
and UUO (7, 14 and 21 days) kidneys from wild type mice via the  incorporation of 
TexasRed-cadaverine into endogenous substrates in the presence of either 5 mM CaCl2 or, 
as a negative control, 10 mM EDTA. The green auto-fluorescence of the kidney tissue was 
used as a area normaliser. 3 non-overlapping images acquired by confocal microscopy 
were quantified for each kidney sample. Normal kidneys, n=48. UUO kidneys, n=8.  The 
arrows point at the TG distribution in the ECM surrounding tubules and glomeruli. The 
bar indicates 50 μm.  
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Figure  6-10 Measurement of TG activity in situ in normal and fibrotic (UUO) kidneys 
from Sdc-4 -/- mice. The staining was performed on normal and UUO (7, 14 and 21 days) 
from Sdc-4 null mice as described in the legend of Figure  6-9. Normal kidneys, n=48. 
UUO kidneys, n=8. The arrows point at the TG distribution in the ECM surrounding 
tubules and glomeruli. The bar indicates 50 μm.  
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Figure  6-11 Quantification of TG in situ activity in normal and fibrotic (UUO) 
kidneys. The data represent the average values obtained from quantification of the 
fluorescent signal of 4 to 10 kidneys from wild type (Sdc-4 +/+) and Sdc-4  -/- mice at 7, 
14 and 21 days after UUO induction. TG activity of normal kidneys is shown as a control. 
5 images taken from non-overlapping fields were analysed for each kidney sample. 
Average in situ activity ± SD is shown. Normal kidneys, n=48. UUO kidneys, n=8. *, p ≤ 
0.05; **, p<0.01. 
 
 
Linear correlation (Pearson’s correlation) between renal scarring (estimated with Masson’s 
trichrome quantification) and in situ TG activity was determined using GraphPad software. 
The analysis revealed a coefficient of linear correlation (r) equal to 0.6532 when measured 
considering Masson’s trichrome as scarring index (Figure  6-12); the linear correlation 
resulted statistically significant (p<0.0001). It has to be considered that the large number of 
samples analysed can determine a low p value and significant correlation even though from 
the graph many samples do not appear to fit with the correlation line. 
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Figure  6-12 Correlation between TG activity and renal scarring index after the 
induction of UUO. Correlation was determined between in situ TG activity and scarring 
index (measured with Masson’s trichrome staining) using GraphPad Prism software. 
Values relative to all the samples used in the study (normal and UUO kidneys from wild 
type and Sdc-4 null mine) are plotted. R2 indicates the fitting with the regression line. r, 
Pearson’s coefficient of linear correlation; p is relative to positive correlation. 
 
 
Linear correlation was also estimated separately for wild type and Sdc-4 samples (normal 
and UUO). The data in Figure  6-13 show clearly that in wild type samples the levels of 
both TG activity and scarring index are higher compared to Sdc-4 null samples. In both 
wild type and Sdc-4 -/- there was a positive correlation between TG activity and scarring 
index (r= 0.6355 and r=0.5318, respectively) and the correlation was statistically 
significant (p=0.0001 and p=0.003, respectively). It is interesting to see how the values of 
TG activity start to increase before the scarring index in UUO samples compared to normal 
samples (Figure  6-13). This observation is consistent with a role of TG activity in the 
development of the fibrotic status, where the accumulation of ECM is a consequence of 
TG activity.  
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Figure  6-13 Effect of Sdc-4 on the correlation between TG in situ activity and 
scarring index. Correlation was determined between in situ TG activity and scarring 
index (measured with Masson’s trichrome staining) using GraphPad Prism software. 
Values relative to wild type samples (normal and UUO) are presented in A; values relative 
to Sdc-4 null samples (normal and UUO) are shown in B. R2 indicates the fitting with the 
regression line. r, Pearson’s coefficient of correlation; p is relative to positive correlation. 
 
 
Controls on TG2 expression level were performed by Western blotting on normal and 21 
days UUO kidney sample from wild type and Sdc-4 -/- animals. The results presented in 
Figure  6-14 show that there was no significant difference in the level of TG2 expression in 
normal kidneys from wild type and Sdc-4 null mice. The level of TG2 was increased in an 
analogous way in wild type and Sdc-4 null kidneys at 21 days after the induction of UUO, 
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Figure  6-14 TG2 level in kidney extracts from wild type and Sdc-4 null mice. TG2 
expression was measured by Western blotting in protein extracts of normal and UUO 
kidneys from Sdc-4+/+ and Sdc-4 -/- mice. 25 μg protein extract were loaded; three 
separate samples were analysed for each condition.  TG2 was detected by anti-TG2 
polyclonal antibody Ab10445 and revealed by incubation with HRP-conjugated secondary 
antibody. Cyclophilin A (CypA) was used as a control for equiloading. The histogram 
shows TG2 level expressed as ratio TG2/CypA. Mr, indicates gpTG2 standard, 100 ng.
 178
Chapter 6: Physiological significance of TG2 binding to Sdc4 in tissue fibrosis 
 179
Kidney fibrosis, characterised by glomerular sclerosis accompanied by interstitial fibrosis 
is a common consequence of several renal diseases of different aetiology. For this reason, 
understanding the mechanisms regulating the development of kidney fibrosis is particularly 
important in order to develop specific therapies aimed to the reduction of fibrotic diseases 
progression. UUO was chosen as experimental model for progressive proliferative renal 
fibrosis since it is a well established model for rodents which permits the development of 
fibrotic state in a relatively short time without the use of exogenous toxins and without the 
development of uremia (Chevalier et al., 2009). Moreover, UUO gives the advantage of the 
availability of the contralateral kidney as a control. The use of UUO as a fibrotic model is 
also particularly significant considering that in infants and children the obstruction of the 
urinary tract due to congenital factors is the principal cause of kidney failure (Seikaly et 
al., 2003). One important disadvantage of this model is that, since the urinary tract is 
blocked, it is not possible to perform studies on renal functionality (i.e. analysis on urine 
samples). On the other side, given the high correlation between UUO-induced renal 
insufficiency and interstitial fibrosis (Schainuck et al., 1970), UUO represent a valid 
experimental model for fibrotic studies.  
The first step of the investigation consisted in the measurement of changes in ECM 
deposition (collagen) in wild type and Sdc-4 null kidneys after the induction of UUO. 
Quantification of Masson’s trichrome staining, which allows an estimation of collagen 
fibres deposition, revealed a significantly higher level of scarring in wild type kidneys 
compared to the Sdc-4 -/- at all the time points considered, suggesting a protective role for 
Sdc-4 against the development of kidney fibrosis. This finding was confirmed by the 
measurement of hydroxyl-Pro in kidney homogenates, directly correlated to the amount of 
collagen. Samples prepared from UUO Sdc-4 null kidneys displayed a significantly lower 
level of the amino acid compared to the wild type at 21 days UUO. Being kidney fibrosis 
related to an un-regulated tissue repair process, this result is in accordance with the 
involvement of Sdc-4 in wound healing and the reported delay in wound healing in Sdc-4 -
/-mice (Echtermeyer et al., 2001). Our findings of a protective role of Sdc-4 in kidney 
fibrosis appeared to be in contrast with a previous study focused on the role of Sdc-4 in 
kidney diseases induced by unilateral nephrectomy (UNX). In the reported study, the 
absence of Sdc-4 determined an increased level of glomerulosclerosis after UNX, which 
was however correlated to the compensatory overexpression of Sdc-2 in Sdc-4 -/- kidneys 
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(Cevikbas et al. 42-52). Indeed, Sdc-2 promotes the activity of pro-fibrotic TGF-β1, a key 
mediator of glomerulosclerosis (Chin et al., 2001; Gagliardini and Benigni, 2006). 
Moreover, Cevikbas and colleagues did not show any significant changes in wild type 
kidneys after UNX. The UUO model used in the current study analyses the effect of Sdc-4 
knock out from a different perspective compared to UNX model, where one of the kidneys 
is eliminated and the remaining kidney is subjected to glomerular hyperfiltration. This may 
explain the differences observed in the development of renal fibrosis between the present 
study and the one reported by Cecikbas et al. (2008), where no interstitial fibrosis was 
detected.  
Several studies have been published on gender effect in the susceptibility to renal diseases 
such as ischemia/reperfusion injury (Hu et al., 2009), polycistc kidney disease (Stringer et 
al., 2005) and diabetic nephropathy (Tomiyoshi et al., 2002). When the effect of gender 
was investigated in the current study, no significant differences were detected in the 
development of kidney fibrosis after UUO induction, suggesting that hormonal levels do 
not influence this experimental model of kidney fibrosis. However, the analysis of a higher 
number of samples would be required in order to have a more representative study on 
gender effect on kidney fibrosis. 
Given the direct association of TG2 and Sdc-4 demonstrated in this study, next the role of 
Sdc-4 in the regulation of TG activity was studied in normal and fibrotic kidneys. TG 
activity was found to be distributed in the same regions where collagen deposition was 
detected, in particular in the periglomerular area and in the extracellular space surrounding 
the tubules. The amount of in situ TG activity was found to be increased with the 
progression of the disease in both wild type and Sdc-4 ko kidneys, in accordance with 
previous reports (Fisher et al., 2009). At any time point considered (7, 14 and 21 days post 
UUO induction) TG2 activity was always significantly higher in wild type kidneys 
compared to Sdc-4 -/-. TG2 in situ activity was also positively correlated with the collagen 
deposition quantified by Masson’s trichrome staining. Since the TG activity level was 
comparable in normal wild type and Sdc-4 -/- kidneys, as well as the level of TG2 
expression, these data suggest a possible role for Sdc-4 in the regulation of extracellular 
TG2 activity correlated with the development of kidney fibrosis. Expression analysis of 
TG2 antigen failed to show a significantly increased TG2 level in wild type kidneys 
compared to Sdc-4 null kidneys at 21 days UUO. This finding suggests that the reduced 
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TG2 activity observed in Sdc-4 -/- kidneys post UUO may be due to the involvement of 
Sdc-4 in TG2 externalisation, as reported in vitro in this study (Chapter 5). The analysis 
also failed to show a significant difference in TG2 antigen between normal and post UUO 
samples, both wild type and Sdc-4 -/-. This finding is surprisingly, given that previous 
reports have shown an increased level of TG2 expression in kidney fibrotic diseases (El 
Nahas et al. 2004; Johnson et al., 2003; Johnson et al., 1999). 
In conclusion, these data suggest that the role of Sdc-4 is not directly related to the 
activation of TG2 expression, but it may involve the translocation of the enzyme in the 
extracellular environment, where the conditions are favourable for the Ca2+-dependent 
transamidating activity.  
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Chapter 7: General discussion 
TG2 plays an important role in the ECM, regulating cell-matrix interactions in 
physiological conditions and in situations of cell stress/wound healing by influencing cell 
adhesion and matrix stabilisation. The results presented in the first part of this thesis aimed 
to investigate the specific role of extracellular TG2 in the early stages of cell adhesion to 
FN, which was studied in primary fibroblasts for the first time. In order for TG2 to mediate 
extracellular events, the enzyme needs to be externalised and presented at the cell surface. 
This concept has been clearly demonstrated by the results presented in Chapter 3, showing 
FA formation in TG2 -/- MEF with or without added-back matrix TG2. Moreover, it is 
known that extracellular TG2 combined to FN mediates a novel adhesion mechanism, 
independent from integrin binding to FN (RGD-independent cell adhesion) (Verderio et 
al., 2003). This mechanism plays an important role in mediating cell survival in situations 
of cell stress, when the ECM is fragmented and RGD-dependent adhesion is impaired 
(Davis et al., 2000; Verderio et al., 2003). However, even though TG2 is known to be 
externalised, the mechanism regulating its cell-surface trafficking is still not fully 
understood. TG2-mediated RGD-independent cell-adhesion relies on the presence of cell-
surface HS chains (Verderio et al., 2003), moreover, TG2 has been known for a long time 
to have a certain affinity for heparin (analogue of HS) (Gambetti et al., 2005; Signorini et 
al., 1988). In this study HSPG like Sdc-4 were investigated as possible receptors for TG2 
at the cell surface.  
These results presented in Chapter 3 are in accordance with previous reports describing the 
presence of TG2, in association with FN, in the pericellular matrix and in the ECM of 
Swiss 3T3 fibroblasts (Gaudry et al., 1999; Verderio et al., 1998). In fact both TG2 antigen 
and activity could be detected at the cell surface of primary fibroblasts starting from 20 
minutes of cell adhesion on FN. TG2 localisation at cell-matrix contacts supported the idea 
of a role for the enzyme in early cell adhesion. Further studies aimed to investigate the role 
of externalised TG2 in cell adhesion were based on the use of primary cells isolated from 
mice where TG2 was disrupted by homologous recombination (De Laurenzi and Melino, 
2001). TG2 was selectively re-introduced on these cells either by cell transfection with a 
pEGFPTG construct or by plating the cells on a matrix of TG2 bound to FN. Cell adhesion 
was evaluated by monitoring FAK activation (phosphorylation of Tyr 397), actin 
cytoskeleton morphology and formation of vinculin-containing FA. Cells lacking TG2 
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displayed a significantly lower level of FAK-P in the early stages of cell adhesion, 
moreover they failed to form correct actin SF and vinculin-containing FA. These 
observations suggested a role for TG2 in the initial activation of FAK, showing that TG2 is 
involved in this step of FAK activation together with participating to the following 
activation by phosphorylation at Tyr 576 and Tyr 577 as previously described by Stephens 
et al. (2004).  
Syndecans and glypicans are the two families of membrane-bound proteoglycans, and both 
carry HS chains (Bernfield et al., 1992). The difference between the two families is that 
syndecans are type-1 transmembrane receptors, while glypicans are linked to the cell 
surface by a C-terminal GPI anchor (Bernfield et al., 1992). Since the current work aimed 
to understand the mechanism which regulates TG2 externalisation and biological activity 
at the cell surface, the attention was focused on syndecans for a number of reasons. Firstly, 
given their transmembrane and cytosolic domains, they can be involved in cell membrane 
trafficking. Secondly, TG2-mediated RGD-independent cell adhesion has been shown to 
be repressed by a specific inhibitor of PKCα (Go6976) (Verderio et al., 2003) and Sdc-4 
mediates PKCα activation (Defilippi et al., 1997; Slater et al., 2001). Thirdly, Sdc-4 is a 
widespread component of FA (Echtermeyer et al., 1999; Woods and Couchman, 1994), a 
site where TG2 was also found to be localised (Chapter 3 and Chapter 5). In order to 
investigate the role of Sdc-4 in TG2-mediated RGD-independent cell adhesion, 
experiments were performed on primary MDF isolated from mice lacking Sdc-4 (Ishiguro 
et al., 2000) using wild type MDF as a control. It is well known that, following initial cell 
attachment to FN via α5β1 integrins, Sdc-4 is essential for the formation of actin SF 
(Baciu and Goetinck, 1995; Woods and Couchman, 1994; Woods and Couchman, 2001) . 
However, the results showed in this thesis indicated that Sdc-4 -/- primary fibroblasts can 
still spread and form stress fibers when plated on FN. Anyway, SF of Sdc-4 null cells 
appeared to be less thick compared to those of wild type fibroblasts, indicating impairment 
in the spreading process. This hypothesis fits with the results obtained on the 
phosphorylation level of FAK. FAK phosphorylation at Tyr397 is an early event in FA 
formation. Results showed that Sdc-4 -/- MDF have a significantly lower amount of 
activated FAK compared to wild type cells; this could be the justification for the defects in 
actin cytoskeleton assembly, since FAK has a role in the modulation of stress fibers 
formation mediated by the small GTPase RhoA (Arthur and Burridge, 2001). This 
observation is in accordance with what previously published, stating that lack of Sdc-4 
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only affects cell spreading when the cell-binding domain of FN is missing (Ishiguro et al., 
2000). Measurements of FAK phosphorylation and SF formation revealed that the lack of 
Sdc-4 impairs TG2-mediated RGD-independent focal adhesion, which was rescued when 
Sdc-4 was added back to Sdc-4 null cells via transfection with pcDNAhS4 construct. 
While this study was being conducted, a parallel work stating the importance of Sdc-4 in 
FN-bound TG2-mediated RGD-independent cell adhesion was published (Telci et al., 
2008). The cited work did not explore the contribution of Sdc-4 to TG2-mediated RGD-
independent FAK activation, which is an original outcome of the studies presented in this 
thesis.  
Syndecans are constituted by a transmembrane protein which carries GAG chains 
(predominantly HS) on the extracellular domain; these chains, spanning outside the cell 
surface, are mostly responsible for binding properties of syndecans (Bernfield et al., 1992). 
For these reasons, binding studies were performed using purified TG2 and heparin (highly 
sulphated analogue of HS) or HS. Both SPR and solid-binding assays revealed a high 
binding affinity of TG2 for heparin/HS, estimated to be in the nM range. The apparent 
affinity of TG2 for both heparin and HS was measured, with a Kd of approximately 20 nM, 
when estimated with solid binding assay; the apparent affinity of TG2 for heparin was 90 
nM when measured by SPR. It is interesting to notice that the affinity of TG2 for 
heparin/HS is slightly higher of the measured affinity of TG2 for FN (Kd= 180 nM, 
measured by SPR), which, so far, has been considered the main binding partner for TG2 
(Hang et al., 2005). However, given the high affinity of TG2 for both FN and HS and, in 
turn, the affinity of FN for HS chains, collectively these data suggest a possible triangular 
association of TG2, HS chains of Sdc-4 and FN at cell-matrix contacts. Janiak et al. (2006) 
proposed an association of TG2 and β1 integrins at the cell surface, leading to integrin-
mediated signalling involved in cell adhesion. Our results lead to the hypothesis that TG2 
may exist in complex with Sdc-4 and FN at the cell surface. It is tempting to propose that 
TG2 may mediate the cross-talking between integrins and Sdc-4 leading to full adhesion 
and spreading (Saoncella et al., 1999).  
The work was carried on by showing that endogenous TG2 secreted by primary fibroblasts 
can interact with immobilised extracellular heparin/HS, indicating the possibility of a 
physiological role for the interaction of TG2 with HSPG, as already introduced in the work 
by Verderio et al (2003). This hypothesis was validated by studies on the physical 
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association of TG2 and Sdc-4 in vitro, which revealed a direct association of the two 
molecules at the cell surface of different cell types when analysed by co-
immunoprecipitation studies. In a parallel work exogenous FN-bound TG2 has been shown 
to co-immunoprecipitate with Sdc-4 (Telci et al., 2008). The work by Telci and colleagues 
however did not investigate the association of endogenous TG2 and Sdc-4. On the 
contrary, the results presented in this thesis (Chapter 4) show for the first time that cell-
secreted TG2 is associated with Sdc-4 at the cell surface and the interaction involves TG2-
binding of Sdc-4 HS chains. 
In this study, the extracellular localization and the cell-surface activity of TG2 were found 
to be regulated by Sdc-4 in primary fibroblasts, since MDF lacking Sdc-4 failed to show 
TG2 antigen and activity on the cell surface and the enzyme appeared to be retained 
intracellularly. In addition, added back Sdc-4 restored TG2 cell-surface activity in Sdc-4 
null cells. Further studies showed that the interference with cell-surface HS chains, either 
via heparitinase treatment or the HS antagonist surfen, significantly decreased the level of 
cell-surface TG2 activity. Since the HS chains did not appear to alter the intrinsic 
transamidation activity of TG2, these findings collectively demonstrated that HS chains of 
Sdc-4 influence cell-surface TG2 activity by controlling the localisation of the enzyme and 
not by affecting its transamidating activity.  
TG2 externalisation is enhanced in situations of cell stress and TG2 activity assumes an 
important role in the wound repair process, where it contributes to cell adhesion and to the 
stabilisation of the ECM. When the wound repair mechanism is altered, or when the insult 
causing the wound becomes chronic, there is the development of a fibrotic condition, 
characterised by an excess of ECM deposition leading to block of function of the interested 
organ (Singer and Clark, 1999). The involvement of TG2 in kidney fibrosis has been 
already described (El Nahas et al., 1997; Haroon et al., 1999; Johnson et al., 1999), and 
experiments performed on animal models have shown that lack of TG2 is protective 
against the development of renal fibrosis (Johnson et al., 2003). Therefore TG2 may be 
regarded as a novel therapeutic target for the cure of kidney fibrosis; consequently, current 
work in the field is aimed to find a way to regulate TG2 externalisation and activity 
(Johnson et al., 2007). 
 After studying the interaction of TG2 and Sdc-4 in vitro and defying a role for Sdc-4 HS 
chains in the localisation of TG2 biological activity, further studies were performed in 
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order to see if Sdc-4 regulates TG2 activity in vivo. Using an experimental model of kidney 
fibrosis (UUO) it was shown that the absence of Sdc-4 is protective against the 
development of kidney fibrosis. This data is in accordance with data previously published 
illustrating the role of Sdc-4 in the wound repair process and showing that wound repair is 
delayed in Sdc-4 null mice (Echtermeyer et al., 2001). TG activity was measured in situ in 
normal and fibrotic kidneys from wild type and Sdc-4 mice and its level was found to be 
positively correlated to the level of ECM accumulation. Even though normal kidneys from 
wild type and Sdc-4 null mice displayed the same level of in situ TG activity, this was 
found to be significantly lower in Sdc-4 -/- kidneys subjected to UUO compared to wild 
type kidneys. This result is reminiscent of what obtained with MDF isolated from wild 
type and Sdc-4 null mice, with wild type cells showing a higher level of cell-surface TG2 
activity compared to Sdc-4 null MDF. Therefore it is possible that Sdc-4 may also be 
involved in TG2-mediated ECM accumulation in fibrotic diseases (Verderio et al., 2008). 
In recent years much research in the area focused on the development of inhibitors of TG 
activity, in order to block TG2 action and therefore the progression of the fibrotic disease 
(Johnson et al., 2007). The major problem in designing these inhibitors is the lack of 
specificity. In fact, aiming the TG conserved catalytic site, they interfere with the activity 
of all the members of the TG family causing severe side effects such as problems in blood 
coagulation (FXIIIa) and in maintenance of skin integrity (TG1 and TG3) (Huang et al., 
2009). In order to achieve a higher level of specificity, new inhibitors have been designed 
in order to target only externalised transglutaminases (Huang et al., 2009), however, even 
though these inhibitors have a more limited target, the side effects related to the inhibition 
of FXIII, another member of the TG family to be externalised, are still present. Given the 
problems related to the use of TG inhibitors, it would be of great interest to have a better 
understanding on the mechanism of TG2 localisation, in order to control the secretion of 
the enzyme and hence its extracellular role.  
In conclusion, this study has shown that the association of TG2 with Sdc-4 could have 
several key roles. In fact Sd-4 is involved in TG2 cell-surface trafficking (Figure  7-1 point 
1) and, therefore, it indirectly regulates TG2 transamidation in the ECM (Figure  7-1 point 
2). Moreover, by acting as a cell surface receptor, Sdc-4 regulates TG2-mediated signalling 
in cell adhesion events in co-operation with integrins (Figure  7-1 point 3). In situations of 
cell stress, when integrin-mediated adhesion is inhibited and ECM is fragmented, 
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Figure  7-1 Events mediated by TG2 association with Sdc-4. 1) Sdc-4 regulates TG2 
cell-surface trafficking. 2) Extracellular TG2 associates to and stabilises FN. 3) Signalling 
from FN-associated TG2 in co-operation with Sdc-4 and integrins promotes cell adhesion 
and migration. 4) Externalised FN-bound TG2 mediates RGD-independent cell adhesion 
in a Sdc-4 dependent way 5) In fibrotic diseases, extracellular TG2 promotes ECM 
accumulation in a Sdc-4 dependent mechanism.  
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Substrates Isoenzyme Localization 
Proteins acting as amine donor 
Actin TG2  Intracellular 
Aldehyde dehydrogenase TG activity of the nematode C. elegans    
Amines (monoamines, diamines, polyamines): 
cadaverine and monodansilcadaverine, histamine, 
putrescine, serotonine, spermidine, spermine  
Different isoenzymes   
Beta amyloid peptide TG2   
Aspartyl protease TG2 and Factor XIII Viral protein (HIV-1) 
Bacteriorhodopsin Bacterial TG   
Calgizzarin—S100C protein—MLN 70—S100A11 TG1 and TG2 Keratinocyte cornified envelope (CE) 
Cell adhesion molecule C-CAM TG2   
Alpha B-crystallin TG2 Intracellular 
Cystatin TG2 and possibly others   
Beta-endorphin TG2 Endogenous opiates 
Fibrinogen A alpha TG2 and factor XIII Extracellular 
Glutamate dehydrogenase TG activity of the nematode Caenorhabditis elegans   
Glutathione S-transferase TG2 Intracellular 
Glyceraldeheyde 3 phosphate dehydrogenase TG2 Intracellular 
gp41 TG2 Transmembrane 
Keratin, type II cytoskeletal 1 TG2 and TG3   
Keratin, type II cytoskeletal 2 epidermal TG2 and TG3   
Keratin, type II cytoskeletal 5 TG2 and TG3   
Keratin, type II cytoskeletal 6 TG2 and TG3   
Alpha ketoglutarate dehydrogenase TG2 Intracellular (Mitocondrial) 
Alpha-lactalbumin TG2 and Streptoverticillium TG (MTG) Secretory protein 
Beta lactoglobulin TG2 (?) Secretory protein 
Laminin FXIII   
Loricrin   Cell envelopes 
Microtubule-associated protein tau—isoform Tau-F 
(Tau-4) TG2 Intracellular 
Monellin (analog of) Microbial TG   
Root and leaf pea proteins     
Protein disulfide isomerase TG activity of the nematode Caenorhabditis elegans   
Seminal vesicle secretory protein IV TG2 Extracellular 
S-peptide Microbial TG (MTG) from Streptomyces mobaraensis   
Thymosin beta 4   Intracellular (cytoplasmatic) 
Vasoactive intestinal peptide (VIP) TG2   
Vimentin TG2   
Proteins acting as amine acceptor (i.e. glutamine donor) 
Acetylcholine esterase TG2 Intracellular 
Actin TG2 Intracellular (cytoplasmatic) 
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Beta amyloid peptide TG2   
Annexin I (lipocortin I) TG2 Intracellular 
Alpha(2)-antiplasmin FXIII better than TG2 Extracellular 
Aspartyl protease TG2 and Factor XIII Viral protein (HIV-1) 
ATP synthase alpha subunit TG of the nematode C. elegans    
Bacteriorhodopsin Bacterial TG   
Calgizzarin—S100C protein—MLN 70—S100A11 TG1 and TG2 Keratinocyte cornified envelope (CE) 
Calpactin I light chain (S100A10) TG2   
Caraxin-1 (horseshoe crab)     
Beta casein Factor XIII Secreted protein 
Chloroplast proteins Plant TG(s)   
Collagen alpha 1(III) TG2 Extracellular 
Beta A3 crystallin TG2 Intracellular 
Beta B3 crystallin   Intracellular 
Beta Bp (betaB2) crystallin   Intracellular 
Cytocrome c TG2 Intracellular 
Beta-endorphin TG2 Endogenous opiates 
Enolase 
Transglutaminase of the 
nematode Caenorhabditis 
elegans 
Intracellular 
(Cytoplasmic) 
Erythrocyte anion transporter—band 3 anion transport 
protein 
Intrinsic TG of human red 
blood cell Intracellular 
Fibrinogen A alpha TG2 and factor XIII Extracellular 
Fibrinogen gamma Factor XIII Extracellular 
FibN (peptide derived from the N-terminal sequence 
of fibronectin)   Extracellular  
Glucagon TG2   
Glutathione S-transferase TG2 Intracellular 
gp41 TG2 Transmembrane 
gp120 TG2 Viral envelope 
H3 histone TG2 Intracellular 
H4 histone TG2 Intracellular  
H2A histone TG2 Intracellular 
H2B histone TG2 Intracellular 
Hemoglobin (denatured)     
Hepatitis C virus core protein TG2 Viral protein 
Insulin A chain TG2   
Insulin B chain TG2   
Insulin-like growth factor-binding protein-1 TG2   
Interleukin 2 Microbial transglutaminase (M-TG)   
Involucrin TG1 Membrane 
Alpha-lactalbumin TG2 and Streptoverticillium TG (MTG) Secretory protein 
Beta lactoglobulin TG2 (?) Secretory protein 
Laminin FXIII   
Loricrin   Cell envelopes 
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Alpha-2-macroglobulin receptor-associated protein   Extracellular 
Mellittin TG2   
Microtubule-associated protein tau—isoform Tau-F 
(Tau-4) TG2 Intracellular 
Midkine TG2   
Monellin (analog of) Microbial TG   
Nidogen (entactin) TG2 Extracellular 
Osteonectin TG2 Extracellular 
Osteopontin (extracellular matrix cell adhesion 
protein) TG2 Extracellular 
Root and leaf pea proteins     
Phosphoglycerate kinase   Intracellular ? 
Phospholipase A2 TG2 Extracellular 
Alpha2 plasmin inhibitor FXIII Extracellular? 
Plasminogen-activator inhibitor type-2 TG2 and FXIII   
Polyglutamine repeats TG2   
Procarboxypeptidase U (EC 3.4.17.20) plasma 
procarboxypeptidase B TG2 and factor XIII   
S100 calcium-binding protein A7—Psoriasin (S100A7 
or PSOR1) TG2   
Seminal vesicle secrtorey protein IV TG2 Extracellular 
S-peptide Microbial TG (MTG) from Streptomyces mobaraensis   
Substance P TG2 Extracellular 
Synapsin I TG2 Intracellular 
Tetanus toxin TG2   
Vasoactive intestinal peptide—VIP TG2   
Vimentin TG2   
Vitronectin Factor XIII Extracellular 
Von Willebrand factor Factor XIII   
Unknown acceptor/donor function, non-protein substrates, other molecules and activities 
Aldolase   Intracellular 
Androgen receptor TG2 Intracellular (nuclear receptor) 
CD38 TG2 Intracellular  
Clara Cell p10 Kda     
eIF5A (initiation factor 5A) TG2 and Factor XIII Intracellular 
Drugs (antibiotics) TG homologue   
Fibronectin Factor XIII Extracellular 
Filaggrin linker segment peptide (FLSP) TG3   
Galectin 3 TG2   
Glutathione S-transferase TG2 Intracellular 
Gluten proteins (alpha/beta-, gamma-gliadin, and low 
molecular weight glutenin) TG2 Extracellular 
Growth hormone TG2   
Small GTPases   Intracellular 
Histidine-rich glycoprotein FXIII Expressed by the liver and secreted in plasma 
Alpha2 HS-glycoprotein (AHSG) TG2   
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Huntingtin TG2   
Importin alpha3 TG2 Nuclear transport protein 
Insulin-like growth factor binding protein-3 (IGFBP-
3) TG2   
Latent TGF-beta binding protein-1 (LTBP-1) TG2 Extracellular 
Lipoprotein a TG2 and FXIII   
Alpha2 macroglobulin     
Myoglobin TG2   
Myosin   Intracellular 
Nucleotide(s) binding/hydrolyzing TG2 TG3 TG5 Intracellular 
Osteocalcin   Extracellular 
Periplakin TG2   
Phosphorylase kinase   Intracellular 
Proapoptotic kinase DLK TG2   
Protein disulfide isomerase TG activity of the nematode Caenorhabditis elegans    
Retinoblastoma protein     
Rho A   Intracellular 
Ribonuclease A TG2   
Semenogelin I Factor XIII   
Semenogelin II Factor XIII   
Bone sialoprotein (BSP) TG2 Bone matrix 
Soybean proteins   Extracellular 
Alpha-synuclein TG2 Intracellular 
Thrombospondin factor XIII Extracellular 
Troponin T   Intracellular 
Tubulin   Intracellular 
Uteroglobin TG2 FXIII? Extracellular 
Vinculin Factor XIII   
Whey proteins Microbial TG Extracellular 
 
Appendix 1 Substrates of transglutaminases (Facchiano and Facchiano, 2009).  
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Appendix 2 Schematic representation of the human TG2 expression vector pSG5-
TGase (Gentile et al., 1992). Human TG2 cDNA was EcoRI inserted into pSG5 vector. 
SV-40 early gene enhancer and promoter, intron II of the rabbit beta-globin gene (b-
globin), T7 bacteriophage promoter, and SV-40 polyadenilation sequence (polyA) are 
shown; Amp, ampicillin resistance gene.  
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